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ABSTRACT 
 
Pulmonary  arterial  hypertension  (PAH)  is  a  rare  and  progressive  disease 
characterised  by  increased  pulmonary  vascular  resistance  and  elevated 
pulmonary  artery  pressure,  leading  to  right  ventricular  failure  and  eventually 
death.  The monoamine 5-hydroxytryptamine (5HT) has been implicated in the 
processes of pulmonary vasoconstriction and pulmonary artery remodelling that 
contribute to the development of the PAH.  However, the signalling mechanisms 
utilised  by  5HT  that  contribute  to  pulmonary  vascular  remodelling  are  still 
unclear and appear to be cell-type specific, with much of the work having been 
carried out in pulmonary artery smooth muscle cells (PASMCs).  Fibroblasts 
also contribute significantly to the pulmonary vascular remodelling that occurs 
during PAH, however little is known of the role 5HT plays in this cell type.  Using 
Chinese  Hamster  Lung  Fibroblast  (CCL-39)  cells  as  a  model  system  to 
investigate the mitogenic effects of 5HT, this study has characterised potential 
5HT-mediated  signalling  pathways  in  fibroblasts  that  may  contribute  to 
pulmonary vascular remodelling.  
5HT  was  found  to  induce  a  rapid  and  transient  activation  of  extracellular 
regulated  mitogen-activated  protein  kinase  (ERK),  a  process  central  to  the 
mitogenic effects of 5HT in CCL-39 cells.  Furthermore, the 5HT transporter 
(5HTT),  5HT1B  and  5HT2A  receptors  were  all  required  for  optimal  ERK-
dependent  proliferation.    Pharmacological  inhibition  of  the  Rho/ROCK  (Rho-
associated  kinase)  pathway  significantly  inhibited  5HT-stimulated  ERK 
activation, cyclin D1 accumulation and proliferation.  Inhibition of ROCK had no 
effect  on  the  translocation  of  active  ERK  to  the  nucleus,  but  did  however 
selectively  inhibit  5HT-induced  activation  of  a  cytoplasmic  pool  of  ERK.  
Additionally,  ROCK  inhibition  had  no  effect  on  the  ability  of  5HT  to  activate 
mitogen-activated protein kinase kinase (MEK), suggesting ROCK is required 
for maintaining functional interactions between MEK and ERK.  Sensitivity to 
ROCK inhibition is restricted to 5HT1B receptor activation of the ERK pathway.  
Moreover, the role of ROCK in maintaining cytoskeletal integrity is important in 
mediating 5HT-induced ERK activation, as disruption of the actin cytoskeleton 
markedly and specifically reduces 5HT- stimulated ERK activation.   III 
Using  a  model  of  PAH,  arising  from  overexpression  of  5HTT  (5HTT
+),  the 
effects of ROCK inhibition in vivo were investigated.  ROCK 1 and ROCK 2 
transcripts  were  upregulated  in  response  to  chronic  hypoxia,  with  the 
upregulation  of  ROCK  1  potentiated  in  5HTT
+  mice.    Administration  of  the 
ROCK  inhibitor  Y27632  had  significantly  greater  effects  in  5HTT
+  mice 
compared  to  WT,  highlighting  the  functional  importance  of  the  increase  in 
ROCK  1  transcript.    Hypoxia-induced  pulmonary  vascular  remodelling  and 
elevated right ventricular pressure were attenuated more significantly by ROCK 
inhibition  in  5HTT
+  mice  than  in  WT.      Furthermore,  ROCK  inhibition  only 
reduced  hypoxia-derived  right  ventricular  hypertrophy  significantly  in  5HTT
+ 
animals and not WT. 
In conclusion, this study highlights a role for ROCK in the pulmonary vascular 
changes  that  occur  during  PAH  and  proposes  a  new  mechanism  by  which 
cross-talk between ROCK and 5HT signalling systems occurs.   IV 
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Chapter 1 
INTRODUCTION   2 
1.1  PULMONARY ARTERIAL HYPERTENSION 
 
Pulmonary arterial hypertension can be characterised by sustained elevation of 
pulmonary  vascular  resistance  (PVR)  and  pulmonary  artery  pressure  (PAP), 
leading to impaired right-heart function and eventually failure.  The condition is 
defined clinically by a mean pulmonary arterial pressure exceeding 25 mmHg at 
rest  or  30  mmHg  during  exercise  (Barst  et  al.,  2004).    Common  symptoms 
include fatigue, exertional dyspnea, edema and syncope (Rich et al., 1987).  As 
symptoms  experienced  by  most  patients  are  non-specific,  diagnosis  is 
frequently delayed.  
Pulmonary hypertension is classified into 5 main categories: pulmonary arterial 
hypertension (PAH), pulmonary hypertension with left heart disease, pulmonary 
hypertension  associated  with  lung  diseases  and/or  hypoxaemia,  pulmonary 
hypertension  due  to  chronic  thrombotic  and/or  embolic  disease,  and 
miscellaneous (Simonneau et al., 2004) (Table 1.1).  Around 10% of patients 
that present with PAH without any identifiable cause have a family history of the 
disease, and are referred to as having familial PAH (Loyd et al., 1984), with 
remaining patients classified as having idiopathic PAH (IPAH).  Familal PAH is 
an  autosomal  dominant  disorder  with  incomplete  penetrance  and  genetic 
anticipation,  that  was  initially  mapped  to  a  locus  designated  PPH1  on 
chromosome 2q31-32 (Morse et al., 1997, Nichols et al., 1997).  PPH1 was 
subsequently fine mapped to a 3cM region on chromosome 2q33 (Deng et al., 
2000a), that has been associated with mutations in the BMPR2 gene encoding 
bone  morphogenetic  protein  (BMP)  type  2  receptor  (BMPR-2)  (Lane  et  al., 
2000, Deng et al., 2000a).  Germline mutations in BMPR-2 have been identified 
in 60% of patients with familial PAH and also in around 10% to 30% of those 
with the idiopathic form of the condition (Lane et al., 2000, Deng et al., 2000b, 
Thomson et al., 2000).  Other genetic factors, such as polymorphisms in the 5-
hydroxytryptamine (5HT) transporter gene, have also been associated with the 
development of the condition (Eddahibi et al., 2001).  Moreover, PAH may occur 
secondary  to  other  conditions,  including  collagen  vascular  disease,  HIV 
infection  or  lung  diseases  such  as  chronic  obstructive  pulmonary  disease 
(COPD) (Simonneau et al., 2004).   3 
The idiopathic form of the disease occurs more frequently in women than men 
(>2:1) and is usually fatal within 3 years if untreated (Newman et al., 2004).  
Current  therapies,  such  as  prostacyclin  and  endothelin antagonists  markedly 
improve physical function and survival, with the 5 year mortality rate around 
50% (Newman et al., 2004).    4 
Revised World Health Organisation Clinical Classification of 
Pulmonary Hypertension (Venice 2003)  
 
Pulmonary arterial hypertension 
 
Primary pulmonary hypertension 
Idiopathic 
Familial 
Related to: 
Collagen vascular disease 
Congenital systemic to pulmonary shunts 
Portal hypertension 
HIV infection 
Drugs/Toxins 
Anorexigens 
Other 
Associated with significant venous or capillary involvement 
  Pulmonary veno-occlusive disease 
  Pulmonary capillary haemangiomatosis 
  Persistent pulmonary hypertension of the newborn 
 
Pulmonary venous hypertension 
 
Left-sided atrial or ventricular heart disease 
Left-sided valvular heart disease 
 
Pulmonary hypertension associated with lung diseases and/or 
hypoxaemia 
 
Chronic obstructive pulmonary disease 
Interstitial lung disease 
Sleep-disordered breathing 
Alveolar hypoventilation disorders 
Chronic exposure to high altitude 
Developmental abnormalities 
 
Pulmonary hypertension due to chronic thrombotic and/or embolic 
disease 
 
Thromboembolic obstruction of proximal pulmonary arteries 
Thromboembolic obstruction of distal pulmonary arteries 
  Nonthrombotic pulmonary embolism (tumour, parasites, foreign material) 
 
Miscellaneous 
 
Sarcoidosis, histiocytosis X, lymphangiomatosis, compression of pulmonary vessels 
(adenopathy, tumour, fibrosing mediostinitis) 
 
 
 
 
 
 
Table 1.1  Revised Clinical Classification of Pulmonary Hypertension.   
The  aim  of  classification  was  to  identify  different  categories  of  pulmonary 
hypertension  that  shared  similarities  in  pathophysiological  mechanisms  and 
clinical symptoms.  Clinical classification is important in standardising diagnosis 
and treatment.   5 
1.2    THE PULMONARY CIRCULATION 
 
The pulmonary circulation is a closed circuit of vessels carrying blood between 
the  heart  and  lungs.    In  healthy  adults  the  system  is  a  low-pressure,  low-
resistance circuit, with a mean PAP between 9 - 19 mmHg at sea level (Chemla 
et al., 2002).  In addition to this, the pulmonary vessels are thin-walled and 
highly distensible, able to accommodate large increases in blood flow, such as 
that occurring during exercise, with minimal increases in PAP (Chemla et al., 
2002, Vonk-Noordegraaf et al., 2005). 
Pulmonary  blood  vessels  are  arranged  to  facilitate  efficient  gas  exchange, 
carrying blood into the pulmonary microvasculature of the alveoli, where uptake 
of oxygen and the unloading of excess carbon dioxide occurs.  The pulmonary 
arteries run alongside the airways, branching with them and producing a large 
surface area within the alveolar region by means of a capillary network sheet 
flow  (Mandegar  et  al.,  2004,  Hislop  and  Pierce,  2000).    Blood  flow  in  the 
pulmonary arteries must be sufficient and at a linear velocity with the counter 
current for gas exchange to occur (Hislop and Pierce, 2000).  Larger vessels in 
the proximal region of the pulmonary arterial network are elastic in structure 
with several layers of smooth muscle separated by collagen and elastic laminae 
(Hislop and Pierce, 2000).  As the arterial tree advances distally and the vessels 
decrease  in  diameter,  there  is  a  gradual  decrease  in  the  level  of 
muscularisation,  with  arteries  only  partially  muscular  or  completely  non-
muscular (Hislop and Pierce, 2000, Meyrick and Reid, 1983, MacLean et al., 
2000). 
Unlike the systemic circulation, where hypoxic conditions result in vasodilation, 
in  the  pulmonary  circulation  vasoconstriction  occurs  (Aaronson  et  al.,  2006).  
Hypoxic  pulmonary  vasoconstriction  (HPV)  is  thought  to  be  an  adaptive 
mechanism, unique to the vessels of the lungs.  HPV is greatest in resistance 
pulmonary  arteries  (200-300   m  diameter).    In  contrast,  large  pulmonary 
arteries  behave  like  systemic  arteries,  relaxing  in  response  to  hypoxic 
conditions.  HPV appears to be an intrinsic property of pulmonary artery smooth 
muscle cells (PASMCs) (Murray et al., 1990, Yuan et al., 1990) and is important 
in  redirecting  blood  flow  from  poorly  ventilated  areas  of  the  lung  to  better 
ventilated  areas,  maximising  oxygenation  of  pulmonary  venous  blood   6 
(Mandegar et al., 2004, Moudgil et al., 2005).  The mechanisms of HPV are not 
fully  understood  but  appear  to  involve  the  coordinated  inhibition  of  voltage-
gated K
+ (Kv) channels and activation of voltage-gated L-type calcium channels 
in  resistance  PASMCs  (Weir  et  al.,  2005).    Furthermore,  mitochondrial 
generation  of  reactive  oxygen  species  (ROS)  have  been  implicated  in  the 
mechanism of HPV.  However, controversy exists as to whether an increase or 
decrease in ROS production occurs in response to hypoxia (Weissmann et al., 
2006). 
 
1.3   PATHOBIOLOGY OF PAH 
 
Pulmonary hypertension is a disease of the small pulmonary arteries, resulting 
from the combined effects of pulmonary vasoconstriction, vascular remodelling 
and thrombosis (Gurbanov and Shiliang, 2006, Mandegar et al., 2004).  These 
processes contribute to the increases in PVR and PAP witnessed in patients 
with PAH, putting excessive burden on the right ventricle due to the increased 
workload  required  to  compensate  for  elevated  downstream  pressure,  and 
eventually results in right-sided heart failure (Mandegar et al., 2004, Humbert et 
al., 2004).  The pathogenesis of PAH is complicated and multifactorial. 
 
1.3.1  PULMONARY VASOCONSTRICTION IN PAH 
 
Pulmonary  vasoconstriction  is  a  main  contributing  factor  to  PVR  and  thus 
elevated PAP.  Hypoxia plays a major role in vasoconstriction during PAH.  For 
instance, in patients with conditions such as COPD and high altitude pulmonary 
edema,  sustained  alveolar  hypoxia  results  in  vasoconstriction  of  pulmonary 
vessels  and  vascular  remodelling  leading  to  the  development  of  PAH 
(Mandegar et al., 2004).  Excessive pulmonary vasoconstriction has also been 
related  to  abnormal  K
+  channel  functions  and/or  expression  as  well  as 
endothelial dysfunction and calcium sensitisation (Moudgil et al., 2005). 
   7 
ROLE OF K
+ CHANNELS IN PULMONARY VASOCONSTRICTION    
 
K
+ channels play an important role in the regulation of pulmonary vascular tone 
(Nelson et al., 1990).  Inhibition of K
+ channels depolarises PASMCs, resulting 
in  the  opening  of  voltage-gated  Ca
2+  channels,  increasing  cytoplasmic  Ca
2+ 
levels (Nelson et al., 1990, Yuan, 1995), which may trigger pulmonary artery 
vasoconstriction.  Indeed, blockade of Kv channels using 4-aminopyridine has 
been  found  to  cause  pulmonary  vasoconstriction  (Hasunuma  et  al.,  1991).  
Hypoxia also inhibits K
+ currents and depolarises PASMC membranes (Post et 
al., 1992, Yuan et al., 1993), suggesting a role for K
+ channels in mediating 
HPV .  Certain K
+ channels are sensitive to O2 levels as they possess cysteine 
and methionine  groups  which  are  subject  to  reduction  or  oxidation  by  redox 
mediators, such as reactive oxygen species (Moudgil et al., 2005).  
 Some Kv 
channels, such as the Kv1.5 channel, respond to redox mediators by altering 
their gating and open-state probability (Archer et al., 2004).  Oxidants, including 
H2O2, increase potassium currents in PASMCs, whereas reducing agents inhibit 
them  (Reeve  et  al.,  1995).    The  redox  theory  of  HPV  suggests  that  under 
normoxic conditions, there is basal production of reactive oxygen species, such 
as H2O2 by the electron transport chain of PASMC mitochondria maintaining the 
Kv current (Archer et al., 1986, Reeve et al., 1995).  However, this mechanism 
is  upset  during  hypoxic  conditions,  resulting  in  the  decreased  production  of 
H2O2 inhibiting Kv channels and resulting in activation of voltage gated L-type 
Ca
2+  channels,  which  subsequently  increases  intracellular  Ca
2+  levels  and 
induces HPV (Moudgil et al., 2005, Moudgil et al., 2006) (Figure 1.1).  Several 
O2-sensitive Kv channels may be involved in mediating HPV, including Kv1.5 
(Archer et al., 1998, Archer et al., 2001), Kv2.1 (Archer et al., 1998, Patel et al., 
1997)  and  possibly  Kv1.2  (Hulme  et  al.,  1999)  and  Kv3.1b  (Osipenko  et  al., 
2000).  For instance, in mice deficient in Kv1.5, HPV is markedly attenuated 
(Archer  et  al.,  2001).    Indeed,  Kv1.5  channels  have  been  found  to  be 
downregulated in PASMCs from patients with PAH (Yuan et al., 1998), as have 
both  Kv1.5  and  Kv2.1  channels  in  rats  with  chronic  hypoxia-induced  PAH 
(Michelakis et al., 2002b).   
   8 
ROLE OF INTRACELLULAR Ca
2+ HOMEOSTASIS IN PULMONARY 
VASOCONSTRICTION  
 
Intracellular  Ca
2+  plays  an  essential  role  in  pulmonary  vasoconstriction,  with 
both extracellular calcium influx and release of intracellular calcium from the 
sarcoplasmic  reticulum  involved  in mediating  HPV  (Salvaterra and  Goldman, 
1993, Gelband and Gelband, 1997).  Smooth muscle contraction is initiated by 
an  elevation  in  intracellular  free  calcium  concentration  ([Ca
2+]i).    Calmodulin 
(CaM), an intracellular Ca
2+-binding protein, binds to Ca
2+ as [Ca
2+]i rises.  The 
resulting  CaM/Ca
2+  complex  then  binds  to  and  activates  myosin  light  chain 
kinase (MLCK) leading to phosphorylation of the myosin light chain (MLC) of the 
contractile  apparatus.    This  process  stimulates  the  activation  of  the  myosin 
ATPase, hydrolysing ATP to generate energy for the cycling of myosin cross-
bridges with actin filaments.  The formation of these cross bridges brings about 
smooth muscle contraction, resulting in vasoconstriction (Somlyo and Somlyo, 
1994) (Figure 1.2). 
[Ca
2+]i is elevated in PASMCs exposed to hypoxia (Salvaterra and Goldman, 
1993, Wang et al., 2005, Bakhramov et al., 1998, Cornfield et al., 1993).  This 
hypoxia-induced increase in [Ca
2+]i results in PASMC contraction (Murray et al., 
1990,  Leach  et  al.,  1994,  Jin  et  al.,  1992).  Furthermore,  hypoxia  triggers 
increases  in  [Ca
2+]i    and  contraction  in  small  intrapulmonary  arteries  that  is 
sustained  during  the  hypoxic  period  and  reversed  on  return  to  normoxia 
(Robertson  et  al.,  2000b).    Several  studies  have  reported  the  predominant 
source  of  Ca
2+  contributing  to  elevated  [Ca
2+]i  during  hypoxic  conditions  is 
extracellular and enters PASMCs via the voltage-gated L-type calcium channel 
(Bakhramov et al., 1998, Cornfield et al., 1993).  Inhibition of these channels 
has been shown to attenuate hypoxic responses in pulmonary arteries (Jin et 
al.,  1992,  Leach  et  al.,  1994)  and  HPV  in  isolated  lungs  and  intact  animals 
(Redding et al., 1984, Stanbrook et al., 1984, Simonneau et al., 1981, McMurtry 
et al., 1976). 
In addition to this, the release of calcium from intracellular stores has also been 
proposed to mediate HPV.  Gelband and Gelband (1997) reported that in rat 
pulmonary  arteries,  the  initial  event  in  HPV  is  the  release  of  Ca
2+  from 
intracellular stores, resulting in elevated [Ca
2+]i and increased pulmonary artery   9 
tone.    Furthermore,  in  canine  pulmonary  arteries,  release  of  Ca
2+  from  the 
sarcoplasmic reticulum was found to contribute significantly to HPV (Jabr et al., 
1997).    Depletion  of  Ca
2+  stores  have  also  been  shown  to  abolish  hypoxic 
responses  in  PASMCs  (Dipp  et  al.,  2001).    Similarly,  release  of  intracellular 
calcium,  from  ryanodine-sensitive  stores  contributes  significantly  to  HPV  in 
perfused lungs (Morio and McMurtry, 2002). 
Entry of Ca
2+ via store-operated Ca
2+ channels (SOCCs) may also be important 
in mediating HPV.  As mentioned previously, in PASMC under acute hypoxic 
conditions, release of Ca
2+ from intracellular stores has been observed resulting 
in increased [Ca
2+]i .  In some instances this has been reported to enhance 
capacitative Ca
2+ entry via SOCCs (Kang et al., 2003, Ng et al., 2005) and may 
therefore contribute to HPV.  Furthermore, in another study where intracellular 
Ca
2+  stores  were  depleted  and  voltage-gated  L-type  Ca
2+  channels  blocked, 
hypoxia still resulted in an increase in [Ca
2+]i.  This was attributed to the ability 
of  acute  hypoxia  to  enhance  Ca
2+  entry  via  SOCCs  (Wang  et  al.,  2005).  
Chronic hypoxia has also been found to upregulate members of the canonical 
transient receptor potential channel (TRPC) gene family (TPRC1 and TPRC6) 
in  pulmonary  arteries,  resulting  in  increased  expression  of  SOCCs  and 
receptor-operated Ca
2+ channels (ROCs) in PASMCs.  The enhanced activity of 
these  channels  under  hypoxic  conditions  contributes  to  elevated  [Ca
2+]i  and 
increased  pulmonary  vascular  tone  (Lin  et  al.,  2004)  (Figure  1.3).    Further 
highlighting the role of intracellular Ca
2+ release in mediating HPV, cyclic ADP 
ribose, which acts on ryanodine receptors to stimulate intracellular Ca
2+ release, 
is elevated by hypoxia in small pulmonary arteries.  Moreover, contraction to 
hypoxia in these arteries was completely suppressed by using a cyclic ADP 
ribose antagonist (Wilson et al., 2001). 
Smooth muscle cell contraction is dependent not only on [Ca
2+]i but also on the 
Ca
2+ sensitivity of the contractile apparatus (Morgan, 1987).  Under conditions 
of agonist-mediated contraction, Ca
2+ sensitisation can occur.  For example, in 
permeabilised  SMCs,  agonists  can  enhance  the  force  of  contraction  when 
intracellular Ca
2+ remains constant (Kitazawa et al., 1989).  One mechanism of 
Ca
2+  sensitisation  suggests  altered  relations  between myosin  regulatory  light 
chain  phosphorylation  and  intracellular  Ca
2+,  involving  the  MLCK  or 
phosphatase  cascades  (de  Lanerolle  and  Paul,  1991).    Another  possible   10 
mechanism  of  sensitisation  involves  alterations  in  Ca
2+  affinity  of  regulatory 
proteins such as caldesmon and calponin.  These proteins are associated with 
thin filaments and inhibit actin-myosin interaction, a process attenuated by Ca
2+ 
(Winder  et  al.,  1998).    Ca
2+  sensitisation  also  occurs  in  pulmonary  arteries 
under hypoxic condition.  During sustained HPV, force development continues 
to  increase  while  [Ca
2+]i  attains  a  constant  level  (Robertson  et  al.,  1995, 
Robertson  et  al.,  2003).    In  addition  to  this,  Rho-associated  kinase  (ROCK) 
inhibition has been shown to suppress sustained HPV in pulmonary arteries and 
perfused  lung  (Robertson  et  al.,  2000a).    Furthermore,  ROCK  has  been 
proposed  to  contribute  to  sustained  HPV  by  mediating  Ca
2+  sensitisation  in 
pulmonary arteries (Nagaoka et al., 2004).  
   
ROLE OF REACTIVE OXYGEN SPECIES IN PULMONARY 
VASOCONSTRICTION 
 
HPV  is  an  important  physiological  response  of  the  lung  to  alveolar  hypoxia, 
required to redistribute pulmonary blood flow from areas of low oxygen to high 
oxygen  availability.    However,  the  underlying  oxygen  sensing  and  signal 
transduction  mechanisms  of  HPV  remain  unclear.    Several  studies  have 
reported  that  inhibition  of  the  mitochondrial  electron  transport  chain  (ETC) 
specifically  inhibits  HPV  (Michelakis  et  al.,  2002a,  Weissmann  et  al.,  2003, 
Waypa et al., 2001).  These findings suggest a role for mitochondria as oxygen 
sensors for HPV.  Two conflicting hypotheses have developed concerning a role 
for mitochondria in HPV.  (1)  The redox hypothesis of HPV suggests that a 
decrease  in  mitochondrial  ROS  occurs  during  hypoxia,  shifting  the  cellular 
redox balance towards a more reduced state.  As mentioned previously, this 
can result in the inhibition and closure of Kv channels, a process mediated by 
the redox pairs GSH/GSSG and NADH/NAD (Moudgil et al., 2005, Michelakis et 
al.,  2002c).    (2)    In  direct  contrast  to  this,  a  hypoxia-induced  increase  in 
mitochondrial ROS production has also been reported.  This increase in ROS is 
thought to mediate HPV by triggering intracellular calcium release (Waypa et 
al., 2001, Waypa and Schumacker, 2005). 
In support of the former hypothesis, rotenone and antimycin A (inhibitors of the 
proximal  region  of  the  ETC),  were  shown  to  mimick  the  effects  of  HPV  in   11 
isolated  pulmonary  arteries  and  PASMCs,  decreasing  ROS  production  and 
subsequently resulting in the inhibition of potassium channels (Michelakis et al., 
2002a).  Furthermore, under normoxic conditions, pharmacological inhibition of 
the ETC proximal to complexes II and III (sites of mitochondrial ROS release) 
resulted in a reduction in ROS production and an increased pulmonary artery 
pressure (Michelakis et al., 2004).  Taken together these findings suggest a 
decrease in mitochondrial-produced ROS mediates HPV. 
On the other hand, others have provided evidence that increased ROS release 
from ETC complex III occurs under hypoxic conditions in isolated rat lung, and 
that this increase in ROS mediates HPV (Waypa et al., 2001).  Furthermore, 
inhibition of the proximal region of the ETC was found to attenuate hypoxia-
induced constriction in PASMCs by decreasing intracellular Ca
2+ levels (Waypa 
et al., 2002).  Conversely, hypoxia has been reported to trigger increases in 
[Ca
2+]i by augmenting ROS signalling from mitochondria (Waypa et al., 2006). 
Therefore, these findings suggest an increase in mitochondrial-produced ROS 
mediates HPV by facilitating increases in [Ca
2+]i. 
NAD(P)H-oxidases, enzymes that function to generate superoxide, have also 
been  proposed  as  possible  oxygen  sensors  of  HPV.    Again,  two  conflicting 
concepts exist as to the contribution of NAD(P)H-oxidase-derived superoxide in 
HPV,  with  one  reporting  an  upregulation  and  another  reporting  a 
downregulation  of  superoxide.    Reports  that  NADPH-oxidase  is  activated  in 
response to hypoxia in PASMCs (Marshall et al., 1996), and that the generation 
of  superoxide  and  subsequent  formation  of  H2O2  are  required  for  HPV  in 
perfused rabbit lung (Weissmann et al., 1998), suggest that NADPH-mediated 
increases in superoxide are required to mediate HPV.  Increased superoxide 
generation  and  an  increased  expression  of  NADPH-oxidase  has  also  been 
observed  in  pulmonary  arteries  from  pulmonary  hypertensive  fetal  lambs 
(Brennan  et  al.,  2003).    The  hypothesis  that  NADPH-mediated  superoxide 
production  contributes  to  HPV  is  further  confirmed  by  the  ability  of  NADPH-
oxidase inhibitors to attenuate HPV in intact lungs (Weissmann et al., 2000).  
But,  it  has  also  been  suggested  an  NADPH-oxidase-mediated  decrease  in 
superoxide  occurs  during  HPV  (Wolin  et  al.,  1999).    Several  studies  have 
reported  decreases  in  superoxide  and  H2O2  generation  under  hypoxic 
conditions. This has been suggested to attenuate the cellular levels of cyclic   12 
guanosine 3’, 5’ monophosphate (cGMP) due to reduced stimulation of soluble 
guanylyl cyclase and thus results in vasoconstriction (Burke-Wolin and Wolin, 
1989, Burke-Wolin and Wolin, 1990, Cherry et al., 1990, Wolin et al., 1999).   
In summary, while ROS play a key role in mediating pulmonary vascular tone in 
hypoxia, there is no consensus as to whether ROS are increased or decreased 
under hypoxic conditions. 
 
ROLE OF ENDOTHELIAL DYSFUNCTION IN PULMONARY  
VASOCONSTRICTION 
 
Endothelial dysfunction results in an imbalance in the production of vasodilatory 
and vasoconstrictive agents.  In PAH an insufficient level of vasodilators such 
as nitric oxide (NO) and prostacyclin, in addition to an increase in the production 
of vasoconstrictors such as endothelin-1 (ET-1), favours the vasoconstriction of 
pulmonary arteries.  For instance, prostacyclin synthesis has been found to be 
decreased in endothelial cells from patients with PAH due to a reduction in the 
expression of prostacyclin synthase, the enzyme responsible for its synthesis 
(Christman et al., 1992, Tuder et al., 1999).  Endothelium-derived vasodilators 
are  further  decreased  in  PAH  by  the  reduction  of  endothelial  NO  synthesis 
(eNOS) expression, reported in endothelial cells of patients (Giaid and Saleh, 
1995).    In  addition  to  this,  vasoactive  interstitial  peptide  (VIP),  a  potent 
pulmonary vasodilator, has also been found to be reduced in serum from PAH 
patients  (Petkov  et  al.,  2003).    To  further  contribute  to  the  vasoconstrictive 
environment,  increased  levels  of  ET-1,  which  induces  vasoconstriction,  have 
been reported in both animal models and patients with PAH (Giaid et al., 1993).  
It can therefore be seen that endothelial dysfunction results in an imbalance of 
endothelium-derived mediators, favouring vasoconstriction and contributing to 
the pathobiology of PAH.    13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1  The role of potassium channel activity in mediating hypoxic 
pulmonary vasoconstriction.   
Normoxia  is  associated  with  open,  oxidised  Kv  channels.    Under  hypoxic 
conditions,  Kv  channels  become  reduced,  resulting  in  their  closure  and 
membrane depolarisation.  This facilitates the opening of voltage-gated L-type 
Ca
2+  channels.    Ca
2+  influx  via  these  channels  elevates  intracellular  Ca
2+ 
concentrations, resulting in vasoconstriction.  Oxidising compounds mimic the 
effects of normoxia, while reducing agents mimic the effects of hypoxia.   14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2  Signal transduction mechanisms mediating contraction of vascular smooth muscle. 
The level of free intracellular calcium (Ca
2+) is a major determinant of smooth muscle contraction.  As free intracellular calcium 
(Ca
2+) rises, it binds and forms a complex with calmodulin (CaM).  The Ca
2+/CaM complex then activates myosin light chain kinase 
(MLCK), which subsequently phosphorylates the myosin light chain (MLC).  This stimulates myosin ATPase activity and promotes 
crossbridge cycling with actin filaments.  The formation of these crossbridges underlies smooth muscle cell contraction and results 
in vasoconstriction. 
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Figure 1.3 Diagram of the proposed mechanisms contributing to increased intracellular Ca
2+ concentrations and hypoxic 
pulmonary vasoconstriction (HPV). 
Hypoxia results in decreased activity of Kv channels and membrane depolarisation, thereby initiating the opening of L-type Ca
2+ 
channels and allowing Ca
2+ influx.  Intracellular Ca
2+ is also elevated by the hypoxic activation of receptor-operated Ca
2+ channels 
(ROC) and store-operated Ca
2+ channels (SOCC).  In addition, hypoxia induces calcium release from intracellular stores in the 
sarcoplasmic reticulum, further elevating intracellular Ca
2+.  The depletion of these stores is also thought to contribute to the 
activation of SOCC.    16 
1.3.2  PULMONARY VASCULAR REMODELLING 
 
Vascular remodelling is a term often used to describe structural and functional 
alterations to blood vessels, allowing them to function more effectively.  It is an 
adaptive  process  which  occurs  in  response  to  long-term  changes  in 
haemodynamic  conditions  that  occur  during  development  (Mulvany  et  al., 
1996).    However,  the  process  can  contribute  to  the  pathobiology  of  various 
vascular diseases, including PAH. 
Under normal conditions the diameter of the pulmonary artery wall is maintained 
by  a  balance  between  proliferation  and  apoptosis  of  pulmonary  artery 
fibroblasts  (PAFs),  PASMCs  and  pulmonary  artery  endothelial  cells  (PAECs) 
(Gurbanov and Shiliang, 2006, Mandegar et al., 2004).  In PAH this balance is 
disrupted in the favour of proliferation, resulting in an increase in the thickness 
of the artery wall and a narrowing of the vessel lumen which eventually results 
in  its  complete  occlusion.    These  structural  changes  result  in  the  loss  of 
vascular compliance and are responsible for the increase in PVR observed in 
PAH  patients  (Mandegar  et  al.,  2004,  Gurbanov  and  Shiliang,  2006).  
Pulmonary vascular remodelling can be initiated by a variety of stimuli, including 
anorectic drugs, collagen vascular disease and chronic hypoxia (Mandegar et 
al., 2004).  This process involves all layers of the vessel wall and is complicated 
by the cellular heterogeneity that exists within the pulmonary artery wall (Jeffery 
and Morrell, 2002) (Figure 1.4).   
 
CONTRIBUTION  OF  PULMONARY  ARTERY  SMOOTH  MUSCLE  CELLS 
(PASMCs) TO VASCULAR REMODELLING 
 
Common to the pathogenesis of all forms of human PAH is an increase in the 
thickness  of  the  medial  layer  of  muscular  pulmonary  arteries  and  the 
muscularisation of distal, previously non-muscular pulmonary arteries (Humbert 
et  al.,  2004,  Stenmark  and  Mecham,  1997,  MacLean  et  al.,  2000).    The 
increased  thickness  of  the  medial  compartment  is  due  to  hypertrophy  and 
proliferation  of  SMCs  and  the  increased  synthesis  and  deposition  of  matrix 
proteins including elastin and collagen (Stenmark and Mecham, 1997).  The   17 
muscularisation  of  previously  non-muscular  arteries  may  be  due  to  the 
differentiation and hypertrophy of intermediate cells and pericytes present in the 
vessel  wall,  which  acquire  a  smooth  muscle  like  appearance  (Meyrick  and 
Perkett, 1989, Durmowicz and Stenmark, 1999) .  During PAH, changes in the 
phenotype  of  PASMCs  occur,  which  contribute  to  the  process  of  vascular 
remodelling.  For instance, PASMCs taken from patients with PAH have been 
shown  to  have  increased  proliferative  capabilities  (Eddahibi  et  al.,  2001).  
Furthermore, it has also been suggested that smooth muscle cells (SMCs) may 
contribute to intimal thickening and neointima formation by migrating from the 
media to the subendothelial layer, where they change phenotype from contactile 
to synthetic and secrete excessive extracellular matrix proteins (Olschewski et 
al.,  2001).    In  addition  to  this,  the  pulmonary  artery  is  composed  of 
phenotypically  diverse  SMC  populations  (Frid  et  al.,  1994).    These 
subpopulations exhibit different proliferative responses to hypoxia-induced PAH, 
a property that be may important in the process of medial remodelling (Wohrley 
et al., 1995)(Figure 1.4). 
 
CONTRIBUTION  OF  PULMONARY  ARTERY  FIBROBLASTS  (PAFs)  TO 
VASCULAR REMODELLING 
 
Fibroblasts also play an important role in vascular remodelling.  Located in the 
adventitial  compartment,  fibroblasts  proliferate,  hypertrophy  and  increase 
production of extracellular matrix proteins (Stenmark et al., 2002, Stenmark and 
Mecham, 1997).  The most dramatic structural changes occur in the adventitia 
of small pulmonary arteries as a result of these processes (Stenmark et al., 
1987, Murphy et al., 1981, Durmowicz et al., 1994).  The pulmonary vasculature 
appears to contain multiple, functionally distinct subpopulations of fibroblasts.  
These subpopulations have marked differences in morphology and proliferative 
capabilities and this may play a crucial role in regulating vascular remodelling 
(Das et al., 2002).  Unlike, SMCs, hypoxia induces proliferation in pulmonary 
artery  fibroblasts  in  the  absence  of  exogenous  growth  factors  (Falanga  and 
Kirsner, 1993, Storch and Talley, 1988).  Furthermore, fibroblasts have been 
observed  to  proliferate  earlier  and  have  a  greater  response  to  hypoxia  than 
endothelial or SMCs (Belknap et al., 1997).  In addition to an increase in the   18 
number of fibroblasts in the adventitial layer of hypoxic pulmonary arteries, a 
large increase in matrix protein deposition has been observed, with increases in 
collagen, elastin and tropoelastin reported (Durmowicz et al., 1994).  Fibroblasts 
have also been shown undergo changes in cytoskeletal and contractile protein 
expression,  significantly  altering  their  function.    This  process  results  in  the 
expression of α-smooth muscle actin within the cells, suggesting conversion to 
myofibroblasts, which may contribute to the development of PAH (Short et al., 
2004).  The hypoxic activation of fibroblasts may also have some bearing on the 
increase in SMC proliferation observed in PAH (Rose et al., 2002).  Moreover, 
fibroblasts have been proposed to migrate to the medial and intimal layers of 
pulmonary vessels during PAH contributing to neointimal formation (Humbert et 
al., 2004) (Figure 1.4). 
 
CONTRIBUTION OF PULMONARY ARTERY ENOTHELIAL CELLS (PAECs) 
TO VASCULAR REMODELLING 
 
In chronic hypoxic PAH, increases in intimal thickness occur due to hypertrophy 
and hyperplasia in both the endothelial and sub-endothelial layers (Stenmark 
and Mecham, 1997).  Plexiform lesions occur in a large percentage of patients 
with PAH  (Tuder et al., 1994).  These lesions originate in small precapillary 
vessels  usually  at  blood  vessel  bifurications  (Stevens,  2005).    Increases  in 
endothelial cell proliferation contribute to the formation of such lesions (Tuder et 
al., 1994, Voelkel and Tuder, 1995) and in some instances plexiform lesions 
occur as a result of monoclonal endothelial cell proliferation (Lee et al., 1998a).  
Plexiform lesions grow into the vessel resulting in lumen occlusion (Stevens, 
2005).    Enothelial  cells  within  these  lesions  have  a  pro-proliferative,  anti-
apoptotic  phenotype  and  no  longer  grow  in  a  monolayer,  with  the  resulting 
intravascular  growth  resembling  a  tumour  (Tuder  et  al.,  2001).      Other 
abnormalities  have  been  observed  in  the  endothelial  cells  of  these  lesions 
compared  to  normal  pulmonary  endothelial  cells  (Loscalzo,  1992).    For 
example, a decreased production of vasodilators (Tuder et al., 1999, Giaid and 
Saleh, 1995)  and increased production of vasoconstrictors have been reported 
(Giaid  et  al.,  1993).    Furthermore,  these  endothelial  cells  also  express  pro-
angiogenic  molecules  such  as  vascular  endothelial  derived  growth  factor   19 
(VEGF) and VEGF receptor (VEGFR), which may contribute to cell proliferation 
and  vascular  remodelling  (Tuder  and  Voelkel,  2001).    Changes  in  surface 
coagulant properties and proinflammatory cytokine production have also been 
observed in endothelial cells from PAH patients.  For instance, under hypoxic 
conditions, thrombomodulin production is suppressed and procoagulant activity 
increased  (Ogawa  et  al.,  1990).    Furthermore,  hypoxia  also  increases 
interleukin-1α  (IL-1α)  production  by  endothelial  cells  and  upregulates 
endothelial-leukocyte adhesion molecule-1 (ELAM-1) and intracellular adhesion 
molecule-1  (ICAM-1)  on  the  cell  surface  (Shreeniwas  et  al.,  1992).    This 
suggests  hypoxia  induces  changes  in  the  endothelial  layer  promoting 
coagulation  and  increasing  the  interaction  of  endothelial  cell  with  circulating 
inflammatory  cells.    In  support  of  this  hypothesis,  increased  adherence  of 
leukocytes and platelets has been observed in in vivo models of PAH (Hung et 
al.,  1986).    Increased  inflammatory  infiltrates  have  also  been  observed  in  a 
variety of plexiform lesions (Balabanian et al., 2002).  Recently, it has also been 
proposed  that  PAECs  may  contribute  to  vascular  remodelling  under  chronic 
hypoxic conditions by transdifferentiating into smooth muscle-like cells (Zhu et 
al., 2006).  This may be an alternative explanation for the muscularisation of 
previously non-muscular vessels in the process of PAH (Figure 1.4). 
 
ROLE OF APOPTOSIS IN VASCULAR REMODELLING 
 
Apoptosis,  or  programmed  cell  death,  is  a  fundamental  biological  function 
involved in many physiological and pathological processes.  It can be defined as 
a well ordered form of cell death comprised of a regulated sequence of events, 
resulting in removal of cell material without the release of harmful substances to 
surrounding  tissue  (Renehan  et  al.,  2001).    In  PAH  the  balance  between 
proliferation  and  apoptosis  is  disturbed.    In  PASMCs,  increased  proliferation 
and decreased  apoptosis  contribute  to the  thickening  of  the  vessel  wall  and 
vascular remodelling (Stenmark and Mecham, 1997, Mandegar et al., 2004).  
Several  lines  of  investigation  implicate  decreases  in  apoptosis  in  the 
development and maintenance of PAH.  For instance, PASMCs from patients 
with PAH have been shown to be resistant to apoptotic inducers such as BMP -
2,  5  and  7  (Zhang  et  al.,  2003).    Furthermore,  a  reduction  in  Kv  channel   20 
expression  and  function  in  PASMCs  attenuates  programmed  cell  death  by 
decelerating  apoptotic  volume  decrease  (AVD)  and  inhibiting  cytoplasmic 
caspases (Zhang et al., 2003).  The anti-apoptotic protein Bcl-2 has also been 
reported to be increased in the lungs of PAH patients.  Further highlighting the 
role of apoptosis in pulmonary vascular remodelling, the induction of apoptosis 
in models of PAH has been found to result in the regression of hypertrophied 
PASMCs (Cowan et al., 1999, Rabinovitch, 1998)(Figure 1.4). 
 
1.3.3  VASCULAR THROMBOSIS 
 
Thrombosis often occurs in the pulmonary arterioles of many PAH patients and 
may  result  from  injury  to  the  endothelium,  abnormal  fibrinolysis,  enhanced 
procoagulant activity and platelet abnormalities (Humbert et al., 2004, Veyssier-
Belot and Cacoub, 1999, Herve et al., 2001).  Indeed, decreased fibrinolytic 
activity has been observed in the plasma of patients with PAH  (Welsh et al., 
1996, Frank et al., 1997).  Furthermore, the endothelium plays an important role 
in regulating coagulation.  The decrease in production of prostacyclin and NO 
by endothelial cells of PAH patients is likely to contribute to thrombosis as both 
of  these  mediators  inhibit  platelet  aggregation  (Moncada  and  Vane,  1979, 
Moncada  et  al.,  1991).    Moreover,  the  production  of  thrombomodulin,  a  co-
factor  produced  by  endothelial  cells  that  binds  and  inactivates  thrombin  to 
attenuate coagulation, is significantly decreased in individuals with PAH (Welsh 
et al., 1996).  The imbalance in the level of pro- and anti-coagulant factors in the 
favour of coagulation contributes to thrombus formation in PAH patients (Figure 
1.4). 
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Figure  1.4    Schematic  diagram  of  how  individual  pathophysiological  components  contribute  to  increased  pulmonary 
vascular resistance and pulmonary artery pressure during pulmonary hypertension. 
Changes in cellular function within the wall of pulmonary arteries contribute to pulmonary vascular remodelling, vasoconstriction 
and thrombosis, leading to increased pulmonary vascular resistance (PVR) and pulmonary artery pressure (PAP), characteristic of 
pulmonary hypertension.  Figure adapted from Mandegar et al., (2004).   22 
1.3.4  MEDIATORS OF PAH 
 
Given  the  multifactorial  pathobiology  of  PAH,  various  mediators  have  been 
implicated in the development and progression of the disease.  Several factors 
mentioned  previously,  which  affect  vascular  tone,  also  promote  vascular 
remodelling  e.g.  ET-1  and  Kv  channels  (Mandegar  et  al.,  2004).    Genetic 
factors,  such  as  mutations  in  the  BMPR-2  gene  also  contribute  to  the 
development of the condition, however in most cases PAH is not attributed to 
inherited genetic mutations (Thomson et al., 2000).   Therefore, other external 
stimuli play a major role in contributing to the development of PAH.  Some of 
the key mediators involved in the development and maintenance of PAH are 
described below. 
 
ROLE  OF  THE  TRANSFORMING  GROWTH  FACTOR-β  (TGF-β) 
SUPERFAMILY  AND  SIGNALLING  PATHWAYS  IN  VASCULAR 
REMODELLING 
 
The TGF-β superfamily of structurally related cytokines includes TGF-β, BMPs 
and activins.  The TGF-β superfamily members induce a multitude of effects 
such as cell differentiation, proliferation, migration and apoptosis in a variety of 
cell types (Roberts and Sporn, 1993). As mentioned previously, mutations in the 
BMPR-2 gene have been associated with the pathogenesis of PAH, as have 
somatic mutations in the TGF-β type 1 receptor (TGF-βR1) and abnormalities in 
TGF-β signalling (Yeager et al., 2001, Richter et al., 2004).    Briefly, signal 
transduction of TGF-β superfamily receptor ligands requires the ligand-induced 
formation  of  heteromeric  complexes  of  type  1  and  type  2  transmembrane 
serine/threonine  kinase  receptors  (Derynck  and  Zhang,  2003).    Different 
receptor combinations allow for differential ligand binding properties and diverse 
signalling responses to the same ligand (Derynck and Zhang, 2003). Ligand 
binding induces the phosphorylation of the GS segment in the type 1 receptor 
by the type 2 receptor kinases.  The active type 1 receptor then phosphorylates 
the  receptor-activated  mothers  against  decapentaplegic  (R-Smad)  proteins.  
Activated  R-Smads  can  then  dimerise  with  a  common  mediator-Smad  (Co-  23 
Smad)  to form  a  signalling  complex  capable  of  translocating  to  the  nucleus, 
resulting in the transcription of Smad-responsive genes, some of which encode 
anti-proliferative and pro-apoptotic proteins (Derynck and Zhang, 2003) (Figure 
1.5).    The  BMPR-2  receptor  has  been  documented  to  interact  with  three 
different  type  1  receptors  (ALK-2, ALK-3  and  ALK-6)  and  signals  via  the  R-
Smads, Smad 1,5 and 8 (Derynck and Zhang, 2003, Moustakas et al., 2001) 
(Figure 1.5).  
The  exact  mechanisms  as  to  how  BMPR-2  and  TGF-β  mutations  and 
alterations in signalling pathways contribute to vascular remodelling in PAH are 
not  fully  understood,  but  it  is  thought  they  have  a  negative  effect  on  pro-
apoptotic Smad complexes.  In normal human PASMCs, treatment with BMPs 
results in increased apoptosis and a reduction in levels of the anti-apoptotic 
protein Bcl-2, thereby triggering the release of cytochrome C from mitochondria 
and activating caspases 3, 8 and 9 (Lagna et al., 2006, Zhang et al., 2003).  
However,  in  cells  taken  from  patients  with  PAH,  BMP-induced  apoptosis  is 
significantly  attenuated  (Zhang  et al., 2003,  Yang  et  al., 2005, Lagna  et al., 
2006).    These  cells  displayed  mutations  in  the  kinase  domain  or  carboxy-
teminus  of  BMPR-2  and  were  also  found  to  be  deficient  in  Smad  signalling 
(Lagna et al., 2006, Yang et al., 2005, Zhang et al., 2003).  Loss of function 
mutants  in  BMPR-2  have  also  been  reported  to  contribute  to  increased 
endothelial cell survival and decreased apoptosis (Teichert-Kuliszewska et al., 
2006).    In  addition  to  this,  in  the  monocrotaline-rat  model  of  PAH,  TGF-β 
receptor (TGF-βR) 1 and TGF-βR2, as well as Smad 3 and 4, were all found to 
be reduced in the lung and PASMCs, resulting in decreased TGF-β-induced 
signalling  and  apoptosis  (Zakrzewicz  et  al.,  2007).  Furthermore,  in  mice 
developed to incorporate an inducible dominant-negative mutant of the TGF-
βR2  receptor,  chronic  hypoxia-induced  pulmonary  hypertension  was 
significantly attenuated (Chen et al., 2006).   
TGF-β  activity  may  also  influence  other  factors  implicated  in  vascular 
remodelling.  For instance, TGF-β induces ET-1 production in human pulmonary 
arteries (Markewitz et al., 2001), as well as stimulating connective tissue growth 
factor (CTGF) production in pulmonary fibroblasts (Kucich et al., 2001).  These 
findings suggest a role for the TGF-β superfamily of receptors and downstream 
signalling cascades in the development of pulmonary hypertension, and also   24 
highlight the requirement for a balance between apoptosis and proliferation in 
the maintenance of a healthy vascular system. 
 
POTASSIUM CHANNELS AND VASCULAR REMODELLING 
 
As  mentioned  previously,  Kv  channels  play  an  important  role  in  mediating 
vasoconstriction during PAH.  The downregulation of Kv1.5 and Kv2.1 channels 
that  occurs  during  PAH  also  play  a  significant  role  in  pulmonary  vascular 
remodelling.    Chronic  decreases  in  K
+  channel  expression  induces  PASMC 
proliferation and hypertrophy (Mandegar et al., 2004). This is thought to occur 
as loss of Kv current depolarises the cell membrane resulting in the intracellular 
accumulation  of  calcium,  with  the  Ca
2+/Calmodulin  complex  subsequently 
formed responsible for activating several steps of the cell cycle and thus favours 
cellular  proliferation  (Hardingham  et  al.,  1997).    In  addition  to  the 
downregulation of Kv channels contributing to proliferation, it also appears to 
have an effect on apoptotic processes.  Previously, activation of Kv channels 
has  been  reported  to  play  an  important  role  in  both  early  and  late  volume 
decrease associated with the induction of apoptosis (Platoshyn et al., 2002).  
Therefore, the downregulation of these channels in PAH has an inhibitory effect 
on apoptosis.  Furthermore, the resulting intracellular accumulation of K
+ ions 
due to the loss of Kv channels has been shown to inhibit caspases and thus 
decrease  apoptosis  (Thornberry  and  Lazebnik,  1998,  Bortner  and  Cidlowski, 
1999, Bortner et al., 1997).  In addition to this, survivin, a known inhibitor of 
apoptosis has been reported to be expressed in PAH, resulting in Kv channel 
downregulation in PASMCs (McMurtry et al., 2005).  Overexpression of survivin 
in  normal  PASMCs  promotes  proliferation  and  decreases  Kv  current.  
Conversly, treatment with a dominant negative survivin mutant was found to 
significantly increase Kv current  in PASMC from PAH patients and attenuate 
the effects of  experimental PAH in vivo (McMurtry et al., 2005). 
In  summary,  it  can  be  seen  that  Kv  channels  play  an  important  role  in 
maintaining  the  balance  between  apoptosis  and  proliferation  in  pulmonary 
smooth muscle cells, and that the downregulation of these channels in PAH tips 
the  balance  in  favour  of  proliferation  and  thus  contributes  to  vascular 
remodelling.    25 
ENDOTHELIUM-DERIVED FACTORS AND VASCULAR REMODELLING 
 
As mentioned previously, endothelial-derived factors play an important role in 
regulating vascular tone.  However, changes in the synthesis and expression of 
these mediators during PAH also contribute to vascular remodelling.  In addition 
to  its  potent  vasodilatory  effects  NO  also  has  anti-proliferative  capabilities.  
Therefore  its  reduction  in  PAH  may  be  a  factor  in  the  remodelling  process.  
Indeed, decreases in endothelial NOS (eNOS) expression were reported in the 
vascular endothelium of patients with PAH, with expression levels correlating 
inversely to the severity of the histological changes observed (Giaid and Saleh, 
1995).  Furthermore, in a hypoxic model of PAH, prolonged inhaled NO therapy 
resulted in a marked attenuation in the level of muscularised arteries and right 
ventricular hypertrophy (RVH) (Horstman et al., 1998).  Inhaled NO has also 
been  used  in  the  treatment  of  patients,  markedly  reducing  pulmonary  artery 
pressure and PVR (Channick et al., 1996). 
NO  mediates  it  effects  by  binding  to  and  activating  guanylyl  cyclase,  thus 
elevating intracellular levels of cGMP (Stasch et al., 2002).  Phosphodiesterase 
(PDE)  enzymes  are  important  in  regulating  the  cellular  levels  of  cGMP  and 
cyclic  3’,  5’  adenosine  monophosphate  (cAMP),  by  controlling  their  rates  of 
degradation  (Bender  and  Beavo,  2006).    Several  studies  have  reported  the 
upregulation of PDEs during PAH, including elevated levels of PDE1, 3 and 5 
(Schermuly et al., 2007, Murray et al., 2002, Murray et al., 2007, Maclean et al., 
1997).    Selective  inhibition  of  these  PDEs  has  been  found  to  have 
antiproliferative effects (Murray et al., 2007, Wharton et al., 2005) and reduce 
pulmonary  vascular  remodelling  (Schermuly  et  al.,  2004,  Schermuly  et  al., 
2007, Sebkhi et al., 2003, Garg et al., 2006). 
In  addition  to  its  vasoconstrictive  effects,  ET-1  acts  as  a  growth  factor 
(Yanagisawa,  1994)  and  has  been  found  to  play  a  crucial  role  in  vascular 
remodelling  during  PAH.    ET-1  predominantly  binds  to  two  receptors, 
endothelin-A  (ETA)  and  endothelin-B  (ETB)  receptors.  Responses  to  ET-1 
appear to be mainly via the ETA receptor subtype (Arai et al., 1990, Barnes and 
Liu, 1995).  ETA receptors are found on smooth muscle cells only and, when 
activated, induce vasoconstriction and cellular proliferation. ETB receptors on 
smooth muscle cells, when activated, cause vasoconstriction, whereas those on   26 
endothelial cells produce vasodilation (via production of NO) and clearance of 
circulating ET-1 (Galie et al., 2004).  Hypoxia has been shown to attenuate ETB-
induced vasoconstriction in rat pulmonary arteries.  This study suggested that 
the hypoxia-induced production of ROS increases ET-1 release from endothelial 
cells and results in the downregulation of ETB receptors on SMCs (Wang et al., 
2006).  
The upregulation of ET-1 occurs in the lungs of patients with various etiologies 
of PAH (Giaid et al., 1993).  Confirming the role of ET-1 in the development of 
PAH,  treatment  with  ET  antagonists  have  been  found  to  attenuate  the 
development of pulmonary vascular remodelling in a variety of models of the 
condition (Kim et al., 2000, Oparil et al., 1995, Eddahibi et al., 1995, Okada et 
al., 1995).  Furthermore, bosentan, a competitive antagonist at both ETA and 
ETB receptors, is benefical in the treatment of human PAH (Rubin et al., 2002).  
Therefore,  endothelial-derived  mediators  play  an  important  role  in  regulating 
vascular  tone  and  cell  proliferation  within  the  pulmonary  vasculature,  with 
dysregulation of these mediators significantly contributing to the development of 
PAH. 
 
THE  POTENTIAL  ROLE  OF  EICOSANOIDS  IN  PULMONARY  VASCULAR 
REMODELLING 
 
Eicosanoids  such  as  prostacyclin  and  thromboxane  A2  (TXA2)  have  been 
implicated  in  the  pathophysiology  of  PAH.    As  mentioned  previously,  TXA2 
levels are elevated in endothelial cells from patients with PAH.  This contributes 
to vasoconstriction during PAH and also has mitogenic effects, in addition to 
contributing to platelet aggregation.  Patients with PAH have elevated levels of 
urinary 11-dehydro-TXB2, a major urinary metabolite of TXA2, suggesting a role 
for TXA2 in the pathogenesis of PAH (Christman et al., 1992).  In an in vivo 
model of the condition, inhibition of TXA2 significantly reduced arterial media 
thickness, as well as RVH, delaying the onset of PAH.  These beneficial effects 
were  suggested  to  be  mediated  mainly  by  inhibiting  platelet  aggregation 
(Nagata et al., 1997). 
Prostacyclin synthesis is also altered in PAH.  In addition to its vasodlilatory 
properties,  prostacyclin  inhibits  smooth  muscle  cell  proliferation  and  platelet   27 
aggregation  (Fetalvero  et  al.,  2007).    As  mentioned  earlier,  endothelial  cells 
from  patients  with  PAH  have  reduced  expression  of  prostacyclin  synthase 
(Tuder et al., 1999) and decreased levels of prostacyclin metabolites have been 
observed in the urine of such patients (Christman et al., 1992).  Prostacylin 
therapy is a mainstay in the treatment of PAH, with many prostacylin analogues 
such  as  epoprostenol,  treprostinil  and  beraprost  improving  the  pulmonary 
function of patients (Lee and Rubin, 2005).  Another such analogue, iloprost, 
has been reported to have beneficial effects on pulmonary vascular remodelling 
in vivo; reducing RVH, medial wall thickness and the number of muscularised 
pulmonary arteries in monocrotaline-induced PAH (Schermuly et al., 2005b).  In 
summary,  the  balance  between  the  actions  of  TXA2  and  prostacyclin  are 
important in maintaining a healthy pulmonary vasculature.  Alterations in levels 
of these mediators during PAH contribute to the progression of the disease. 
 
ANGIOGENIC AND GROWTH FACTORS AND VASCULAR REMODELLING 
 
Abnormalities in the expression of various angiogenic factors and growth factors 
have been suggested to play a role in PAH.  One such factor, namely VEGF, 
has  been  implicated  in  various  etiologies  of  PAH.    VEGF  is  a  vascular 
endothelial cell-specific mitogen with pro-angiogenic properties and is secreted 
by various cell types.  In systemic vessels, increases in VEGF bioavailability at 
sites of endothelial injury accelerate repair and attenuate neointimal formation 
(Asahara  et  al.,  1995).    In  addition  to  this,  VEGF  overexpression  within  the 
vascular wall restores endothelium dependent relaxation and protects against 
vasoconstriction and platelet aggregation (Thomas, 1996).  VEGF is abundant 
in  the  adult  lung  (Monacci  et  al.,  1993)  and  can  be  regulated  by  hypoxia 
(Monacci et al., 1993, Liu et al., 1995).  Indeed, increase in VEGF, VEGFR1 
and VEGFR2 have been observed in the lungs of hypoxic rats (Tuder et al., 
1995, Christou et al., 1998).  Similary, the upregulation of VEGF has also been 
observed in platelets from patients with PAH (Eddahibi et al., 2000b), in addition 
to increased levels of VEGF and VEGFRs in the lungs of such patients (Hirose 
et  al.,  2000).    In  particular  VEGF  and  VEGFR  expression  appears  to  be 
upregulated in plexform lesions (Tuder and Voelkel, 2001), with VEGF levels 
elevated  in  SMCs  inside  and  adjacent  to  these  areas  (Hirose  et  al.,  2000).    28 
Furthermore, VEGFRs were also observed to be expressed on endothelial cells 
in and around these lesions (Hirose et al., 2000).  In addition to its beneficial 
effects in the systemic circulation, overexpression of VEGF also appears to play 
a protective role in the pulmonary circulation, as highlighted by various in vivo 
studies.  For instance, VEGFR2 inhibition in chronically hypoxic rats results in 
severe  PAH  (Taraseviciene-Stewart  et  al.,  2001).    Conversly,  VEGFA 
overexpression markedly attenuates the development of hypoxic PAH in rats.  
Comparable effects were also observed in rats where gene transfer of VEGFA 
to the pulmonary microvasculature had been undertaken.  In these animals the 
effects of monocrotaline-induced PAH were significantly reduced even in PAH 
that was already established (Campbell et al., 2001).  VEGFA overexpression in 
chronically  hypoxic  rats  also  has  a  protective  effect  (Partovian  et  al.,  2000).  
Similarly, overexpression of VEGFB has also been reported to have beneficial 
effects (Louzier et al., 2003).  It has been suggested the advantageous effects 
of VEGF overexpression may be due to its ability to protect endothelial function 
and upregulate mediators such as eNOS (Kroll and Waltenberger, 1998, Hood 
et al., 1998, Partovian et al., 2000).  Furthermore, it has also been proposed 
that  endogenous  levels  of  VEGF  do  not  counteract  PAH,  but  that  it  is  the 
upregulation of VEGF that assists in combating the condition.  This is supported 
by  data  showing  that  in  mice,  where  VEGFB  has  been  knocked  out, 
haemodynamic changes in response to hypoxia remain unaffected (Louzier et 
al., 2003).  Moreover, in patients with PAH receiving prostacyclin therapy, levels 
of VEGF are elevated compared to control (Eddahibi et al., 2000b). 
Angiopoetin-1 (Ang-1), a smooth muscle-secreted ligand that plays a pivitol role 
in  vasculogenesis  and  is  an  important  mediator  of  both  physiological  and 
pathological angiogenesis (Hayes et al., 1999), has also been implicated in the 
development  of  PAH.    Ang-1  signal  transduction  occurs  via  the  endothelial-
specific receptor Tie2 (Davis et al., 1996).  Ang-1 is absent in normal adult lung 
tissue, but appears to be constitutively expressed in lungs from PAH patients 
(Du  et  al.,  2003).    A  potential  role  for  Ang-1  in  PAH  is  also  highlighted  by 
development of the condition in rodents genetically engineered to constitutively 
express Ang-1 in the lung (Sullivan et al., 2003).  Furthermore, Ang-1 has also 
been reported to attenuate the expression of BMPR1a, which is required for 
BMPR2 signalling in PAECs (Du et al., 2003).  Given the role of BMPR2 in   29 
PAH, inhibition of its signalling by Ang-1 may contribute to vascular remodelling.  
It  has  also  been  suggested  that  Ang-1  may  contribute  to  pulmonary  artery 
remodelling by stimulating the proliferation of PASMCs.   Human PAECs treated 
with  Ang-1  have  been  shown  to  produce  5HT,  which  then  acts  on  SMCs 
resulting in their proliferation (Sullivan et al., 2003).  However, in contrast to a 
notion that Ang-1 contributes to the development of PAH, a protective role has 
also  been  reported.    In  this  study,  Ang-1  gene  therapy  reduced  mortality, 
systolic  right  ventricular  pressure  (sRVP)  and  RVH  in monocrotaline-induced 
PAH (Zhao et al., 2003).  Although contradictory, these studies imply a role for 
Ang-1  in  the  pulmonary  hypertensive  process.    More  recently,  other  studies 
have confirmed the pathogenic effects of Ang-1 in PAH.  For instance in some 
rodent models of PAH, gene transfer of a Tie2 receptor antagonist markedly 
reduced  the  development  of  PAH  (Kido et  al.,  2005).    Furthermore,  another 
study showed increased levels of Tie2 receptor expression and phosphorylation 
in PAECs from PAH patients (Dewachter et al., 2006).  This also suggests the 
Ang-1/Tie 2 pathway is potentiated in PAH patients, resulting in the increased 
production  of  endothelial  cell-derived  growth  factors  such  as  ET-1  and  5HT 
which may then contribute to SMC proliferation. 
Platelet-derived growth factor (PDGF) may also contribute to PAH.  In an animal 
model  of  the  condition,  increased  levels  of  PDGF  receptors  (PDGFR)  have 
been observed (Balasubramaniam et al., 2003).  Furthermore, it has also been 
reported  that  PDGF  antagonists  have  beneficial  effects  in  rats  with 
monocrotaline-induced PAH, in addition to the chronic hypoxic mouse model of 
the condition, reversing vascular remodelling in both instances (Schermuly et 
al., 2005a).   
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Figure 1.5  TGF-β receptor signal transduction pathway induced by BMP ligands. 
 
BMP ligands (BMP-2,-4,-7) bind the receptor complex at the cell surface inducing phosphorylation of the type 1 receptor by the type 
2 receptor.  The active type 1 receptor then phosphorylates and activates Smad1/5/8, which subsequently dimerise and interact 
with the common mediator Smad, Smad 4.  This complex then translocates to the nucleus resulting in the transcription of Smad-
responsive genes such as Id (inhibitor of differentiation) and Msx-1 (Miyazono et al., 2005, Alvarez Martinez et al., 2002).  Figure 
adapted from Derynck and Zhang (2003).   31 
1.4  5-HYDROXYTRYPTAMINE (5HT) 
 
In addition to the mediators of PAH mentioned previously, 5HT has been shown 
to play a pivitol role in the disease process, as will be described in the following 
section. 
 
1.4.1  5HT STRUCTURE, SYNTHESIS AND METABOLISM  
 
5HT, or “serotonin”, was chemically identified by Rapport et al (1948) as one of 
the  major  vasoconstricting  substances  in  defibrinated  blood,  originating  from 
platelets.  It was subsequently found to also act as a major neurotransmitter, 
being  involved  in  a  variety  of    processes carried  out  by  the  central  nervous 
system (CNS), as well as regulating several functions in the periphery (Hoyer et 
al.,  2002).    5HT  is  a  monoamine,  its  structure  comprising  an  amino  group 
connected to an “indole” group by an ethyl chain (Figure 1.6).   
Production  of  5HT  occurs  in  a  variety  of  cells  including  neurons, 
enterochromafin cells and endothelial cells.  The biosynthesis pathway converts 
dietary  tryptophan  to  5-hyroxytryptophan  by  the  action  of  the  enzyme 
tryptophan  hydroxylase  (TPH).    This  process  is  the  rate-limiting  step  in  the 
generation  of  5HT.    Two  isoforms  of  TPH  exist;  TPH2  which  is  expressed 
abundantly in the brain, and TPH1, which is responsible for the synthesis of 
5HT in the periphery (Nakamura and Hasegawa, 2007).  5-hydroxytryptophan is 
then decarboxylated by a ubiquitous animo-acid decarboxylase, resulting in the 
formation of 5HT (Figure 1.7).  Upon synthesis, 5HT is taken up and stored by 
platelets as they pass through the intestinal circulation, as well as being stored 
in neurons and chromaffin cells. 
Degradation and inactivation of 5HT occurs through the action of monoamine 
oxidases  (MAO),  which  catalyse  its  oxidative  deamination.    Monoamine 
oxidases are found in most tissues and exist in 2 forms encoded by different 
genes,  MAO-A  and  MAO-B.    It  is  MAO-A  that  preferentially  catalyses  the 
degradation of 5HT (Youdim and Bakhle, 2006).  Deamination by MAO-A is 
then followed by oxidation to 5-hydroxyindoleacetic acid, which is excreted in 
the urine (Figure 1.7).    32 
1.4.2  PHYSIOLOGICAL FUNCTIONS OF 5HT 
 
The actions of 5HT are numerous and complex, varying between species and 
this is reflected by the large array of 5HT receptors that have been identified.  
The  physiological  effects  of  5HT  are  mediated  by  14  different  receptor 
subtypes.  These receptors are divided into 7 distinct classes (5HT1 – 5HT7), 
mainly on the basis of their structural and functional characteristics (Hoyer et 
al.,  2002).    5HT  is  also  a  substrate  for  the  5HT  transporter  (5HTT),  which 
actively uptakes 5HT into cells (Torres et al., 2003).   
The gastrointestinal tract is one of the main sites of action of 5HT, where the 
monoamine stimulates gastrointestinal motility, fluid secretion and is involved in 
eliciting nausea and vomiting (Gershon and Tack, 2007).  In addition to this, 
5HT is also involved in the process of platelet aggregation, the dysregulation of 
which can contribute to thrombus formation and vascular disease (McNicol and 
Israels, 2003, Torr et al., 1990, Noble and Drake-Holland, 1990).  5HT also 
plays a role in nociception, stimulating nociceptive sensory nerve endings in a 
variety of tissues (Goadsby, 2000, Graven-Nielsen and Mense, 2001, Jeong et 
al., 2004).  Drugs targeting 5HT receptors are widely used in the treatment of 
migrane (Villalon et al., 2003).  Furthermore, a variety of processes in the CNS 
are regulated by 5HT; these include hallucinations and behavioural changes, 
sleep  wakefulness,  mood,  feeding  behaviour  and  control  of  sensory 
transmission  (Barnes  and  Sharp,  1999).  Clinical  conditions  associated  with 
disturbed  5HT  function  include  depression,  anxiety,  schizophrenia,  carcinoid 
syndrome, and, as mentioned previously, migraine. (Bleich et al., 1988),  
 
1.4.3  GPCR REGULATION 
 
With the exception of the 5HT3 receptor, which is a ligand-gated ion channel, 
the  5HT  receptors  are  members  of  the  G-protein-coupled  receptor  (GPCR) 
suprefamily  (Hoyer  et  al.,  2002).    GPCRs  regulate  many  physiological 
processes and include receptors for a range of chemically diverse hormones, 
neurotransmitters  and  chemokines  (Pierce  et  al.,  2002).    Comprised  of  an 
extracellular N-terminus, 7 transmembrane spanning helices and an intracellular 
C-terminus, most GPCRs signal by activating heterotrimeric G-proteins (Pierce   33 
et al., 2002) (Figure 1.8).  G-proteins consist of α, β and γ subunits, and are 
generally referred to by their α-subunit.  To date 16 Gα subunits have been 
identified  and  grouped  into  4  families,  Gs,  Gq,  Gi  and  G12/13  (Milligan  and 
Kostenis, 2006).  In addition to this, 5 β and 12 γ subunits have been reported 
(Milligan  and  Kostenis,  2006).    The  pathways  stimulated  by  GPCRs  are 
dependent on the type of G-protein they associate with and receptors typically 
couple with one or more type of G-protein (Hamm, 1998).  The association of G-
protein with receptor is generally via the second or third intracellular loop of the 
GPCR (Hawes et al., 1994, Lameh et al., 1992).  The binding of agonist to its 
receptor results in a conformational change, facilitating the activation of the G-
protein by promoting the exchange of GDP for GTP at the guanine nucleotide 
binding site of Gα-subunit (Hamm, 1998, Pierce et al., 2002).  This process 
results  in  the  dissociation  of  the  Gα  subunit  from  the  Gβγ  subunits,  which 
remain bound together.  The activated Gα subunit and βγ dimer are then free to 
act  as  mediators  of  receptor-stimulated  signalling  pathways  (Hamm,  1998) 
(Figure 1.9).  Giα subunits mediate intracellular signalling by inhibiting adenylyl 
cyclase, where as Gsα subunits stimulate adenylyl cyclase (Pierce et al., 2002).  
In  addition  to  this,  Gqα,  activates  phospholipase  Cβ,  while  G12/13  have  been 
shown to be involved in small G protein activation and cytoskeletal remodelling 
(Pierce et al., 2002, Ulloa-Aguirre et al., 1999).  Furthermore, Gβγ subunits can 
activate a variety of proteins, including PLCβ, (Clapham and Neer, 1997). 
   
1.4.4  5HT RECEPTOR CLASSES 
 
5HT  mediates  its  physiological  effects  via  activation  of  its  multiple  receptor 
subytpes.  The 5HT1 receptor class consists of 5 receptor subtypes:  5HT1A, 
5HT1B, 5HT1D, 5ht1E and 5ht1F receptors.  In humans these receptors share 40-
63% sequence identity and mediate their effects by coupling preferentially to 
Giα, thus inhibiting adenylyl cyclase and  cAMP production (Hoyer et al., 2002).  
5ht1E  and  5ht1F  receptors  are  designated  with  lower  case  to  indicate  that  a 
physiological  role  for  these  endogenous  receptor  has  not  yet  been 
demonstrated (Hoyer et al., 2002).  However, physiological functions for 5HT1A, 
5HT1B and 5HT1D receptors have been well characterised.  5HT1A receptors are 
largely  distributed  throughout  the  CNS  and  in  the  raphe  nuclei  act  as   34 
autoreceptors to attenuate serotonergic neuron firing (Hoyer et al., 2002).  This 
receptor subtype is also  involved in modulating many behavioural effects such 
as anxiety and depression (Hoyer et al., 2002).  Currently, the 5HT1A receptor 
agonist buspirone is used clinically in the treatment of these conditions (Den 
Boer et al., 2000).   
5HT1B  receptors  are  expressed  in  the  CNS  where  they  act  as  terminal 
autoreceptors (Hoyer et al., 2002) and may also be involved in controlling the 
release  of  other  neurotransmitters  such  as  acetylcholine  and  noradrenaline 
(Pauwels, 1997).  Also located on cerebral arteries and other vascular tissues, 
they  play  a  role  in  mediating  contraction  (Hoyer  et  al.,  2002).    The  5HT1D 
receptor possesses 63% structural homology with the 5HT1B receptor, although 
its  expression  is  low  compared  with  the  5HT1B  (Hoyer  et  al.,  2002).    5HT1D 
receptors  have  been  found  in  the  human  heart  where  they  modulate  5HT 
release (Hoyer et al., 2002).  In addition to this, the receptor may also play a 
role  in  neurogenic  inflammation  and  nociception.    Indeed,  5HT1D  receptor 
antagonists  have  been  shown  to  suppress  these  processes  in  guinea  pig 
models, suggesting it may be a therapeutic target in the treatment of migraine 
(Cutrer et al., 1999). Many currently available drugs used in the treatment of 
migraine act as antagonists at both 5HT1B and 5HT1D receptors (Hoyer et al., 
2002). 
The  5HT2  class  of  receptor  includes  the  5HT2A,  5HT2B  and  5HT2C  receptors 
which  exhibit  46-50%  overall  sequence  homology.    These  receptors  couple 
preferentially to Gq, activating phospholipase C (PLC) to increase the formation 
of inositol 1,4,5 trisphosphate and elevate cytosolic Ca
2+ (Hoyer et al., 2002).  
5HT2A receptors are widely expressed in both the CNS and periphery, where 
they are involved in mediating vascular SMC contraction in bronchial, uterine 
and urinary tissues (Hoyer et al., 2002).  5HT2A receptors are also involved in 
mediating platelet aggregation, thrombosis and increased capillary permeability 
following exposure to 5HT (Nagatomo et al., 2004).  In the CNS, stimulation of 
this receptor mediates secretion of hormones such as renin and prolactin (Van 
de  Kar  et  al.,  2001).    Furthermore,  activation  of  this  receptor  class  also 
mediates  many  behavioural  functions  and  has  been  implicated  in  conditions 
such  as  schizophrenia  (de  Angelis,  2002).    The  5HT2B  receptor  has  been 
located in the gastric fundus where it mediates fundic SMC contraction (Hoyer   35 
et al., 2002).  They are also expressed in the heart, brain and lung (Hoyer et al., 
2002).    The  5HT2B  receptor  has  been  associated  with  promoting  cell  cycle 
progression  in  fibroblasts  (Nebigil  et  al.,  2000b)  and  cell  survival  in 
cardiomyocytes  (Nebigil  et  al.,  2003).    It  may  also  contribute  to  cardiac 
hypertophy (Nebigil and Maroteaux, 2003).  Furthermore, the 5HT2B receptor is 
required  for  normal  heart  formation  during  embryogenesis  (Nebigil  et  al., 
2000a). Expression of the 5HT2C receptor is widespread throughout the CNS 
and also found in the choroid plexus (Hoyer et al., 2002).  5HT2C receptors have 
been  found  to  mediate  various  behavioural  effects  and  are  involved  in 
conditions  such  as  anxiety,  depression  and  panic  disorders  (Lacivita  and 
Leopoldo,  2006).    This  receptor  subtype  also  plays  a  role  in  regulating 
dopaminergic function and inhibits dopaminergic transmission (Di Matteo et al., 
2002).    Additionally,  5HT2C  receptors  have  been  found  to  be  involved  in 
mediating seizures and convulsion and as such are being considered in the 
treatment  of  epilepsy  (Isaac,  2005).    Furthermore,  appetite  and  glucose 
homeostasis  as  also  controlled,  in  part  by  the  5HT2C  receptor  (Lacivita  and 
Leopoldo, 2006).  Notably, many antipsychotic drugs mediate their effects via 
antagonism of 5HT2A and 5HT2C receptors (Leysen, 2004).  
Located  on  both  central  and  peripheral  neurones,  the  5HT3  receptors  are 
ligand-gated  ion  channels  which  trigger  rapid  depolarisation  due  to  Na
+  and 
Ca
2+ influx and K
+ efflux (Hoyer et al., 2002).  5HT3 receptors play a particularly 
important  role  in  the  gut,  regulating  gastric  motility  and  intestinal  secretion 
(Hoyer  et  al.,  2002).  These  receptors  are  also  involved  in  mediating 
chemotherapy- and radiotherapy-induced nausea and emesis (Gandara et al., 
1998, Hoyer et al., 2002). 
5HT4, 5ht6 and 5HT7 receptors all couple preferentially to Gs, promoting cAMP 
formation (Hoyer et al., 2002).  Located in the GI tract, heart and CNS, 5HT4 
receptors mediate a variety of functions (Hoyer et al., 2002).  In the gut, 5HT4 
receptors are involved in regulating gastric motility (Degen et al., 2001) and as a 
result, 5HT4-selective agonists such as prucalopride are used in the treatment 
of some forms of irritable bowel syndrome (IBS) (De Schryver and Samsom, 
2000, Spiller, 2004). In addition to this, 5HT4 receptors have been found in atria 
and  ventricles  of  the  heart,  where  they  regulate  heart  rate,  atrial  contractile 
force and relaxation (Bach et al., 2001, Hegde and Eglen, 1996).  Furthermore,   36 
CNS  effects  of  the  5HT4  receptor  include  modulation  of  neurotransmitter 
release, enhanced synaptic transmission and a potential role in memory (Hoyer 
et al., 2002). 5ht6 receptors are almost exclusively expressed in the CNS, where 
they  have  been  shown  to  regulate  glutamatergic  and  cholinergic  neuronal 
activity  (Woolley  et  al.,  2004).    This  receptor  may  also  be  involved  in  the 
regulation of cognition and feeding (Woolley et al., 2004).  5HT7 receptors are 
expressed  extensively  in  the  vasculature  and  also  in  nonvascular  smooth 
muscle, where it mediates relaxation (Thomas and Hagan, 2004).  In the CNS, 
this  receptor  may  also  be  involved  in  anxiety  and  cognitive  disturbances 
(Thomas  and  Hagan,  2004).    Possible  roles  in  circadian  rhythms,  sleep, 
thermoregulation and learning and memory have also been reported (Hedlund 
and Sutcliffe, 2004, Jovanovska and Prosser, 2002, Thomas and Hagan, 2004).  
Little is known about the 5ht5 receptor class.  Two subtypes (5ht5A and 5ht5b) 
have been identified in rodents, however only the 5ht5A gene has been found to 
encode  a  functional  protein  in  humans  (Nelson,  2004).    5ht5  receptors  are 
thought  to  couple  to  Gi/o,  decreasing  levels  of  cAMP  (Carson  et  al.,  1996, 
Francken et al., 1998).   With widespread expression in the CNS, the 5ht5A 
receptor has been proposed to act as an autoreceptor and may also be involved 
in the control of circadian rhythms (Thomas, 2006) (Figue 1.10).   
 
1.4.5  5HT TRANSPORTER (5HTT) 
 
The 5HT tansporter is a member of the NaCl-dependent transporter family that 
cotransport their substrate together with Na
+ and Cl
- ions (Torres et al., 2003).  
5HTT is responsible for the clearance of 5HT from the synaptic cleft following 
release  of  the  neurotransmitter,  thereby  terminating  its  action  (Torres  et  al., 
2003).  Other cell types also express 5HTT, including platelets (Talvenheimo 
and Rudnick, 1980), which acquire extracellular 5HT for subsequent release in 
the process of platelet activation (Cirillo et al., 1999). Expression has also been 
observed in the intestinal tract (Wade et al., 1996), adrenal gland (Schroeter et 
al., 1997), blood vessels, heart (Ni and Watts, 2006) and lungs (Marcos et al., 
2004).  Furthermore, 5HTT is one of the primary targets for drugs used in the 
treatment  of  depression,  including  tricyclic  antidepressants  and  selective 
serotonin reuptake inhibitors (SSRIs) (Zohar and Westenberg, 2000), as well as   37 
being a target for drugs of abuse such as amphetamines, NMDA and cocaine 
(Ricaurte et al., 2000, Koob, 2000). 
Structurally, 5HTT consists of 12 transmembrane domains (TMDs), connected 
by 6 extracellular and 5 cytoplasmic loops, with both the amino and carboxyl 
termini  residing  in  the  cytoplasm  (Torres et  al.,  2003,  Nelson, 1998)  (Figure 
1.11).  In TMD1, an aspartic acid residue (D98) is key for substrate recognition, 
possibly  through  interactions  between  the  carboxyl  group  and  the  positive 
change of the amine group of 5HT (Barker et al., 1999).  In addition to this 
TMD3 and the third intracellular loop are also important in the function of 5HT 
binding  and  translocation.  The  TMD3  binds  5HT  at  a  site  located  in  the 
translocation path, while the third intracellular loop contains a reactive cysteine 
residue (Cys357), sensitive to conformational changes that result from ion and 
ligand binding (Androutsellis-Theotokis et al., 2001). 
The driving force for 5HT uptake is the ion concentration gradient generated by 
the plasma membrane Na
+/K
+ ATPase.  5HTT cotransports 5HT with one Na
+ 
and one Cl
- ion, while the counter-transport of K
+ outwards is required in the 
translocation mechanism (Torres et al., 2003, Nelson, 1998).  Binding of 5HT, 
Na
+  and  Cl
-  induces  a  conformational  change  in  the  transporter  allowing 
exposure of the 5HT binding site to the opposite side of the membrane and thus 
transport  of  substrate  and  ions  (Nelson,  1998,  Torres  et  al.,  2003).    The 
reorientation  of  5HTT  then  requires  the  binding  and  outward  transport  of 
intracellular  K
+  ions  (Nelson,  1998,  Torres  et  al.,  2003).    In  certain 
circumstances 5HTT may act in reverse, transporting 5HT out of the cell.  This 
mechanism is especially important in the action of amphetamines, which induce 
massive release of monoamines (Seiden et al., 1993).    
The  activity  of  5HTT  can  be  regulated  by  both  pre-  and  post-transcriptional 
modifications.    5HTT is  encoded  by  a  single  gene  on  chromosome  17q11.2 
(Ramamoorthy et al., 1993).  Polymorphisms in this gene have been identified 
and found to alter the activity of 5HTT.  These polymorphisms occur in the 5’- 
flanking promoter region and consist of multi-allelic 17-bp tandem repeat and an 
insertion/deletion of a 44-bp sequence (Lesch et al., 1996).  This results in long 
(L) and short (S) alleles, with the S form shown to have reduced transcriptional 
efficiency, decreased 5HTT expression and 5HT uptake (Lesch et al., 1996).   38 
Posttranscriptionally, protein kinase C (PKC), protein phosphatase 2A (PP2A) 
and p38 are all involved in the regulation of 5HTT activity.  Multiple serine and 
threonine phosphorylation sites have been located on the cytoplasmic domains 
of 5HTT and phosphorylation appears to play a major role in regulating 5HTT 
trafficking  and  thus  its  ability  to  take  up  5HT.    Activation  of  PKC  has  been 
shown to phosphorylate 5HTT in a calcium-dependent manner, resulting in its 
internalisation and a decreased activity (Jayanthi et al., 2005, Ramamoorthy et 
al., 1998, Samuvel et al., 2005).  Conversly, inhibition of protein phosphatase 
2A (PP2A) also increases 5HTT phosphorylation and subsequent internalisation 
(Ramamoorthy  et  al.,  1998),  highlighting  the  important  role  phosphorylation 
plays in regulating 5HTT.  Interestingly 5HT has been found to decrease 5HTT 
phosphorylation, thus inhibiting its internalisation (Ramamoorthy et al., 1998).  
This may be a negative feedback mechanism to prevent 5HTT downregulation 
when  high  levels  of  extracellular  5HT  are  present.      The  mitogen-activated 
protein  kinase  (MAPK)  p38  also  regulates  the  activity  of  5HTT  in  manner 
distinct  from  that  of  PKC,  by  regulating  the  delivery  of  5HTT  to  the  plasma 
membrane (Samuvel et al., 2005).  In this study inhibition of p38 decreased 5HT 
uptake by attenuating the levels of the transporter present at the membrane.  
Furthermore, receptor mediated activation of p38 has been shown to result in 
enhanced 5HTT activity, by a process that was independent of 5HTT trafficking 
(Zhu  et  al.,  2005).    This  effect  was  dependent  on  activity  of  PP2A.    Taken 
together,  these  finding  suggest  the  importance  of  phosphorylation  in  the 
regulation of 5HTT activity, in addition to its regulation at a genetic level (Figure 
1.12). 
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Figure  1.6    Diagram  of  the  chemical  structure  of  5-hydroxytryptamine 
(5HT). 
 
5HT is a biogenic amine. It structure comprises of an amino group, which is 
attached to an indole group by an ethyl chain.   40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7  5HT biosynthesis and metabolism pathway. 
 
5HT is synthesised from dietary tryptophan, which is converted to 5-hydroxytryptophan by the enzyme tryprophan hydroxylase, 
then to 5HT by a non-specific decarboxylase.  Degradation occurs by the enzyme monoamine oxidase-A, resulting in the formation 
of 5-hydroxyindoleacetic acid, which is excreted in urine.   41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8  General Structure of a GPCR. 
 
Diagram  represents  a  typical  GPCR,  consisting  of  seven  transmembrane-
spanning  α-helices,  with  an  extracellular  N-terminus  and  intracellular  C-
terminus.  The central core comprises transmembrane domain II, III, V and VI, 
and is essential in ligand binding.  Glycosylation sites towards the N-terminus 
as thought to be involved in receptor trafficking.  Figure adapted from Ulloa-
Aguirre et al (1999). 
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Figure 1.9  The function of the G-protein in mediating agonist induced signal transduction. 
 
The binding of agonist to a GPCR results in coupling of the α-subunit of its associated G-protein to the receptor and subsequent 
exchange of GDP for GTP.  Exchange of GDP for GTP results in the dissociation of α and βγ subunits, allowing them to interact 
with  effector  proteins and  initiate  cellular  responses.  The  intrinsic  GTPase  activity  of the α-subunit hydrolyses  GTP  to  GDP, 
resulting in the reassociation of α and βγ subunits and terminates receptor signalling.   43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10  Diagram summarising mechanisms by which 5HT receptors mediate their response. 
 
All 5HT receptors except the 5HT3 are G-protein-coupled receptors, with different receptors coupled to different G-proteins to elicit 
a reponse.  The 5HT3 receptor is a ligand-gated non-selective cation channel.  44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11  Diagram of proposed topology of the 5HT transporter (5HTT). 
 
5HTT is comprised of 12 transmembrane domains connected by intracellular and extracellular loops with both the C- and N-
terminus located in the cytoplasm.  Figure adapted from Torres et al (2003).   45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  1.12    Post-translational  regulation  of  the  activity  of  the  5HT 
transporter (5HTT). 
 
Activation  of  protein  kinase  C  (PKC)  results  in  the  phosphorylation  and 
subsequent  inactivation  and  internalisation  of  5HTT.    The  presence  of  5HT 
inhibits 5HTT phosphorylation retaining active 5HTT at the plasma membrane.  
p38 MAP kinase is required for the trafficking of active 5HTT back to the plasma 
membrane.  Furthermore the activation of p38 by cell surface receptors such as 
the adenosine receptor is important in maintaining 5HTT in its active state, a 
process that is dependent on protein phosphatase 2A (PP2A).   46 
1.5  ROLE OF 5HT AND 5HTT IN PULMONARY HYPERTENSION 
 
In the lungs, 5HT is locally released from pulmonary neuroendocrine cells and 
neuroepithelial cell bodies distributed throughout the airways.  The lungs play 
an important role in the removal of 5HT from the circulation, with as much as 
95% being taken up or inactivated (Gaddum et al., 1953, Thomas and Vane, 
1967,  Wiersma  and  Roth,  1980).    Under  normal  circumstances,  pulmonary 
tissue is exposed to low levels of 5HT as it is taken up and stored in platelets, 
thus  removing  it  from  the  circulation.    However,  under  hypoxic  conditions 
(Johnson and Georgieff, 1989) and during situations involving mechanical strain 
(Pan  et  al.,  2006)  large  amounts  of  5HT  are  secreted.    In  the  pulmonary 
circulation  5HT  is  thought  to  play  a  role  in  promoting  SMC  proliferation, 
vasoconstriction  and  thrombosis,  processes  involved  in  the  development  of 
PAH. 
A large body of evidence now exists implicating 5HT in the development of the 
condition.  For instance, several patients with PAH have elevated plasma levels 
of 5HT, in addition to a decrease in the levels of 5HT stored in platelets (Herve 
et al., 1995).  Moreover, 5HT was also implicated in the development of PAH in 
patients  following  treatment  with  anorexigens  such  as  aminorex  and 
fenfluramine derivatives.  Aminorex increases plasma levels of 5HT by inducing 
its  release  from  platelets  and  attenuating  its  breakdown  by  inhibiting  MAO 
(Zheng et al., 1997, Fishman, 1999).  Fenfluramine derivatives also increase 
levels of circulating 5HT.  These anorexigens interact with 5HTT, stimulating the 
release  of  5HT  from  platelets  and  inhibit  its  reuptake  (Buczko  et  al.,  1975, 
Fristrom  et  al., 1977).  Furthermore,  in  PAECs  from  PAH  patients,  increased 
TPH1 expression and 5HT synthesis has been observed and this was thought 
to contribute to increased SMC proliferation (Eddahibi et al., 2006).  Another 
study  found  that  the effects of  chronic  hypoxia  were  markedly  attenuated  in 
mice deficient in TPH, with reductions in right ventricular pressure (RVP) and 
vascular  remodelling  reported  (Morecroft  et  al.,  2007).    Together,  these 
observations confirm an important role for 5HT in vascular remodelling during 
PAH.   47 
Both 5HT receptors and 5HTT contribute to the actions of 5HT in the pulmonary 
hypertensive  process.    5HT  is  a  potent  vasoconstrictor  and  in  the  human 
pulmonary arteries mediates its effects via the 5HT1B receptor (Morecroft et al., 
1999), whilst the 5HT2A receptor is important in the contractile response in other 
species,  including  rats  (Chand  and  Altura,  1980,  MacLean  et  al.,  1996).  
However,  in  rats  maintained  under  chronic  hypoxic  conditions,  contractile 
responses to 5HT are enhanced and this process is mediated by both 5HT2A 
and  5HT1B  receptors  (MacLean  et  al.,  1996,  Keegan  et  al.,  2001).    5HT1B 
receptors  have  also  been  found  to  be  upregulated  in  experimental  PAH 
(Rondelet  et  al.,  2003).    In  addition  to  the  role  of  5HT  receptors  in 
vasoconstriction, they also play a role in mediating vascular remodelling.  In 
chronically  hypoxic  rats,  administration  of  a  5HT1B  antagonist  significantly 
reduced  hypoxia-induced  right  ventricular  hypertrophy  (RVH)  and  vascular 
remodelling  (Keegan  et  al.,  2001).    Furthermore,  in  5HT1B  knock-out  mice, 
chronic  hypoxia-induced  PAH  was  also  markedly  attenuated  (Keegan  et  al., 
2001).  The 5HT2B receptor has also been reported to facilitate the development 
of PAH.  In one study, chronically hypoxic mice with inactive 5HT2B receptors 
failed  to  develop  PAH  (Launay  et  al.,  2002).    This  study  also  observed  an 
increase  in  5HT2B  receptor  transcript  in  patients  with  idiopathic  PAH.  
Additionally,  treatment  with  5HT2A  receptor-selective  antagonists  have  been 
found  to  have  beneficial  effects,  improving  survival  and  reducing  vascular 
remodelling  in  monocrotaline-induced  PAH  (Hironaka  et  al.,  2003).  
Furthermore, several cellular studies have highlighted the mitogenic effects of 
5HT in the pulmonary cells and therefore its potential contribution to vascular 
remodelling.  In some cell types the mitogenic effects are mediated via 5HT 
receptors. In rat pulmonary artery fibroblasts for example, inhibition of the 5HT2A 
receptor  markedly  reduced  5HT-induced  proliferation  (Welsh  et  al.,  2004).  
Similar effects have also been observed in other fibroblast cell lines (Lee et al., 
1999).  However, it is the 5HTT that has attracted most attention in recent times 
and  several  lines  of  evidence  suggest  a  major  role  for  5HTT  in  vascular 
remodelling. 
5HTT expression has been found to be elevated in the lungs of many patients 
with PAH.  This increased expression has been associated with polymorphisms 
in the 5HTT gene (Eddahibi et al., 2003).  In a study carried out by Eddahibi et   48 
al (2001), 65% of patients with idiopathic PAH were found to be homozygeous 
for the L-allelic variant, conferring increased expression of 5HTT, compared to 
only 27% of controls.  Subsequently, in patients with the LL-genotype, PAH was 
found to be more severe than those with LS or SS-genotypes who expressed 
lower  levels  of  5HTT  (Eddahibi  et  al.,  2003).    Various  animal  models  also 
support  the  role of  5HTT  in  the  development  of PAH  and  its  contribution  to 
vascular remodelling.  Such studies have shown that administration of 5HTT-
selective  inhibitors  protect  against  both  hypoxia-  and  monocrotaline-induced 
PAH (Guignabert et al., 2005, Marcos et al., 2003).  Furthermore, mice deficient 
in  5HTT  display  a  marked  reduction  in  RVH  and  vascular  remodelling  in 
response to hypoxia compared with control (Eddahibi et al., 2000a).  Conversly, 
mice over-expressing 5HTT display increased RVP under normoxic conditions, 
and  have  notably  exaggerated  responses  to  hypoxia  compared  to  control 
animals, with elevated vascular remodelling and RVH (MacLean et al., 2004). 
The levels of 5HTT, as well as 5HT1B, 5HT2A and 5HT2B receptors have all been 
found to be elevated in pulmonary arteries of patients with PAH (Marcos et al., 
2004).  However, only 5HTT is upregulated in PASMCs (Marcos et al., 2004), 
suggesting it may contribute specifically to SMC hyperplasia and play a role in 
mediating vascular remodelling.    In fact, in mice engineered to over-express 
5HTT in SMCs only, increases in RVP, RVH and vascular remodelling were 
observed  to  occur  spontaneously  by  8  weeks  of  age,  with  these  effects 
worsening  with  time  (Guignabert  et  al.,  2006).    Furthermore,  augmented 
proliferative  capabilities  of  PASMCs  from  patients  with  PAH  have  been 
associated  with  increased  expression  levels  of  5HTT  (Marcos  et  al.,  2004, 
Eddahibi  et  al.,  2001).    The  enhanced  proliferation  of  these  cells  to  5HT  or 
serum can be abolished by 5HTT inhibitors such as citalopram and fluoxetine 
(Marcos et al., 2004).  In further support of its role in vascular remodelling, the 
increase in 5HTT expression observed in PAH patients was located mainly in 
the medial layer of remodelled vessels (Eddahibi et al., 2001).  Hypoxia has 
also been found to result in increased 5HTT expression and transport activity, 
augmenting mitogenic responses in PASMCs (Eddahibi et al., 1999). Therefore, 
through the actions of 5HTT and its receptors, 5HT appears to play a major role 
in  the  development  of  pulmonary  hypertension,  contributing  to  both 
vasoconstriction and vascular remodelling.   49 
1.6  ERK MAP KINASE PATHWAY 
 
The extracellular-signal regulated kinase (ERK) MAP kinase pathway is crucial 
in mediating the mitogenic effects of 5HT (Lee et al., 1999, Lee et al., 2001, 
Suzuki et al., 2003, Liu et al., 2004).  MAP kinases (MAPKs) are a family of 
well-conserved proteins expressed in all eukaryotic cells.  Three major classes 
of MAPKs have been identified: ERK, p38 and c-jun N-terminal kinase (JNK).  
MAPKs are serine/threonine kinases and are activated by phosphorylation on a 
Thr-X-Tyr motif.  ERK has the dual phosphorylation motif Thr-Glu-Tyr, JNK has 
Thr-Pro-Tyr and the Thr-Gly-Tyr motif is present on p38 (Davis, 1995).  The 
overall sequence identity among ERK, p38 and JNK is 40-45%.  p38 and JNK 
are activated by various stress stimuli, including cytokines, osmotic shock and 
hypoxia  (Welsh  et  al.,  2001b,  Davis,  2000,  Zarubin  and  Han,  2005)  (Figure 
1.13).   
Currently  eight  ERK  MAPKs  have  been  identified,  termed  as  ERK1-8 
(Bogoyevitch  and  Court,  2004).    ERK1  and  ERK2  were  the  first  identified 
members  and  are  the  most  extensively  studied.    They  are  expressed 
ubiquitously  and  have  90%  sequence  identity  (Boulton  et  al.,  1991).    The 
Ras/Raf/MEK/ERK cascade is a well conserved pathway that is involved in the 
control  of  many  fundamental  cellular  processes  such  as  proliferation, 
differentiation and apoptosis (Lewis et al., 1998, Pearson et al., 2001).  A wide 
range  of  extracellular  stimuli  have  been  found  to  activate  ERK,  via  the 
stimulation of tyrosine receptor kinases and GPCRs, through Ras-dependent 
and Ras-independent pathways (Lewis et al., 1998).  The Ras/Raf/MEK/ERK 
pathway conveys signals in the form of a cascade of phosphorylation events.  
Receptor-mediated  activation  of  Ras,  a  small  GTPase,  at  the  plasma 
membrane promotes its binding to the N-terminus of Raf kinases (Raf-1, A-Raf, 
B-Raf), recruiting Raf to the membrane and subsequently activating them.  Raf 
activation is also dependent on phosphorylation at multiple sites.  In the case of 
Raf-1,  phosphorylation  sites  important  for  its  activation  at  Ser338,  Tyr341, 
Thr491 and Ser 949 have been identified (Chong et al., 2001). Once active Raf, 
then phosphorylates MEK (mitogen activated protein kinase kinase) within its 
activation  loop  at  two  serine  residues  (Ser  217  and  Ser  221)  (Alessi  et  al.,   50 
1994).  MEK may then subsequently activate ERK by phosphorylating tyrosine 
and threonine residues located within its kinase activation loop.  In the case of 
human  ERK1,  phoshorylation  occurs  at  Tyr202  and  Thr  204,  while  human 
ERK2 is phosphorylated on Tyr185 and Thr197.  Unlike MEK, significant ERK 
activation  requires  phosphorylation  at  both  sites,  with  Tyr  phosphorylation 
preceeding that of Thr (Ferrell and Bhatt, 1997).  Active ERK is then able to 
mediate many cellular processes by acting on substrates in the nucleus and 
cytoplasm (Kolch, 2005) (Table 1.2).   
In quiescent cells ERK is localised in the cytoplasm (Torii et al., 2004).  Under 
these circumstances, ERK forms a complex with MEK, which retains it in the 
cytoplasm  due  to  the  presence  of  a  nuclear  export  sequence  in  the  amino-
terminal domain of MEK (Fukuda et al., 1996).  Activation of ERK leads to the 
dissociation  of  the  MEK/ERK  complex  allowing  ERK  to  translocate  to  the 
nucleus where it can phosphorylate multiple transcription factors (refer to Table 
1.2),  modulating  gene  transcription  and  mediating  many  physiological 
responses (Torii et al., 2004, Brunet et al., 1999, Lewis et al., 1998, Pearson et 
al., 2001) (Figure 1.14).  ERK activity is terminated by dephosphorylation of the 
tyrosine  and  threonine  groups  within  its  activation  loop.    Dual  specificity 
phosphatases (DUSPs), which display differing levels of specificity for MAPKs, 
play an important regulatory role by dephosphorylating and inactivating ERKs.  
At least nine DUSPs have been isolated in mammalian cells and it is thought 
that these phosphatases participate in the negative feedback control of MAPK 
activation  (Keyse,  2000).    Nuclear  accumulation  of  ERK  is  transient  and 
inactivated ERK must relocalise to the cytoplasm, a process which is critical for 
further stimulation to occur.  It has been suggested that the relocalisation of 
inactive  ERK  occurs  by  a  MEK-dependent  transport  system,  whereby  MEK 
transiently enters the nucleus and binds inactive ERK, exporting it back to the 
cytoplasm (Adachi et al., 2000). 
The ERK MAPK cascade is regulated at many levels.  A number of scaffolding 
proteins  regulate  signalling  through  this  pathway  (Kolch,  2005).    Kinase 
suppressor of Ras-1 (KSR1) acts as a scaffold and has been found to bind all 
kinase  members  of  the  ERK  cascade  (Morrison,  2001,  Kolch,  2005).    For 
example, KSR promotes MEK activation by presenting MEK to activated Raf 
(Muller  et  al.,  2001).    Exogenous  inhibitors  of  the  ERK/MAPK  pathway  also   51 
exist.  One such inhibitor RKIP (Raf kinase inhibitor protein) bind both Raf and 
MEK preventing their interaction and thus MEK phosphorylation and activation 
(Yeung et al., 1999).   
β-arrestins, which are known to play a role in desensitizing and internalising 
GPCRs,  also  act  as  scaffolding  proteins  for  the  ERK  cascade.    β-arrestins 
consist  of  two  46kDa  proteins,  β-arrestin-1  and  β-arrestin-2  (Luttrell  and 
Lefkowitz,  2002).    Following  agonist  binding  and  subsequent  GPCR 
phosphorylation by GPCR kinases (GRKs), β-arrestins directly interact with the 
phosphorylated  GPCR  at  the  cell  surface.    β-arrestin  binding  uncouples  the 
receptor from heterotrimeric G proteins and targets it to clathrin-coated pits for 
removal  from  the  plasma  membrane  by  endocytosis  (Ceresa  and  Schmid, 
2000).    β-arrestin  can  simultaneously  bind  various  other  signalling  proteins, 
including components of the ERK cascade.  All three ERK pathway components 
have  been  observed  in  GPCR/β-arrestin  complexes.    In  rat  kidney  epithelial 
cells, protease-activated receptor 2 (PAR2) stimulation results in the formation 
of complexes containing internalised receptor, β-arrestin-1, Raf-1 and activated 
ERK (DeFea et al., 2000).  Similarly, in COS-7 and HEK293 cells, activation of 
the angiotensin type 1a receptor (AT1aR) leads to the formation a receptor, β-
arrestin-2, Raf-1, MEK1 and ERK2 complex (Tohgo et al., 2002). 
β-arrestins  not  only  bind  ERK  cascade  components  but  also  contribute  to 
GPCR-mediated ERK activation.  For instance, overexpression of β-arrestin has 
been  found  to  significantly  increase  angiotensin-mediated  ERK  activation  in 
COS-7 cells (Tohgo et al., 2002).  Furthermore, levels of active ERK bound to 
β-arrestin complexes are increased when Raf-1 is overexpressed and markedly 
reduced when a kinase-inactive MEK protein is expressed, indicating that the β-
arrestin scaffold acts as a platform for signal transmission from Raf to MEK and 
ERK (Luttrell et al., 2001).  In addition to this, β-arrestins appear to target ERK 
activity to a pool of cytoplasmic substrates.  In the case of the AT1aR, β-arrestin 
facilitates  GPCR-mediated  ERK  activation  but  inhibits  ERK-dependent 
transcription by binding to active ERK and retaining it in the cytoplasm (Tohgo 
et  al.,  2002).    Furthermore,  the  stability  of  the  GPCR/  β-arrestin  interaction 
determines the level of β-arrestin-bound ERK, thus influencing the subcellular 
localization  of  activated  ERK  and  the  physiological  consequences  of  ERK 
activation (Tohgo et al., 2003).   52 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13  p38 and JNK signalling cascades. 
 
The  activation  of  p38  and  c-Jun  N-terminal  kinase  (JNK)  requires  a  3-tiered 
cascade.    A  MAP  kinase  (MAPK)  is  activated  by  a  MAP  kinase  kinase 
(MAP2K), which it turn is also activated by phosphorylation by a MAP kinase 
kinase kinase (MAP3K).  MAPKs can be activated by a least 2 MAP2Ks and 
several  MAP3Ks.    MAP2Ks  display  substrate  specificity,  while  MAP3Ks  can 
activate multiple MAPK cascades.  p38 has 4 isoforms, α,β,γ and δ, while JNK 
has 3 isoforms, JNK 1,2 and 3 (Raman and Cobb, 2003).   53 
Transcription 
factors 
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phospatases 
Cytoskeletal 
proteins 
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proteins 
Apoptotic 
proteins/ 
proteinases 
Other 
proteins 
           
ALM1  DAPK  Annexin XI  EGFR  Bad  Amphiphysin 1 
Androgen receptor  ERK1/2  Caldesmon  ENaCβ/γ  Bim-EL  CPSII/CAD 
ATF2  FAK1  CENP-E  Fe65  Calpain  CR16 
BCL6  GRK2  Connexin  FRS2  Caspase 9  GRASP55 
BMAL1  Inhibitor-2  Cortactin  Gab1  EDD  GRASP65 
CBP  Lck  Crystallin  Gab2  IEX1  HABP1 
CEBPβ  MAPKAP3  DOC1R  GAIP  MCL-1  Histone H 
CRY1/2  MAPKAP5  Dystrophin  Grb10  TIS2  HnRNP-K 
E47  MEK1/2  Lamin B2  IRS1  TNFR CD120a  KIP 
Elk1  MKP1/2  MAP1  LAT    MBP 
ER81  MKP3  MAP2  LIFR    PHAS-I 
ERF  MKP7  MAP4  MARCKS    CPLA2 
Estogen receptor  MLCK  MISS  Naf1α    Rb 
c-Fos  MNK1/2  NF-H  PDE4    SAP90/PDS95 
Fra1  MSK1/2  NF-M  PLCγ    Spinophilin 
GATA1/2  PAK1  Paxillin  PLCβ    Topoisomerase II 
HIF1α  PTP2C  Stathmin  KV4.2    Tpr 
HSF1  Raf1  SWI/SNF  KSR1    TTP(Nup47) 
ICER  B-Raf  Synapsin 1  Rab4    Tyrosine  
c-Jun  RSK1-4  Tau  SH2-B    hydroxylase 
Microphthalmia  S6K  Vinexin β  ShcA    Vif 
c-Myc  Syk  Calnexin  Sos1    Vpx 
N-Myc      Spin90     
Net (Sap2)      TSC2     
NFATc4           
NF-IL6           
NGF1-
B/TR3/Nur77 
         
Pax6           
PPARγ           
p53           
Progesteron 
receptor 
         
RNA Pol II           
PUNX2           
Sap1           
Smad1           
Smad2/3           
SP1           
SRC1           
SREBP1/2           
STAT1/3           
STAT5a           
TAL1/SCL           
TFII-I           
TFIIIB           
TGIF           
TIF1A           
Tob           
UBF           
 
Table 1.2  ERK Substrates. 
 
Once  activated  ERK  is  able  to  phosphorylate  its  substrates,  with  different 
activating  stimuli  resulting  in  the  phosphorylation  of  different  substrates.    More 
than 150 cytoplasmic and nuclear ERK substrates have been identified, including 
protein kinases, protein phosphatases, transcription factors, scaffolding proteins, 
signalling  molecules,  cytoskeletal  proteins,  receptor  and  apoptosis-related 
proteins.  Table adapted from Lu and Xu (2006).   54 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14  ERK1/2 MAP kinase signalling pathway. 
 
Generally, ERK1/2 is activated by a cascade initiated by activation of the small G protein Ras, followed by activation of a Raf family 
member and subsequent activation of MEK1/2.  Raf can also be activated independently of Ras resulting in ERK activation (Lu and 
Xu, 2006).  Once active, ERK can then activate substrates in the nucleus, resulting in the transcription of target genes or act on 
substrates in the cytoplasm (refer to Table 1.2 for examples of substrate).   55 
1.7  Rho AND Rho EFFECTORS 
 
Rho  and  its  effectors  have  been  implicated  in  the  signalling  pathways  that 
contribute to vasoconstriction and vascular remodelling during the development 
of PAH and may also be involved in signal transduction downstream of 5HT.   
 
1.7.1  SMALL G-PROTEINS 
 
Rho  belongs  to  the  small  GTP-binding  protein  superfamily  of  monomeric  G 
proteins with molecular masses in the region of 20-40kDa.  Currently, more than 
one hundred small G proteins have been identified in eukaryotic cells, which 
can be characterised into five major families: Ras, Rho, Rab, Sar/Arf and Ran 
(Takai et al., 2001).  Small GTP-binding proteins play an important role in signal 
transduction,  with  the  Ras  family  involved  in  gene  expression,  playing  an 
important  role  in  the  activation  of  the  ERK  MAPK  cascade.  Cytoskeletal 
regulation is mediated via the Rho family, whereas the Rab and Sar1/Arf family 
are involved in regulating vesicular trafficking.  Finally, the Ran family regulate 
nucleocytoplasmic  transport  and  microtubule  dynamics  involved  in  cell  cycle 
progression  (Takai  et  al.,  2001).  The  Rho  family  has  around  20  distinct 
members including, Rho, Rac, Cdc42, RhoD, RhoG, TC10, Rnd and TTF, which 
share  50-55%  identity  (Hall  and  Nobes,  2000).    In  particular,  Rho  has  3 
isoforms A, B and C, with Rho A the most extensively studied.  All Rho isoforms 
can be selectively inhibited by the C3 transferase (C3) enzyme from Clostridium 
Botulinum by ADP-ribosylation  (Aktories et al., 1989).     
 
1.7.2  REGULATION OF Rho-GTPases 
 
Rho-GTPases, like other small G proteins, act as molecular switches by cycling 
between inactive GDP-bound and active GTP-bound states (Schmidt and Hall, 
2002,  Jaffe  and  Hall,  2005).    These  interactions  take  place  at  the  plasma 
membrane and Rho-GTPases interact with the membrane via a twenty-carbon 
chain geranylgeranyl lipid residue attached to their C-terminus (Seabra, 1998).  
Guanine nucleotide exchange factors (GEFs) facilitate the exchange of GDP for   56 
GTP, resulting in activation of the Rho-GTPase and subsequent downstream 
effector pathways.  GTPase activating proteins (GAPs) accelerate the intrinsic 
GTPase  of  Rho  family  members,  resulting  in  their  inactivation.    Guanine 
nucleotide dissociation inhibitors (GDIs) also play a role in regulating the activity 
of  these  small  G  proteins.    GDIs  interact  with  GDP  bound  Rho-GTPases, 
sequestering  them  in  the  cytosol,  inhibiting  GDP  dissociation  and  controlling 
cycling between the membrane and cytosol (Schmidt and Hall, 2002, Jaffe and 
Hall, 2005) (Figure 1.15).  Lysophosphatidic acid (LPA) was the first agonist 
identified to activate Rho (Ridley et al., 1992). Since then several other ligands 
acting on both GPCRs and receptor tyrosine kinases (RTKs) have been found 
to  activate  the  small  GTPase.    GEFs  are  critical  mediators  of  Rho-GTPase 
activity and extracellular stimuli acting on membrane receptors are thought to 
activate  GEFs,  subsequently  resulting  in  the  activation  of  Rho-GTPase  and 
downstream signalling pathways (Schmidt and Hall, 2002).  Some GEFs are 
highly specific towards a single GTPase, for example, p115RhoGEF is selective 
for Rho (Hart et al., 1996), whilst others such as Vav1 regulate the activity of 
Cdc42, Rac and Rho (Olson et al., 1996). 
 
1.7.3  PHYSIOLOGICAL FUNCTIONS OF Rho 
 
The Rho-GTPase family mediates a variety of biological responses.  In addition 
to  the  major  role  regulating  assembly  of  the  actin  cytoskeleton  (Hall,  1998), 
Rho-GTPases also participate in a variety of other functions mediated by a wide 
variety  of  effector  proteins.    These  process  include  cell  polarity,  gene 
transcription, vesicular transport, cell cycle progression, enzyme regulation and 
microtubule  dynamics  (Etienne-Manneville  and  Hall,  2002,  Jaffe  and  Hall, 
2005).   
Rho  itself  mediates  many  diverse  biological  functions.    Implicated  in  the 
regulation of neuronal development, activation of Rho has been found to inhibit 
neurite extension and the formation of dendritic spines (Luo, 2000, Li et al., 
2000, Wong et al., 2000).  Rho also plays an important role in cell contraction.  
In  the  cardiovascular  system  for  instance,  vasoconstriction  and  vasodilation, 
process that control blood flow and are also important to normal physiological 
function can be regulated by Rho.  In aortic smooth muscle, numerous agonists   57 
have been shown to activate Rho, which via its effector protein ROCK induces 
myosin light chain phosphorylation thereby promoting contraction (Fukata et al., 
2001, Sakurada et al., 2001).  Futhermore, Rho is also involved in the control of 
barrier function in vascular endothelial cells, which controls functions such as 
the extravasation of circulating lymphocytes into underlying tissues (van Nieuw 
Amerongen et al., 2000).  The contractile forces generated by Rho activation 
are thought to destabilise endothelial cell-cell junctions (Wojciak-Stothard et al., 
2001).    Moreover,  during  migration,  the  small  GTPase  regulates  contractile 
forces required at the rear of the cell and is also associated with focal adhesion 
assembly  (Raftopoulou  and  Hall,  2004).    In  addition,  Rho  plays  a  role  in 
phagocytosis,  mediating  type  II  phagocytosis  by  macrophages  via  the 
complement receptor (Caron and Hall, 1998).  A role in cell proliferation and cell 
cycle  progression  has  also  been  described.    In  fibroblasts  Rho  plays  two 
important roles in this process, inhibiting expression of cyclin/cyclin dependent 
kinase (Cdk) inhibitor p21
Waf/Cip1 and also inducing cyclin D1 expression in mid-
G1 phase  (Olson et al., 1998, Welsh et al., 2001a).  Rho also participates in the 
secretion of mediators such as histamine from immune cells (Norman et al., 
1996, Pinxteren et al., 2000).  Furthermore, Rho modulates gene expression by 
regulating transcription factors such as serum response factor (SRF) and NFкB  
(Hill et al., 1995, Perona et al., 1997).  The large and diverse array of responses 
elicited by Rho activation are regulated by its many effector proteins.  
 
1.7.4.  Rho EFFECTOR PROTEINS 
 
Several cellular targets of Rho have been identified.  These effectors interact 
specifically with the GTP-bound form of the GTPase at specific sites (Bishop 
and Hall, 2000).  The Rho effectors protein kinase N1 (PKN1) and PKN2 are 
involved in endosomal trafficking.  Other Rho effectors, mammalian diaphanous 
protein 1 (mDia1), mDia 2 and mDia 3 mediate both microtubule stabilisation 
and actin polymerisation.   Citron, another mediator is a kinase that is critical for 
cytokenesis  and  has  also  been  implicated  in  other  elements  of  cell  cycle 
progression.  One of the most widely studied Rho effector proteins is ROCK, 
which plays an important role in mediating cell contractility. 
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1.7.5.  RHO ASSOCIATED KINASE (ROCK) 
 
ROCK, a 160kDa serine/threonine kinase, was the first identified substrate of 
Rho and was initially characterised for its role in mediating stress fibre formation 
and  focal  adhesions  (Leung  et  al.,  1996,  Somlyo  and  Somlyo,  2000).    Two 
isoforms have been identified, ROCK1 and ROCK2, which have 65% overall 
sequence identity.  The kinase domain of these proteins is highly conserved, 
exhibiting 92% identity (Nakagawa et al., 1996).  ROCK1 is widely expressed in 
a  variety  of  tissues  including,  the  heart,  lung,  kidney,  pancreas  and  skeletal 
muscle, with little expression detected in the brain.  ROCK2 however, is highly 
expressed in the brain, with low levels also detected in the lung (Amano et al., 
2000).    Structurally,  ROCK  is  composed  of  an  N-terminal  kinase  domain,  a 
coiled-coil domain and an auto-inhibitory C-terminus.  The auto-inhibitory region 
contains the Rho-binding (RB) and pleckstrin homology (PH) domains.  In its 
resting state, both RB and PH domains can bind independently to the amino 
terminal kinase domain, inhibiting kinase activity.  Binding of Rho-GTP with the 
RB domain alters the conformation of ROCK, disrupting the interaction between 
auto-inhibitory  and  kinase  regions,  freeing  the  kinase  domain  and  thus 
activating ROCK (Amano et al., 2000, Riento and Ridley, 2003) (Figure 1.16).  
ROCK can also be activated independently of Rho by some lipids, especially 
arachadonic acid (AA) (Feng et al., 1999).  Furthermore, other small GTPases, 
including  Gem and  RhoE,  have been  shown  to  bind  to  ROCK and have  an 
inhibitory effect.  RhoE inhibits ROCK1 by binding to its amino-terminal region, 
encompassing  the  kinase  domain,  and  attenuates  the  ability  of  ROCK  to 
phosphorylate its downstream targets (Riento et al., 2003).  Gem on the other 
hand, binds the coiled-coil domain of ROCK adjacent to the RB domain.  This 
has been suggested to modify the substrate specificity of ROCK, as it inhibits 
ROCK-mediated  phosphorylation  of  myosin  light  chain  but  not  LIM  kinase 
(Ward et al., 2002).  
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1.7.6.  ROCK EFFECTOR PROTEINS 
 
ROCK  activates  a  variety  of  proteins  to  mediate  its  effects.    Most  notably, 
ROCK interacts with and phosphorylates both myosin light chain (MLC) and the 
myosin-binding subunit of MLC phosphatase (Amano et al., 1996, Kawano et 
al.,  1999).    MLC  phosphatase  is  inhibited  by  phosphorylation,  resulting  in 
increased MLC phosphorylation. This, in addition to the direct phosphorylation 
of MLC by ROCK, stimulates the actin-activated ATP-ase activity of myosin and 
promotes  the  assembly  of  actin-myosin  filaments  and  mediates  stress  fibre 
formation (Amano et al., 1996, Kawano et al., 1999, Bresnick, 1999).  Activation 
of these substrates also increases tension generation and induces contraction 
in muscular cells (Fukata et al., 2001, Sakurada et al., 2001).  Another ROCK 
target  is  LIM  kinase  (LIMK)  which,  when  phosphorylated  by  ROCK, 
subsequently phosphorylates and inactivates cofilin, resulting in stabilisation of 
actin  filaments  (Bamburg  et  al.,  1999,  Maekawa  et  al.,  1999).    ROCK  also 
activates a ubiquitous Na
+/H
+ exchange protein (NHE1), which also contributes 
to stress fibre formation as well as focal adhesion formation (Tominaga and 
Barber, 1998, Tominaga et al., 1998).  Other ROCK substrates that contribute 
to  actin  assembly  are  adducin  and  the  ERM  (ezrin/radaxin/moesin)  family 
proteins.    Phosphorylation  of  adducin  by  ROCK  may  be  necessary  for 
membrane ruffling, while activation of ERM is thought to be involved in microvilli 
formation (Amano et al., 2000).  Furthermore, the ROCK-mediated activation of 
collapsin response mediator protein-2 (CRMP2) participates in the process of 
neuronal  growth  cone  collapse  (Arimura  et  al.,  2000).    ROCK  also 
phosphorylates the intermediate filament proteins, vimentin, neurofilament and 
glial  fibrillary  acidic  protein  (GFAP)  to  induce  depolymerisation,  a  function 
important in cytokinesis (Kosako et al., 1997, Goto et al., 1998, Hashimoto et 
al., 1998, Yasui et al., 1998).  In summary, it can be seen that ROCK activates 
a wide range of effector proteins necessary to tranduce signals initiated by Rho 
activation  (Figure  1.17).    Activation  of  the  Rho/ROCK  pathway  has  been 
implicated in variety of pathological condition such as hypertension, vascular 
inflammation, atherosclerosis and cerebral ischemia (Rikitake and Liao, 2005).  
ROCK may also play a role in the development of PAH, which is discussed 
extensively in the introduction to Chapter 4.   60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15  Regulation of Rho-GTPase activation. 
 
Small GTPases such as Rho cycle between an inactive GDP-bound form and 
an  active  GTP-bound  form.    Activation  is  controlled  by  guanine  nucleotide 
exchange factors (GEFs), which facilitate exchange of GDP for GTP.  GTPase 
activating  proteins  (GAPs)  increase  intrinsic  GTPase  activity  of  Rho  family 
members thereby deactivating them.  Guanine nucleotide dissociation inhibitors 
(GDIs) also regulate activity by sequestering Rho-GTPases in the cytosol.   61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.16  Regulation of Rho-kinase (ROCK) activity. 
 
Binding  of  Rho-GTP  to  the  Rho-binding  domain  (RB)  of  ROCK  disrupts  an 
autoinhibitory intramolecular interaction, freeing the catalytic kinase domain and 
allowing it to interact with ROCK substrates.  ROCK remains active until GTP 
hydrolysis of Rho occurs.  (PH, pleckstrin homology domain).  Figure adapted 
from Amano et al (2000).   62 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.17.  Summary of ROCK effectors and functions. 
The activation of ROCK by the small G protein Rho results in the phosphorylation of downstream substrates that have multiple 
physiological effects.  ROCK substrates include collapsin response mediator protein 2 (CRMP2), adducin, intermediate filament 
proteins (IFs), LIM kinase (LIMK), ERM family proteins (ezrin/radixin/moesin), myosin light chain (MLC) and the myosin binding 
subunit of myosin phosphatase (MBS).  Figure adapted from Amano et al (2000).   63 
1.8   5HT-INDUCED  SIGNALLING  PATHWAYS  INVOLVED  IN 
VASCULAR REMODELLING 
 
Although  5HTT  appears  to  be  the  major  player  in  mediating  the  mitogenic 
effects of 5HT in human PASMCs (Marcos et al., 2004, Eddahibi et al., 1999), 
5HT  receptors  have  also  been  found  to  contribute  to  the  signalling  process 
required for cellular proliferation even if they do not directly induce proliferation 
in their own right.  Much of the work on 5HT-induced mitogenic signalling has 
been  carried  out  in  bovine  PASMCs.    Briefly,  these  studies  suggest  that 
formation  of  reactive  oxygen  species  (ROS)  by  the  activation  of  NADPH 
oxidase,  following  5HT  entry  via  5HTT,  results  in  the  activation  of  ERK,  a 
process that is pivotal in mediating the proliferative effects of 5HT (Lee et al., 
1999, Lee et al., 2001, Lee et al., 1998b).  Once in the nucleus, activated ERK 
can phosphorylate transcription factors including GATA-4 (Suzuki et al., 2003), 
Elk-1 and Erg-1, as well as inducing cyclin D1 expression (Liu et al., 2004) and 
thus promoting proliferation.  In this cell type, 5HT receptors have also been 
found  to  contribute  to  the  proliferative  effects  of  5HT  independently  of  ERK 
activation.  Stimulation of the 5HT1B/1D receptor has been shown to result in the 
activation of the small G-protein Rho and the resulting activation of ROCK, its 
downstream mediator, facilitates the translocation of ERK to the nucleus where 
it can mediate its mitogenic effects (Liu et al., 2004).  Futhermore, the 5HT2A 
receptor is also involved in the mitogenic response.  This receptor appears to 
activate  the  phosphatidylinositol-3-kinase  (PI3K)/protein  kinase  B  (PKB) 
pathway,  resulting  in  the  downstream  activation  of  the  mammalian  target  of 
rapamycin (mTOR) and subsequent p70 ribosomal S6 kinase (S6K1) activation 
(Liu and Fanburg, 2006).  Reactive oxygen species were also found to be a 
requirement for PKB activation in this instance.  Furthermore, inhibition of MEK 
by  various means blocked 5HT-induced S6K phosphorylation but not that of 
PKB suggesting another pathway may be involved (Liu and Fanburg, 2006). 
Therefore,  in  this  cell  type,  diverse,  independent  signalling  pathways  are 
activated  by  5HT,  via  5HT  receptors  and  5HTT,  resulting  in  PASMCs 
proliferation (Figure 1.18).   64 
The signalling pathways utilised by 5HT appear to be cell type-specific.  In a 
study using commercially available human PASMCs, 5HT was found to induce 
proliferation  by  a  different  mechanism  for  that  seen  in  bovine  PASMCs, 
however this model also highlighted the requirement for both 5HTT and 5HT 
receptors in the mitogenic process.  In this case, the 5HT2A receptor mediated 
ERK activation in response to 5HT, while 5HT transported into the cell via 5HTT 
was subsequently broken down by MAO-A to produce reactive oxygen species 
required to facilitate the translocation of ERK to the nucleus (Lawrie et al., 2005) 
(Figure  1.19).    A  role  for  MAO  has  also  been  suggested  in  5HT  signal 
transduction in cardiac myocytes.  In these cells, the 5HT2B receptor was found 
to  contribute  to  the  proliferative  effects  of 5HT,  as  inhibition  of  this  receptor 
resulted in the reduction of 5HT-mediated ERK activation.  However, inhibition 
of 5HTT had a more marked effect, inhibiting ERK activation by more than 80%.  
As suggested in human PASMCs, entry of 5HT into the cell via 5HTT, resulted 
in the generation of reactive oxygen species by the action of MAO-A.  In this 
instance,  the  generation  of  ROS  were  required  to  induce  ERK  activation 
(Bianchi  et  al.,  2005).    Various  5HT  receptors  has  been  demonstrated  to 
coupled  positively  to  ERK  activation,  including  5HT1A  (Cloez-Tayarani  et  al., 
2004, Adayev et al., 2003), 5HT2A (Gooz et al., 2006), 5HT2B (Nebigil et al., 
2003, Nebigil et al., 2000b), 5HT4 (Norum et al., 2003), and 5HT7 (Lin et al., 
2003, Norum et al., 2003). In the case of the 5HT2B receptor, activation of ERK 
promotes cell survival in addition to progression through the cell cycle (Nebigil 
et al., 2003, Nebigil et al., 2000b).  Taken together, these studies suggest that 
ERK activation is required in order to mediate the mitogenic effects of 5HT and 
also highlight the importance of 5HTT and 5HT receptors in this process.  
In addition to its role in mitogenesis, 5HT has also been found to promote cell 
migration.  In human aortic endothelial cells, 5HT has been shown to potently 
enhance cell migration through a RhoA- and ERK-dependent pathway mediated 
by 5HT1 receptors and 5HTT (Matsusaka and Wakabayashi, 2005a).  Similar 
effects  were  also  observed  in  human  aortic  SMC,  although  in  this  cell  type 
migration was mediated via the 5HT2A receptor (Matsusaka and Wakabayashi, 
2005b).    Likewise,  5HT  induces  PASMC  migration,  a  process  that  may  be 
important  in  vascular  remodelling  given  the  extension  of  PASMCs  into  non-
muscular pulmonary artery during PAH.  Day et al (2006) reported that in bovine   65 
PASMC,  5HT  stimulated  migration  and  cytoskeletal  reorganisation  through 
activation of the 5HT4 receptor, a process that required the elevation of cAMP 
and activation of a chloride channel (Day et al., 2006).  In this cell type, ERK 
activation is also required for migration to occur, although this was not mediated 
by either the 5HT4 receptor subtype or elevation of cAMP.  Regulation of motility 
by  ERK  may  therefore  occur  in  parallel  to  5HT-induced  cytoskeletal 
rearrangments and be mediated by another receptor (Day et al., 2006).   
5HT also plays a role in PAH by influencing other pathways important in the 
development and maintanence of the condition.  For example recently, 5HT was 
found to transactivate PDGFRβ in PASMCs and this process was dependent on 
5HTT.  The transactivation process described was important in mediating SMC 
proliferation and migration (Liu et al., 2007).  Furthermore, 5HT has also been 
observed  to  interact  with  the  BMP  signalling  pathway  and  promote  the 
development of PAH.  In a study using BMPR2-deficient mice, treatment with 
5HT  exaggerated  the  pulmonary  hypertensive  effects  of  chronic  hypoxia 
compared to wild-type littermates.  It was proposed this effect occurred due to 
the  ability  of  5HT  to  inhibit  BMPR2  signalling,  attenuating  Smad  1/5 
phosphorylation and the transcription of BMP/Smad target genes (Long et al., 
2006).    It  can  therefore  be  seen  that  5HT  stimulates  diverse  signalling 
pathways, mediated via 5HTT and various 5HT receptors, and also modulates 
other signalling pathways resulting in the promotion of vascular remodelling and 
thus contributing to the development of PAH.  
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Figure 1.18  5HT-induced mitogenic signalling transduction pathways in bovine pulmonary artery smooth muscle cells 
(PASMCs). 
 
In bovine PASMCs 5HT-induced proliferation requires co-operation between ERK, ROCK and PI3K pathways.  The action of 5HT 
on the 5HT transporter (5HTT) results in the activation of the ERK pathway, a process that is dependent on the production of 
reactive oxygen species (ROS) by NADPH oxidase.  The 5HT1B receptor is involved in mediating the activation of ROCK, which is 
required to facilitate the translocation of active ERK to the nucleus.  Additionally, activation of the PI3K/Akt pathway by the 5HT2A 
receptor is also important in the proliferative response.  Figure adapted from Liu and Fanburg (2006).   67 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.19  5HT-induced mitogenic signal transduction pathways in human PASMCs. 
 
In human PASMCs the 5HT2A receptor and the 5HT transporter (5HTT) co-operate to mediate the proliferative effects of 5HT.  The 
5HT2A receptor is involved in the process of ERK activation, while transport of 5HT into the cell via 5HTT results in the formation of 
reactive  oxygen  species  (ROS)  due  to  5HT  breakdown  by  the  enzyme  monoamine  oxidase-A  (MAO-A).    ROS  produced  are 
required  for  the  translocation  of  ERK  to  the  nucleus,  where  it  activates  the  transcription  factor  GATA-4  and  transcription  of 
mediators that result in cellular proliferation.  Figure adapted from Lawrie et al (2005).   68 
1.9  AIM 
 
The monoamine and mitogen, 5HT has been implicated in the development of 
PAH.  However, the signal transduction pathways utilised by 5HT to induce cell 
proliferation and thus contribute to pulmonary vascular remodelling are not fully 
understood.    Therefore,  the  aim  of  this  thesis  is  to  characterise  cellular 
signalling  pathways  that  contribute  to  the  mitogenic  effects  of  5HT  and 
determine a role for these pathways in vivo.   69 
  
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
MATERIALS AND METHODS   70 
2.1  Materials 
 
Abcam Ltd, Cambridge, UK: 
Anti-SP1 antibody (ab13370), anti-GAPDH antibody (ab8245). 
 
Amersham Biosciences UK Ltd, Buckinghamshire, UK: 
[methyl-
3H]Thymidine (specific activity 2.0Ci/mmol), Rainbow Markers (14.4-220 
kDa). 
 
Biorad Laboratories Ltd, Hemel Hempstead, UK: 
Bradford’s reagent. 
 
Calbiochem, Merck Biosciences Ltd, Nottingham UK: 
Anti-cyclinD1(Ab-3) mouse mAb (CC12), conconavalin A from 
Conconavalin ensiformis (conA), phorbol-12-myristate-13-acetate (PMA), 
U0126, SB203580.  
 
Cambrex Bio Science, Berkshire, UK: 
Dulbecco’s  Modified  Eagle  Medium  with  4.5g/l  glucose  (DMEM),  Dulbecco’s 
Phosphate Buffered Saline without Ca
2+ and Mg
2+ (PBS). 
 
Cell Signaling Technology Inc, Beverly, MA, USA: 
Phospho-MEK1/2 (Ser217/221) antibody (9121), p44/42 MAP Kinase antibody 
(9102),  phospho-p44/42  MAP  Kinase  (Thr202/Tyr204)(E10)  mouse  mAb 
(9106), phospho-p38 MAP Kinase (Thr180/Tyr182) antibody, p38 MAP Kinase 
antibody (9212). 
 
Cytoskeleton Inc, Denver, CO, USA: 
Cell permeable C3 transferase from Clostridium botulinum. 
 
Fisher Scientific, Loughborough, Leicestershire, UK: 
4-2-hydroxyethyl-1-piperazineethanesulphonic acid (HEPES), glycine, 
hydroxymethyl-aminomathane (Tris) base, sucrose, sodium hydroxide, 
ammonium persulphate, concentrated hydrochloric acid, sodium 
carbonate, sodium hydrogen carbonate, sodium dihydrogen ortho-
phosphate, disodium hydrogen ortho-phosphate. 
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Inverclyde Biologicals, Bellshill, Lanarkshire, UK 
Protan nitrocellulose membrane (Scleicher and Schuell; pore size 0.2 m). 
 
Invitrogen Ltd, Paisley, UK: 
AlexaFluor   594 -conjugated phalloidin, Trizol reagent. 
 
McQuilkin Laboratory Supplies: 
Skimmed Milk 
 
Melford Laboratories Ltd, Ipswich, Suffolk, UK: 
Dithiothreitol (DTT). 
 
Meniel-Glaser, Braunschweig, Germany: 
Microscope slides, coverslips. 
 
Perkin Elmer, Boston, MA, USA: 
Western Lightning    Chemiluminescence Reagent Plus, glass fibre filter 
mat A, sample bags, Betaplate Scint for Betaplate. 
 
Pierce, Rockford, IL, USA: 
Western blot stripping solution. 
 
Riedel-de Haen, Germany: 
Ethylenediaminetetra-acetic  acid  (EDTA),  ethyleneglycol-bis(2-aminoethyl)-
N,N,N’,N-tetra acetic acid (EGTA), glycerol, methanol. 
 
Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA: 
Phospho-cofilin (Ser3) antibody (sc12912). 
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Sigma-Aldrich Ltd, Poole, Dorset, UK: 
Cytochalasin D from Zygosporium mansonii (Cyto D), latrunculin B (Lat 
B), monoclonal anti-a a a a tubulin antibody (T9026), goat anti-mouse IgG 
(whole molecule) peroxidase conjugate (A4416), methiothepin (mesylate 
salt), iproniazid (phosphate salt), anisomycin (AN), 5-hydroxytryptamine 
(serotonin)(creatine sulphate salt) (5HT), foetal bovine serum (FBS), L-
glutamine (200mM), penicillin streptomycin solution (10,000 units 
penicillin and 10mg streptomycin per ml in 0.9% NaCl), N-acetyl-L-
cysteine (NAC), goat anti-rabbit IgG peroxidase conjugate (A8275), anti-
sheep IgG peroxidase conjugate (A3415), monodansylcadaverin (MDC), 
30% (w/v) acrylamide/0.8% (w/v) bis-acrylamide, trypsin-EDTA, 
Bromophenol Blue, phenylmethylsulphonyl fluoride (PMSF), benzamidine, 
soybean trypsin inhibitor, Tween-20, Triton X-100, bovine serum albumin 
(BSA), 4,4 dicarboxy-2, 2 biquinoline disodium salt, sodium deoxycholate, 
sodium potassium tartrate, copper (II) sulphate, N,N,N’,N’-
tetramethylethylenediamine (TEMED), paraformaldehyde, nonident P-40 
(NP-40). 
 
Tocris Bioscience, Bristol, UK: 
Y27632  dihydrochloride,  citalopram  hydrobromide,  GR55562  dihydrochloride, 
ketanserin  tartrate,  fluoxetine  hydrochloride,  a-methyl-5-hydroxytryptamine, 
CP94253. 
 
Upstate Biotechnology, Lake Placid, NY, USA: 
Anti-phospho-MYPT1 (Thr 696)(rabbit polyclonal IgG)(07-251), anti-MYPT1 
(sheep immunoaffinity purified IgG)(07-159). 
 
VWR International Ltd, Poole, UK: 
Sodium chloride, sodium dodecyl sulphate (SDS), potassium hydroxide, 
potassium chloride. 
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2.2  METHODS 
 
2.2.1  Cell Culture. 
 
CCL-39 Chinese hamster lung fibroblast cells were cultured in T-75 flasks in 
Dulbecco’s  Modified  Eagle  Medium  (DMEM)  supplemented  with  2mM  L-
glutamine,  100U/ml  penicillin,  100mg/ml  streptomycin  and  10%  (v/v)  foetal 
bovine serum (FBS).  Cells were maintained at 37
oC in a humidified 5% (v/v) 
CO2  atmosphere  (5%  CO2/95%  air)  until  confluent.    Once  confluent  the  cell 
monolayer was washed with Ca
2+- and Mg
2+ - free phosphate buffered saline 
(PBS).  The cells were then detached by addition of 2 ml trypsin, followed by 
incubation  at  37
oC.    6ml  of  media  were  then  added  to  the  flask  and  cells 
resuspended by gentle pipetting.  Thereafter, cells were either passaged into T-
75  flasks  to  maintain  the  cell  line  or  seeded  into  dishes  for  experimental 
analysis. 
 
2.2.2  Preparation of Cell Extracts for Immunoblotting. 
 
Cells  for  immunoblotting  were  grown  to  confluence  in  6-well  tissue  culture 
plates.  Following treatment with the appropriate stimuli, reactions were ceased 
by transferring to ice.  Media was then removed and the cell monolayer washed 
three times with 2 ml ice-cold PBS.  Cells were then lysed by scraping into 
200µl of RIPA buffer (50mM HEPES pH 7.5, 150mM NaCl, 1% (v/v) Triton X-
100,  0.5%  (w/v)  sodium  deoxycholate,  0.1%  (w/v)  SDS,  0.01M  sodium 
phosphate, 5mM EDTA, 0.1mM PMSF, 1µg/ml soybean trypsin inhibitor, 1µg/ml 
benzamidine) and transferred to ice-cold micro-centrifuge tubes, then allowed to 
solublise for 30 minutes with occasional vortexing.  The insoluble cellular debris 
was  then  removed  by  centrifugation  (20,000  g  for  15  min,  4
oC).    150µl  of 
supernatant were then taken for assay to determine protein concentration and 
analysis by SDS-PAGE and immunoblotting. 
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2.2.3  Determination of protein concentration by bicinchoninic acid (BCA) 
protein assay. 
 
BCA assays were carried out in a 96-well plate format with duplicate bovine 
serum albumin (BSA) standards ranging in concentration from 0-2 mg/ml in a 
volume  of  10µl.    The  same  volume  of  each  sample  of  unknown  protein 
concentration was also added in duplicate. Each well was then supplemented 
with 200µl of BCA solution (1% (w/v) 4,4 dicarboxy-2, 2 biquinoline disodium 
salt, 2% (w/v) sodium carbonate, 0.16% (w/v) sodium potassium tartrate, 0.4% 
(w/v)  sodium  hydroxide,  0.95%  (w/v)  sodium  dicarbonate  (pH  11.25),  0.08% 
(w/v)  copper  (II)  sulphate)  and  incubated  at  room  temperature  for  10-15 
minutes.  Protein concentration was then determined by measuring absorbance 
of  samples  at  492nm  (A492)  using  a  MRX-TCII  plate  reader  (Dynex 
Technologies).  The absorbance of the known standards was used to generate 
a best-fit straight-line plot of A492 versus protein concentration, from which the 
protein concentration of the unknown samples could be deduced. 
 
2.2.4.  Determination of protein concentration by Bradford’s protein assay. 
 
Bradford protein assays were carried out in a 96 well plate with duplicate BSA 
standards ranging in concentration from 0-2 mg/ml in a volume of 10µl.  The 
same  volume  of  each  sample  with  unknown  protein  concentration  was  also 
added in duplicate. Each well was then supplemented with 50µl of Bradford’s 
reagent which had been diluted 1:4 in distilled deionised water.  Samples were 
then incubated for 10 minutes at room temperature and protein concentrations 
determine by measuring absorbance at 630nm (A630).  A best-fit straight-line 
plot  of  A630  versus  protein  concentration  was  then  constructed  using  data 
obtained from the standards.  This plot was then used to deduce the unknown 
protein concentration of the experimental test samples. 
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2.2.5  SDS-PAGE and Immunoblotting Analysis. 
 
The  protein  concentrations  of  samples  prepared  for  SDS-PAGE  were 
determined by bicinchoninic acid (BCA) protein assay, unless otherwise stated.  
Samples  were  then  equalised  for  protein  concentration  and  volume,  and  2x 
SDS-PAGE sample buffer (50mM Tris, pH 6.8 at room temperature, 10% (v/v) 
glycerol, 12% (w/v) SDS, 10mM dithiothreitol, 0.0001% (w/v) bromophenol blue) 
added.    Samples  then  underwent  fractionation  by  SDS-PAGE  using  a  10% 
acrylamide resolving gel (10% (w/v) acrylamide, 0.3% (w/v) bisacrylamide, 0.4M 
Tris (pH 8.8), 0.1% (w/v) SDS, 0.01% (w/v) ammonium persulphate and 0.001% 
(v/v) TEMED) and 3% acrylamide stacking gel (3% (v/v) acrylamide, 0.1% (v/v) 
bisacrylamide, 0.1M Tris (pH 6.8), 0.1% SDS, 0.01% ammonium persulphate 
and 0.001% (v/v) TEMED) unless otherwise stated.  Electrophoresis of samples 
was  carried  out  in  the  presence  of  pre-stained  protein  markers  (Rainbow 
Markers  14.3  -  220  kDa,  Amersham  Biosciences)  in  order  to  estimate  the 
molecular mass of immunoreactive proteins.  Using Biorad Mini-Protean III gel 
electrophoresis  systems,  electrophoresis  was  carried  out  at  150V  in  running 
buffer  (27.4mM  Tris,  0.19M  glycine,  0.1%  (w/v)  SDS)  until  the  bromophenol 
blue dye front reached the bottom edge of the gel.  Fractionated proteins were 
then transferred to nitrocellulose membrane at 400mA for 45 minutes in transfer 
buffer  (24.7mM  Tris,  0.19M  glycine  and  20%  (v/v)  methanol).    Following 
transfer,  the  nitrocellulose  membrane  was  washed  briefly  in  Tris  Buffered 
Saline-Tween (TBST) (20mM Tris pH 7.5 at room temperature, 150mM NaCl, 
0.1% Tween 20), before blocking for one hour at room temperature in Blotto 
(5% (w/v) skimmed milk in TBST). Membranes were then incubated overnight 
with  1:1000  dilution  of  primary  antibody  in  5%  BSA  (w/v)  in  TBST  at  4
oC.  
Subsequently, membranes were washed three times in TBST for 10 minutes 
each  wash.    The  appropriate  HRP-conjugated  secondary  antibody  diluted 
1:1000  in  Blotto  was  then  incubated  with  membranes  for  1  hour  at  room 
temperature before three further 10-minute washes in TBST.  Each membrane 
was then treated with ECL reagents (Perkin Elmer) as per the manufacturer’s 
instructions and immunoreactive proteins were then visualised by exposure to 
X-ray film.   76 
Densitometry  was  performed  on  each  resulting  film  exposure  to  determine 
normalized levels of the protein of interest using Total Lab version 2.0 imaging 
software. 
 
2.2.6  [
3H]-Thymidine incorporation assay of  DNA synthesis  
 
Cells were plated out at a density of 2x10
4 cell/ml into 96-well plates and grown 
in full media for 24 hours before serum starving for a further 24 hours.  The 
media  was  then  replaced  with  fresh  media  containing  no  serum  and  the 
appropriate stimuli in a final volume of 200ml.  Each experimental condition was 
carried out in triplicate.  After an incubation period of 18 hours, 0.5mCi/well [
3H]-
thymidine  was  added.    Proliferation  was  stopped  after  a  further  6  hours  by 
harvesting cells onto glass fibre filter mats using a Betaplate 96-well harvester 
(Wallac).  The glass fibre filter mats used are printed on both sides with a grid to 
aid alignment with the wells of 96-well plates. During the harvesting process the 
96-well  plate  harvester  washes  each  well  with  distilled  water  three  times, 
dislodging the cell monolayer.  The contents of the aspirate are then transferred 
directly to the corresponding grid square of the glass fibre filter mat by vacuum 
filtration.  Filter mats are then left to dry before being sealed in clear plastic 
sample  bags  with  10  ml  of  scintillation  fluid  (Betaplate  Scint  for  Betaplate).  
Filters were then placed in a 96-format filtermat cassette and incorporated [
3H]-
thymidine    assessed  by  liquid  scintillation  counting,  using  a  1205  Betaplate 
Liquid Scintilation Counter (Wallac) and results expressed as counts per minute 
(cpm). 
 
2.2.7    Preparation  of  cytosolic  and  nuclear  cell  fractions  for  nuclear 
translocation experiments.  
 
Cells were seeded into 10cm tissue culture dishes and grown to confluence.  
Media  was  then  replaced  with  serum  free  media  and  incubated  overnight.  
Following this, cells were treated with the appropriate stimuli in the presence or 
absence  of  inhibitors  and  the  reaction  stopped  by  transferring  onto  ice.  
Subsequent steps were also performed on ice.  Media was aspirated and the   77 
cell  monolayers  washed  twice  with  ice  cold  PBS.    Cells  were  then  gently 
scraped from each tissue culture dish in a volume of 1ml PBS and transferred to 
ice cold micro-centrifuge tubes.  Samples were centrifuged at a temperature of 
4
oC for 4 minutes at ~2000g.  The resulting pellet was then resuspended in 
400ml of nuclear extraction buffer A (10mM HEPES (pH 7.9 with KOH), 10mM 
KCl, 0.1mM EDTA, 0.1mM EGTA, 1mM DTT) and left to incubate on ice for 15 
minutes,  after  which,  25ml  of  10%  (v/v)  NP-40  were  added  and  samples 
vortexed.    Subsequently,  samples  were  briefly  centrifuged  and  the  resulting 
supernatant containing the cytosolic cellular fraction removed and transferred to 
another micro-centrifuge tube. 
The remaining pellet was then washed 4 times with 500 l buffer A, with brief 
centrifugation  (20,000g  for  15  seconds)  between  each  wash  and  the 
supernatant  discarded.  After  the  final  wash  the  pellet  was  resuspended  in 
nuclear extraction buffer B (20mM HEPES (pH 7.9 with NaOH), 450mM NaCl, 
1mM  EDTA,  1mM  EGTA  1mM  DTT),  vortexed  and  incubated  on  ice  with 
occasional  agitation  for  15  minutes.    Finally,  samples  were  centrifuged  at 
20,000g for 15 minutes and the resulting supernatant, containing the nuclear 
fraction  removed  and  transferred  to  a  fresh  micro-centrifuge  tube.    Protein 
concentrations were measured using Bradfords assay and samples analysed by 
SDS-PAGE and immunoblotting. 
 
2.2.8  Staining of Actin Cytoskeleton 
 
Cells were seeded in 6-well plates (approx 2 x 10
5 cells/ml) onto sterile glass 
coverslips and grown for 16-24 hours, prior to serum starvation for a further 16 
hours. Cells were then treated with agonist in the presence or absence of other 
agents as described for each individual experiment.   
The following steps were carried out at room temperature.  Firstly, the media 
was removed and discarded and coverslips washed three times in 2 ml PBS.  In 
order to fix the cell monolayer, coverslips were then incubated for 15 minutes in 
2  ml  of  4%  (w/v)  paraformaldyde  in  a  5%  (v/v)  sucrose/PBS  solution.  
Subsequently coverslips were washed a further twice with 2 ml PBS and the cell 
monolayer permeabilised by the addition of 2 ml 0.1% (v/v) Triton X-100 in PBS   78 
for 2 minutes.  Coverslips were then washed twice in 2 ml PBS and blocked for 
30  minutes  in  5%  (w/v)  BSA  in  PBS.    100 l  of  Alexa  Fluor  594-conjucated 
phalloidin  diluted  1:20  in  a  5%  (w/v)  BSA/PBS  were  then  added  to  each 
coverslip and incubated fro 20-30 minutes.  Finally, cells were washed twice in 
PBS  and  mounted  on  glass  slides  in  40%  (v/v)  glycerol/PBS.    Fluorescent 
proteins were visualised on a Zeiss fluorescent microscope using x 40 objective 
and pictures obtained using Axiovision AC version 4.4 software. 
 
 
2.3  In Vivo METHODS 
 
2.3.1  In Vivo Experimental Design 
 
Experiments were conducted in accordance with the United Kingdom Animals 
(Scientific  Procedures)  Act  1986.    5HTT
+  mice  that  overexpress  5HTT, 
previously generated as described by Jennings et al 2006, were used in this 
study.  These mice were generated from the C567BL/6 X CBA wildtype (WT) 
strain, which were also used as controls. 
Briefly, the transgene used to develop the 5HTT
+ was 500 kb yeast artificial 
chromosome (YAC35D8) containing the human 5HTT (h5HTT) gene flanked by 
a 150 kb sequence towards the 5’ end and a 300kb towards the 3’ end, with the 
short allele of the 5HTTLPR in the promoter region and a 10-repeat allele of the 
VNTR in intron 2.  The yeast artificial chromosome was modified to include a 
hemagglutinin  epitope  tag  at  the  C-terminus  of  the  5HT  protein and  a  LacZ 
reporter  gene  downstream  of  an  internal  ribosomal  entry  site  as  described 
previously (Shen et al., 2000).  Analysis by in situ hybridisation showed that 
h5HTT  mRNA  was  expressed  in  a  pattern  that  closely  resembled  the 
endogenous mouse 5HTT gene (Jennings et al., 2006). 
For  the  purposes  of  this  study  both  WT  and  5HTT
+  female  mice  aged  5-6 
months  were  maintained  in  either  normoxic  (~  21%  (v/v)  oxygen)  or 
hypoxic/hypobaric  conditions  for  a  period  of  14  days.    To  achieve  hypoxic 
conditions,  animal  were  housed  in  a  hypobaric  chamber  that  was  initially   79 
depressurised slowly by 50 mbar every 15 minutes until the pressure reached 
550 mbar (~10% O2).  Animals were then maintained at 550 mbar for 14 days. 
During this period mice were dosed daily with either vehicle (water) or 30mgkg
-1 
Y27632 (a ROCK inhibitor) by oral gavage. 
 
2.3.2  In Vivo Haemodynamic Measurements 
 
After 14 days of drug dosage, anaesthesia was induced by 3% (v/v) halothane 
and body weight of mice determined.  Anaesthesia was then maintained with 
halothane (1% (v/v) to 1.5% (v/v)) and a mixture of nitrous oxide and oxygen 
(1:6)  using  a  face  mask.      Systemic  arterial  blood  pressure  (SAP)  was 
measured  by  cannulation  of  the  carotid  artery.    In  order  to  do  so,  the  right 
carotid  artery  was  first  isolated  and  tied  off  distally  using  surgical  thread.  
Following this a small artery clip was placed around the proximal end of the 
artery to prevent blood flow.  A small incision was made in the artery and the 
cannula (0.75mm OD, Portex) advanced in the proximal direction.  The cannula 
was then tied in place and the artery clip removed to allow measurement of 
SAP and heart rate (HR). 
Right ventricular pressure was measured using a 25 gauge needle mounted on 
a micromanipulator.  The tip of the needle was aligned with the mid point of the 
sternum and advanced through the diaphragm into the right ventricle.   Entry of 
needle into the right ventricle was confirmed by the morphology of the pressure 
trace  obtained.    Both  cannula  and  needle  were  attached  to  pressure 
transducers (Elcomatic E751A) connected to a MP100 data acquisition system 
(BIOPAC Systems Inc, Santa Barbra, CA). 
Results were analysed using an AcquiKnowledge 3.5 software package. 
Following the measurement of haemodynamics, heart and lungs were removed 
from each animal for analysis. 
 
2.3.3  Meaurment of Right Ventricular Hypertrophy 
 
Hearts  removed  following  haemodynamic  measurements  were  carefully 
dissected.  The atria were first removed, the right ventricular free fall was then 
dissected from the left ventricle plus septum.  The right ventricle free wall and   80 
LV plus septum were weighed separately and the ratio of right ventricle to left 
ventricle calculated.   
 
2.3.4  TaqMan Reverse Transcription-Polymerase Chain Reaction 
 
RNA was extracted from mouse whole lung tissue using Trizol reagent.  Real-
time  fluorogenic  reverse  transcription-polymerase  chain  reaction  (PCR)  was 
then performed by TaqMan® Gene Expression Assay (Applied Biosystems, CA, 
USA)  using  gene  expression  probes  for  mouse  ROCK  1  and  ROCK  2 
(Mn00485745_m1  and  Mm00485761_m1  respectively)  according  to  the 
manufacturers  instructions.    Relative  abundance  of  ROCK  1  and  ROCK  2 
mRNA was determined by using the comparative delta CT method with 18s 
ribosomal RNA as an internal control. 
This work was carried out by Dr J Sheward, University of Edinburgh. 
 
2.3.5  Lung Histology 
 
Three sagittal sections were obtained from left lungs.  Sections were stained 
with Elastica-Van Gieson stain and pulmonary arteries (<80  m) microscopically 
assessed in a blinded fashion for muscularization.  Arteries were considered 
muscularized  if  they  processed  a  distinct  double-elastic  lamina  visible  for  at 
least half the diameter in the vessel cross section.  At least 100 arteries were 
counted per lung section.  The percentage of vessels containing double-elastic 
lamina was calculated as the number of muscularized vessels/total number of 
vessels counted x 100. 
This work was carried out by Dr I Morecroft, University of Glasgow. 
 
2.3.6  Statistical Analysis. 
 
Statistical analyses were carried out using either Students two-tailed unpaired t-
test as described in Graphpad Prism 4 software. Where appropriate, one-way 
analysis  of  variance  (ANOVA)  with  Newman-Keuls  multiple  comparison  post 
test was applied, unless otherwise stated. 
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Chapter 3 
Characterisation of 5HT-stimulated  
Mitogenic Signalling Pathways   82 
3.1  INTRODUCTION 
 
5HT plays an important role in the etiology of PAH, contributing to remodelling 
and  vasoconstriction  of  the  pulmonary  circulation.    As  described  previously, 
5HT  and  the  expression  and  activity  of  5HTT  have  been  reported  to  play  a 
critical role in the disease process.  For instance, 5HT and 5HTT have been 
implicated in pulmonary vascular smooth muscle cell hyperplasia and vascular 
proliferation  in  both  experimental  hypoxic  PAH  and  the  human  condition 
(Eddahibi et al., 2001; Eddahibi et al., 2000b).  Furthermore, polymorphisms in 
the promoter region of the 5HTT gene resulting in increased 5HTT expression 
have been reported in around 65% of patients with familial PAH (Eddahibi et al., 
2003). 
At a cellular level several studies have highlighted the ability of 5HT to induce 
proliferation in a variety of cell types including, cardiac myocytes, endothelial 
cells and PASMCs (Bianchi et al., 2005; Pakala et al., 1999; Liu and Fanburg, 
2006).  The ability of 5HT to mediate cellular proliferation may be an important 
contributing  factor  to  pulmonary  artery  remodelling  during  pulmonary 
hypertension.  An array of intracellular pathways has been proposed to describe 
the signalling mechanisms utilised by 5HT to result in cellular proliferation.  A 
common  theme  of  these  hypotheses  is  the  ability  of  5HT  to  induce  ERK1/2 
activation, a process which appears to be key to the proliferative response (Lee 
et al., 1999; Lee et al., 2001). 
5HT  can  mediate  cell  signalling  by  interacting  with  several  5HT  receptor 
subtypes or through 5HTT, which transports 5HT across the plasma membrane 
using  a  Na
+/Cl
-  gradient.    A  large  body  of  evidence  exists  suggesting  the 
mitogenic effects of 5HT are largely mediated via 5HTT.  Much of this work has 
been  carried  out  in  bovine  PASMCs.    In  this  cell  type,  signal  transduction 
initiated  by  5HT  involves  5HTT-dependent  generation  of  reactive  oxygen 
species (ROS) and activation of the MEK/ERK pathway (Lee et al., 1998b; Lee 
et al., 1999; Lee et al., 2001).  In short, the 5HT-induced signalling response 
includes  the  sequential  activation  of  Ras/Rac-1,  NADPH  oxidase  activation, 
generation of ROS and finally the phosphorylation and activation of ERK MAP 
kinase  (Lee  et  al.,  1999;  Suzuki  et  al.,  2003).    Downstream  transcriptional 
components of this pathway have also been characterised.  For instance, in   83 
PASMCs, stimulation with 5HT has been found to induce the ERK-dependent 
DNA binding of transcription factors, Erg-1, GATA-4, as well as phosphorylation 
of Elk-1 (Liu et al., 2004; Suzuki et al., 2003). 
5HT receptors also appear to be important in the proliferative response, with a 
number of studies reporting the combined action of receptors and transporter 
are required to mediate the effects of 5HT.  For example, in  rat pulmonary 
artery  fibroblasts,  the  5HT2A  receptor  and  5HTT  are  both  involved  in  5HT-
induced proliferation (Welsh et al., 2004).  In another fibroblast cell line, 5HTT, 
5HT1B/1D  and  5HT2A    are  all  thought  to  be  involved  in  5HT-induced  ERK 
activation and proliferation (Lee et al., 1999).  Interactions between 5HTT and 
receptors have also been highlighted in PASMCs, where stimulation of 5HT1B/1D 
and  5HT2  receptors  result  in  the  activation  of  distinct  signalling  pathways 
required to facilitate the activation of ERK via 5HTT (Liu et al., 2004; Liu and 
Fanburg, 2006). 
The role of the p38 MAP kinase cascade in 5HT-mediated signalling is unclear.  
In certain cell types 5HT has been shown to activate p38 (Lieb et al., 2005, 
Welsh et al., 2004) and also play a role in 5HT-mediated contraction (Tasaki et 
al., 2003).  On the other hand, several studies have also shown that 5HT has no 
effect on p38 and is unable to induce its activation (Cloez-Tayarani et al., 2004; 
Lee et al., 2001).  In addition to this, p38 is thought to play an important role in 
the regulation of 5HTT (Prasad et al., 2005; Zhu et al., 2005). 
Another possible mechanism for 5HT induced proliferation has been suggested.  
In this model 5HT entry into the cell may result in proliferation via receptor-
independent reactive oxygen species generation.  It has been reported recently 
that 5HT is able to induce hypertrophy in cultured rat cardiac myocytes (Bianchi 
et al., 2005; Vindis et al., 2000).  This process appears to require the production 
of hydrogen peroxide, generated by the breakdown of 5HT by the enzyme MAO 
A.    Furthermore,  the  reactive  oxygen  species  formed  are  required  for  ERK 
activation, which in turn contributes to the myocardial remodelling.  MAO B has 
also been shown to generate hydrogen peroxide and that this leads to ERK1/2 
dependent mitogenesis (Vindis et al., 2000).   
Other factors  may  also  be  pivotal  in  regulating  5HT-induced  ERK  activation.  
For instance, components of the endocytotic pathway may be involved.  The 
scaffolding  proteins  β-arrestins  have  been  shown  to  bind  ERK1/2  and  thus   84 
regulate its activity (Tohgo et al., 2003; Tohgo et al., 2002).  In addition to this, it 
has  been  shown  that  the  5HT1A  receptor  must  undergo  calcium/calmodulin-
dependent receptor endocytosis in order to activate ERK (Della Rocca et al., 
1999).    Furthermore,  several  other  scaffolding  proteins  have  been  shown  to 
regulate  the  ERK  pathway  including  MEKK1  and  MP1  (Morrison  and  Davis, 
2003).  These proteins could potentially be involved in mediating 5HT-induced 
ERK activation. 
In  summary,  several  potential  signalling  pathways  required  for  5HT-induced 
mitogenesis  have  been  suggested.    However,  much  of  this  work  has  been 
carried  out  in  PASMCs.    As  mentioned  previously,  each  cell  type  within  the 
pulmonary  artery  contributes  to  the  remodelling  process  that  occurs  during 
PAH.  It would therefore be beneficial to investigate the role of 5HT and the 
signalling mechanisms utilised in other cell types.  In this chapter, 5HT induced 
mitogenesis  was  investigated  in  a  fibroblast  cell  line  (Chinese  hamster  lung 
fibroblasts (CCL-39s)) in order to elucidate any novel signalling mechanisms 
that may be involved in the remodelling process. 
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3.2  RESULTS 
 
Prior  to  identifying  components  involved  in  5HT  mitogenic  signalling,  the 
timecourse  of  5HT-induced  ERK1/2  activation  was  first  characterised.  
Quiescent CCL-39 cells were stimulated with 5HT (1 M) over a 24 hour period.  
Subsequent  immunoblotting  using  a  phospho-specific  ERK1/2  antibody 
revealed that addition of 5HT rapidly and transiently induced ERK1/2 activation, 
with  maximal  activation  occurring  around  2  minutes  (p<0.01  versus  vehicle, 
n=3) (Figure 3.1).  Levels returned to that of basal after 30 minutes with no 
further activation noted during the 24 hour period.  5HT was also found to have 
a  mitogenic  effect  in  CCL-39  cells,  inducing  a  dose  dependent  increase  in 
proliferation  as  determined  by  [
3H]-thymidine  incorporation  (Figure  3.2).  
Inhibition of the ERK1/2 MAP kinase signalling cascade using U0126 (1 M), a 
MEK inhibitor, markedly attenuated the effects of 5HT, reducing the maximal 
proliferation by 80±5% (Figure 3.2).  Furthermore, inhibition of MEK significantly 
reduced  5HT-induced  ERK1/2  activation  by  around  73±3%  (p<0.001  versus 
5HT alone, n=3) (Figure 3.3).  Under these circumstances responses to PMA 
were also significantly decreased (p<0.05, n=3), indicating U0126 was effective 
at the concentration used. 
Under certain conditions the p38 MAP kinase cascade has been implicated in 
signal transduction via 5HT receptors (Welsh et al., 2004) and in the regulation 
of  5HTT  (Zhu  et  al.,  2005).    To  investigate  the  involvement  of  p38  in  5HT-
induced signalling in CCL-39 cells, cells were stimulated over a period of time 
with 5HT (1 M).  Treatment with 5HT was found to have no effect on the levels 
of phosphorylated p38 (p-p38) during the timecourse studied, suggesting 5HT is 
unable to activate p38 (Figure 3.4).  In addition to this, the role of p38 in 5HT-
induced proliferation was assessed (Figure 3.5).  Treatment with p38 inhibitor 
SB203580  at a  concentration of  5 M  had no  effect  on  the  ability  of  5HT  to 
induce  proliferation.    In  contrast,  SB203580  at  a  concentration  of  10 M 
markedly reduced 5HT-induced proliferation, resulting in levels of [
3H]-thymidine 
incorporation similar to those witnessed under vehicle conditions.  SB203580 
(5 M) was effective in inhibiting p38 as pre-treatment with the inhibitor resulted 
in a significant attenuation in the response to anisomycin, a known p38 activator 
(63.7±3% reduction, p<0.001, n=3) (Figure 3.6).     86 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1  Timecourse of 5HT-induced ERK activation.   
 
CCL-39 cells were serum starved for 16 hours and then stimulated with 5HT 
(1µM) for 0-24 hours.  Cell lysates  were prepared and equalised for protein 
concentration by BCA assay.  Samples were then analysed by SDS-PAGE and 
immunoblotting using phospho-specific and total ERK antibodies.  Blots shown 
are representative.  Results are expressed as mean ± SEM (n=3).   * p<0.05, ** 
p<0.01 versus vehicle using Newman-Keuls multiple comparison test.   87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.2    Effect  of  MEK  inhibition  by  UO126  on  5HT-induced 
proliferation.   
 
CCL-39 cells were serum starved for 24 hours then incubated with 0-100µM 
5HT in the presence or absence of  UO126 (1µM) (MEK inhibitor) for a further 
24  hours,  with  0.5µCi/well  [
3H]-thymidine  added  for  the  final  6  hours  of  this 
incubation.    Cell  were  then  harvested  onto  a  glass  fibre  filter  mat  and  [
3H]-
thymidine incorporation assessed by liquid scintillation counting.  Data shown 
are  representative  of  n=3.    Results  expressed  as  mean  ±  SEM  of  triplicate 
samples.   ** p<0.01 versus vehicle using an unpaired, two tailed t-test.   88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3  Effects of MEK inhibition with UO126 on ERK activation.   
 
After serum starvation for 16 hours, CCL-39 cells were pre-treated with either 
vehicle or UO126 (1µM) for 30 minutes prior to stimulation with 5HT (1µM) or 
PMA (2 M) for 5 minutes.  Cell lysates were prepared and equalised for protein 
concentration by BCA assay.  Samples were then analysed by SDS-PAGE and 
immunoblotting using phospho-specific and total ERK antibodies.  Blots shown 
are representative.  Results are expressed as mean ± SEM (n=3).  * p<0.05 
versus PMA, *** p<0.001 versus 5HT using Newman-Keuls multiple comparison 
test.   89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4  Timecourse of the effects of 5HT on p38 activation.   
 
Following serum starvation for 16 hours, CCL-39 cells were stimulated with 5HT 
(1µM) for 0-120 minutes or with anisomycin (1 g/ml) for 5 minutes. Cell lysates 
were prepared and equalised for protein concentration by BCA assay.  Samples 
were then analysed by SDS-PAGE and immunoblotting using phospho-specific 
and  total  p38  antibodies.    Blots  shown  are  representative.      Results  are 
expressed  as  mean  ±  SEM  (n=3).    Statistical  analysis  using  Newman-Keuls 
multiple comparison test revealed no significant differences.  Stimulation with 
anisomysin  (1 g/ml)  for  5  minutes  resulted  in  a  1.8±0.3  fold  increase  from 
basal.   90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.5    Effects  of  p38  inhibition  by  SB203580  on  5HT-induced 
proliferation.   
 
CCL-39 cells were serum starved for 24 hours then incubated with 0-100µM 
5HT in the presence or absence of  SB203580 (5µM or 10µM) (p38 inhibitor) for 
a further 24 hours, with 0.5µCi/well [
3H]-thymidine added for the final 6 hours of 
this incubation.  Cell were then harvested onto a glass fibre filter mat and [
3H]-
thymidine incorporation assessed by liquid scintillation counting.  Data shown 
are  representative  of  n=3  assays.    Results  expressed  as  mean  ±  SEM  of 
triplicate samples.  * p<0.05, ** p<0.01 versus vehicle using an unpaired, two 
tailed t-test.   91 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6  Effects of p38 inhibitor SB203580 on p38 activation.   
 
After serum starvation for 16 hours, CCL-39 cells were pre-treated with either 
vehicle or SB203580 (10µM) for 30 minutes prior to stimulation with 5HT (1µM) 
or anisomysin (1 g/ml) for 5 minutes.  Cell lysates were prepared and equalised 
for protein concentration by BCA assay.  Samples were then analysed by SDS-
PAGE  and  immunoblotting  phospho-specific  and  total  p38  antibodies.    Blots 
shown are representative.  Results are expressed as mean ± SEM (n=3). ** 
p<0.01 versus anisomycin using Newman-Keuls multiple comparison test.   92 
However, the ability of SB203580 (10 M) to reduce 5HT-induced proliferation 
maybe  owing  to  the  fact,  that  at  this  concentration  the  p38  inhibitor  also 
significantly reduced responses to PMA by 27±4% (p<0.01, n=3) (Figure 3.7), 
suggesting the ERK1/2 MAP kinase pathway may also be effected.  A large 
body  of  evidence  exists  implicating  5HTT  in  the  development  of  pulmonary 
hypertension.  Therefore, the role of 5HTT in the pathways utilised by 5HT to 
induce  its  mitogenic  effects  were  assessed.    Using  CCL-39  cells  5HTT  was 
blocked  using  citalopram,  a  commonly  used  selective  serotonin  reuptake 
inhibitor (SSRI) and the effects on 5HT-induced ERK1/2 activation monitored.  
Pre-treatment with citalopram (1 M) was found to significantly attenuated the 
dose-dependent increase in ERK1/2 activation induced by 5HT, reducing the 
maximal  5HT  response  by  35±9%  (p<0.05,  n=3)  (Figure  3.8).    Moreover, 
treatment with citalopram also markedly decreased 5HT-induced proliferation by 
82±2% of the maximal response (Figure 3.9). 
5HT receptors, namely 5HT1B/1D and 5HT2A may also be involved in the 5HT-
induced mitogenic response (Lee et al., 1999; Liu and Fanburg, 2006).  Initially, 
the 5HT1/2 receptor antagonist methiothepin was used in order to determine if 
these  5HT  receptors  played  any  role  in  5HT-induced  ERK1/2  activation  and 
proliferation in CCL-39 cells.  Pre-treatment with methiothepin (1 M) was able 
to  significantly  attenuate  the  dose-dependent  increase  in  ERK1/2  activation 
elicited  by  5HT  (Figure  3.10),  with  the  maximal  5HT  response  reduced  by 
50±7% (p<0.01, n=3).  Inhibition of 5HT1/2 receptors using methiothepin also 
almost  completely  abolished  5HT  induced proliferation  reducing  the  maximal 
response by 91±1 % (Figure 3.11). 
The individual contribution of 5HT2A and 5HT1B/1D receptors was then assessed 
pharmacologically.    Pre-treatment  of  cells  with  ketanserin  (1 M),  a  5HT2A 
receptor  antagonist,  significantly  reduced  maximal  5HT-induced  ERK1/2 
activation by 47±9% (p<0.05, n=3) (Figure 3.12).  Similarly, blockade of 5HT2A 
receptors  using  ketanserin  almost  completely  abolished  5HT-induced 
proliferation, resulting in levels of [
3H]-thymidine incorporation similar to those 
witnessed under vehicle conditions (Figure 3.13).  The role of 5HT1B/1D was also 
examined using GR55562, a selective 5HT1B/1D receptor antagonist.  Treatment 
with this compound also significantly reduced 5HT-induced ERK1/2 activation to 
57±7% of the maximal response (p<0.001, n=3) (Figure 3.14).  In addition to   93 
this, 5HT1B/1D receptor antagonism abolished the dose-dependent increase in 
proliferation induced by 5HT (Figure 3.15).  Moreover, simultaneous inhibition of 
5HTT  and  5HT  receptors  using  a  combination  of  citalopram  (1 M)  and 
methiothepin (1 M) did not completely abolish 5HT induced ERK1/2 activation.  
At the maximal response, inhibition of 5HTT and 5HT1/2 receptors reduced 5HT-
induced ERK1/2 activation by 57±5% (p<0.001, n=3) (Figure 3.16).  It should 
also be noted that the SSRI and 5HT antagonists used in this study had no 
effect on the ability of PMA to activate ERK, indicating the reductions in ERK 
activation observed are specific to the 5HT signalling pathway.  Taken together, 
these results suggest 5HTT, 5HT1B/1D and 5HT2A receptors all play a role in 
5HT-induced ERK1/2 activation and proliferation, with inhibition of any one of 
these components resulting in the attenuation of the mitogenic effects of 5HT. 
The role of receptor internalisation in 5HT-mediated ERK1/2 activation was also 
studied.  Endocytosis is known to play an important role in the regulation of 5HT 
receptors and GPCRs in general (Bhatnagar et al., 2001; Le Roy and Wrana, 
2005) as well as in regulating 5HTT signalling (Jayanthi et al., 2005).  Using 
structurally  unrelated  compounds,  the  role  of  endocytosis  in  5HT-induced 
ERK1/2  activation  was  investigated.    Conconavalin  A  (Con  A),  a  lectin  and 
commonly used inhibitor of endocytotic processes (Pippig et al., 1995; Tang et 
al.,  2000)  was  initially  employed.    Con  A  binds  to  α-D-mannosyl  and  α-D-
glucosyl residues on cell surface proteins and lipid with high affinity, inhibiting 
their mobility and thus ability to be internalised (Zhao et al., 2002; Tang et al., 
2000).    Pre-treatment  with  this  compound  was  found  to  significantly  elevate 
basal  levels  of ERK1/2  activity  within  CCL-39  cells  by  31±4%  (p<0.01, n=3) 
(Figure  3.17).    In  addition  to  this,  the  maximal  5HT  response  was  similarly 
increased  in  the  presence  of  Con  A  (40±10%  increase,  p>0.05,  n=3).  
Monodansylcadaverin  (MDC),  a  compound  previously  shown  to  inhibit 
internalisation from the plasma membrane (Schutze et al., 1999; Davies et al., 
1980, Chow et al., 1998) was also used (Figure 3.18).  MDC is an inhibitor of 
transglutaminase,  a  membrane-bound  enzyme  that  participates  in  the 
internalisation of receptors (Schutze et al., 1999; Davies et al., 1980; Chow et 
al.,  1998).    MDC  was  found  to  have  no  effect  on  either  the  basal  levels  of 
pERK1/2 or 5HT-induced ERK1/2 activation.   94 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7  Effects of p38 inhibition by SB203580 on ERK activation.   
 
After serum starvation for 16 hours, CCL-39 cells were pre-treated with either 
vehicle or SB203580 (10µM) for 30 minutes prior to stimulation with PMA (2 M) 
for  5  minutes.    Cell  lysates  were  prepared  and  equalised  for  protein 
concentration by BCA assay.  Samples were then analysed by SDS-PAGE and 
immunoblotting using phospho-specific and total ERK antibodies.  Blots shown 
are representative.  Results are expressed as mean ± SEM (n=3). ** p<0.01 
versus PMA using a two-tailed unpaired t-test.   95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.8    Effects  of  5HTT  inhibitor  citalopram  on  5HT-induced  ERK 
activation.   
 
After serum starvation for 16 hours CCL-39 cells were pre-treated for 1 hour 
with citalopram (1 M) (5HTT inhibitor).  Cells were then stimulated for 5 minutes 
with increasing concentrations of 5HT (0-10 M) or PMA (2 M).  Cell lysates 
were prepared and equalised for protein concentration by BCA assay.  Samples 
were then analysed by SDS-PAGE and immunoblotting using phospho-specific 
and  total  ERK  antibodies.    Blots  shown  are  representative.    Results  are 
expressed as mean ± SEM (n=3).  * p<0.05 versus vehicle pre-treated cells 
using an unpaired, two tailed t-test.   96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.9    Effects  of  5HTT  inhibition  by  citalopram  on  5HT-induced 
proliferation.   
 
CCL-39 cells were serum starved for 24 hours then incubated with 0-100µM 
5HT in the presence or absence of  citalopram (1µM) (5HTT inhibitor) for a 
further 24 hours, with 0.5µCi/well [
3H]-thymidine added for the final 6 hours of 
this incubation.  Cells were then harvested onto a glass fibre filter mat and [
3H]-
thymidine incorporation assessed by liquid scintillation counting.  Data show are 
representative of n=3 assays.  Results expressed as mean ± SEM of triplicate 
samples.  * p<0.05, ** p<0.01 versus vehicle using an unpaired, two tailed t-test.   97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10  Effects of 5HT1/2 receptor antagonist methiothepin on 5HT-
induced ERK activation.   
 
After serum starvation for 16 hours CCL-39 cells were pre-treated for 1 hour 
with  methiothepin  (1 M)  (5HT1/2  receptor  antagonist).    Cells  were  then 
stimulated  for  5  minutes  with  increasing  concentrations  of  5HT  (0-10 M)  or 
PMA (2 M).  Cell lysates were prepared and equalised for protein concentration 
by  BCA  assay.    Samples  were  then  analysed  by  SDS-PAGE  and 
immunoblotting using phospho-specific and total ERK antibodies.  Blots shown 
are representative.  Results are expressed as mean ± SEM (n=3).  * p<0.05, ** 
p<0.01 versus vehicle pre-treated cells using an unpaired, two tailed t-test.   98 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11  Effects of 5HT1/2 receptor antagonist methiothepin on 5HT-
induced proliferation.   
 
CCL-39 cells were serum starved for 24 hours then incubated with 0-100µM 
5HT in the presence or absence of methiothepin (1µM) for a further 24 hours, 
with 0.5µCi/well [
3H]-thymidine added for the final 6 hours of this incubation.  
Cell  were  then  harvested  onto  a  glass  fibre  filter  mat  and  [
3H]-thymidine 
incorporation  assessed  by  liquid  scintillation  counting.    Data  shown  are 
representative of n=3 assays.  Results expressed as mean ± SEM of triplicate 
samples.  *** p<0.001 versus vehicle using an unpaired, two tailed t-test.   99 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.12    Effects  of  5HT2A  receptor  antagonist  ketanserin  on  5HT-
induced ERK activation.   
 
After serum starvation for 16 hours CCL-39 cells were pre-treated for 1 hour 
with ketanserin (1 M) (5HT2A receptor antagonist).  Cells were then stimulated 
for 5 min with increasing concentrations of 5HT (0-10 M) or PMA (2 M).  Cell 
lysates were prepared and equalised for protein concentration by BCA assay.  
Samples  were  then  analysed  by  SDS-PAGE  and  immunoblotting  using 
phospho-specific  and total  ERK  antibodies.   Blots  shown  are  representative.  
Results  are  expressed  as  mean  ±  SEM  (n=3).    *  p<0.05,  **  p<0.01  versus 
vehicle pre-treated cells using an unpaired, two tailed t-test.   100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.13    Effects  of  5HT2A  receptor  antagonist  ketanserin  on  5HT-
induced proliferation.   
 
CCL-39 cells were serum starved for 24 hours then incubated with 0-100µM 
5HT in the presence or absence of ketanserin (1µM) for a further 24 hours, with 
0.5µCi/well [
3H]-thymidine added for the final 6 hours of this incubation.  Cell 
were  then  harvested  onto  a  glass  fibre  filter  mat  and  [
3H]-thymidine 
incorporation  assessed  by  liquid  scintillation  counting.    Data  shown  are 
representative of n=3 assays.  Results expressed as mean ± SEM of triplicate 
samples. ** p<0.01, *** p<0.001 versus vehicle using an unpaired, two tailed t-
test.   101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14  Effects of 5HT1B/1D antagonist GR55562 on 5HT-induced ERK 
activation.   
 
After serum starvation for 16 hours CCL-39 cells were pre-treated for 1 hour 
with GR55562 (1 M) (5HT1B/1D receptor antagonist).  Cells were then stimulated 
for 5 minutes with increasing concentrations of 5HT (0-10 M) or PMA (2 M).  
Cell  lysates  were  prepared  and  equalised  for  protein  concentration  by  BCA 
assay.  Samples were then analysed by SDS-PAGE and immunoblotting using 
phospho-specific  and total  ERK  antibodies.   Blots  shown  are  representative.  
Results are expressed as mean ± SEM (n=3).  ** p<0.01, *** p<0.001 versus 
vehicle pre-treated cells using an unpaired, two tailed t-test.   102 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.15    Effects  of  5HT1B/1D  receptor  antagonist  GR55562  on  5HT-
induced proliferation.   
 
CCL-39 cells were serum starved for 24 hours then incubated with 0-100µM 
5HT in the presence or absence of GR55562 (1µM) for a further 24 hours, with 
0.5µCi/well [
3H]-thymidine added for the final 6 hours of this incubation.  Cell 
were  then  harvested  onto  a  glass  fibre  filter  mat  and  [
3H]-thymidine 
incorporation  assessed  by  liquid  scintillation  counting.    Data  shown  are 
respresentative of n=3 assays.  Results expressed as mean ± SEM (n=3) of 
triplicate  samples.  *  p<0.05,  **  p<0.01,  ***  p<0.001  versus  vehicle  using  an 
unpaired, two tailed t-test. 
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Figure 3.16  Effects of simultaneous 5HT1/2 receptor and 5HTT inhibition 
by methiothepin and citalopram on 5HT-induced ERK activation.   
 
After  serum  starvation  for  16  hours  CCL-39  cells  were  pre-treated 
simultaneously for 1 hour with methiothepin (1 M) and citalopram (1 M).  Cells 
were then stimulated for 5 minutes with increasing concentrations of 5HT (0-
10 M) or PMA (2 M).  Cell lysates were prepared and equalised for protein 
concentration by BCA assay.  Samples were then analysed by SDS-PAGE and 
immunoblotting using phospho-specific and total ERK antibodies.  Blots shown 
are representative.  Results are expressed as mean ± SEM (n=3).  ** p<0.01, 
*** p<0.001 versus vehicle pre-treated cells using an unpaired, two tailed t-test.   104 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.17    Effects  of  conconavalin  A  (conA)  on  5HT-induced  ERK 
activation.   
 
After  serum  starvation  for  16  hours  CCL-39  cells  were  pre-treated  for  30 
minutes with conconavalin A (conA) (0.25mg/ml).  Cells were then stimulated 
for 5 minutes with increasing concentrations of 5HT (0-10 M) or PMA (2 M).  
Cell  lysates  were  prepared  and  equalised  for  protein  concentration  by  BCA 
assay.  Samples were then analysed by SDS-PAGE and immunoblotting using 
phospho-specific  and total  ERK  antibodies.   Blots  shown  are  representative.  
Results are expressed as mean ± SEM (n=3).  * p < 0.05 , ** p < 0.01 versus 
vehicle pre-treated cells using an unpaired, two tailed t-test.   105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18  Effects of monodansylcadaverin (MDC) on 5HT-induced ERK 
activation.   
 
After  serum  starvation  for  16  hours  CCL-39  cells  were  pre-treated  for  30 
minutes with monodansylcadaverin (MDC) (100 M).  Cells were then stimulated 
for 5 minutes with increasing concentrations of 5HT (0-10 M) or PMA (2 M).  
Cell  lysates  were  prepared  and  equalised  for  protein  concentration  by  BCA 
assay.  Samples were then analysed by SDS-PAGE and immunoblotting using 
phospho-specific  and total  ERK  antibodies.   Blots  shown  are  representative.  
Results  are expressed  as mean  ±  SEM  (n=3).    Statistical  analysis  using  an 
unpaired, two tailed t-test revealed no statistical differences between vehicle 
and MDC pre-treated cells. 
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In  an  attempt  to  distinguish  between  ERK1/2  activation  elicited  by  5HT 
receptors  and  5HTT,  selective  inhibitors  of  each  of  these  components  were 
used to determine if endocytosis is important in either 5HT receptor or 5HTT-
mediated responses.  To investigate the role of the endocytotic pathway in 5HT 
receptor-mediated ERK1/2 activation, 5HTT was blocked using fluoxetine (1µM) 
so  that  5HT  applied  to  the  cells  would  act  only  via  5HT  receptors.    In  this 
instance, inhibition of 5HTT with fluoxetine resulted in a significant reduction in 
5HT-induced  ERK1/2  activation  (p<0.05,  n=3)  (Figure  3.19).    However,  pre-
treatment with both fluoxetine and MDC resulted in levels of ERK1/2 activation 
similar to that witnessed in vehicle pre-treated cells.  Conversely, to determine 
the role played by the endocytotic pathway in 5HTT-mediated ERK1/2, 5HT2A 
and  5HT1B/1D  receptors  were  blocked  using  ketanserin  (1µM)  and  GR55562 
(1µM)  respectively.    Inhibition  of  5HT  receptors  was  found  to  significantly 
reduce  5HT-mediated  ERK1/2  activation  (p<0.01,  n=3)  (Figure  3.20).    Pre-
treatment with both MDC and 5HT receptor antagonists resulted in levels of 
ERK1/2  activation  similar  to  that  induced  by  5HT  under  vehicle  pre-treated 
conditions.  These findings suggest endocytosis is not a requirement for 5HT-
induced ERK1/2 activation via either 5HTT or 5HT receptors in CCL-39 cells. 
Possible  downstream  mediators  of  5HTT  and  5HT  receptors  were  then 
investigated.    Several  studies  have  reported  that  the  production  of  reactive 
oxygen  species  (ROS)  may  be  pivotal  in  the  ability  of  5HT  to  produce  its 
mitogenic  response  (Bianchi  et  al.,  2005;  Lawrie  et  al.,  2005).    In  order  to 
determine if ROS are involved in the 5HT-mediated response in CCL-39 cells, 
the antioxidant N-acetyl-cysteine (NAC) was employed.  At 10mM, NAC was 
found to significantly attenuate 5HT-induced ERK1/2 activation, with maximal 
5HT  responses  reduced  by  around  60±18%  (p<0.05,  n=3)  (Figure  3.21).  
Reduction  of  ROS  production  using  NAC  also  markedly  reduced  the 
proliferative effects of 5HT, with the maximal 5HT-induced response attenuated 
by 83±19% (Figure 3.22). 
It has previously been suggested that on entry into cells the breakdown of 5HT 
by  monoamine  oxidases  results  in  the production of  ROS  (Liu  et  al.,  2004).  
Thus, to test this hypothesis, iproniazid, a monoamine oxidase (MAO) inhibitor 
was used and its effects on 5HT-induced ERK1/2 activation and proliferation 
studied.  Pre-treatment with iproniazid (0.1mM) was found to have no effect on   107 
the concentration dependent increase in ERK1/2 activation produced by 5HT 
(Figure 3.23).  Likewise, selective inhibition of MAO did not effect the ability of 
5HT to induce proliferation in this cell type (Figure 3.24).   
ROCK  has  also  been  implicated  in  the  development  of  PAH  and  may  be  a 
downstream mediator  of  the  5HT mitogenic  response  (Lee  et al.,  1999).    In 
CCL-39  cells  inhibition  of  ROCK  using  the  selective  inhibitor  Y27632  (5 M) 
almost  completely  abolished  5HT-induced  proliferation,  attenuating  the 
maximum response by 93±2% (n=3) (Figure 3.25).  In addition to this, Y27632 
also significantly attenuated the concentration-dependent increase in ERK1/2 
activation mediated by 5HT.  In this instance 5HT-induced ERK1/2 activation 
was  reduced  by  52±9%  (p<0.05,  n=3)  (Figure  3.26).    The  effects  of  a  cell 
permeable C3 transferase, which inhibits the function of ROCK by inactivating 
Rho GTPase, an upstream effector in the ROCK pathway, was also utilised.  
Inhibition of the ROCK pathway by this means produced a similar effect as that 
seen  with  Y27632.    C3  transferase  significantly  attenuated  the  increase  in 
ERK1/2 activation produced by 5HT by 43±15% (p<0.05, n=4) (Figure 3.27).    
In order to further determine the role of ROCK in the 5HT-mediated response, 
cyclin D1, a downstream mediator in the ERK1/2 cascade was also monitored.  
5HT (1 M) was found to increase levels of cyclin D1 present in CCL-39 cells in 
a biphasic manner over a 24 hour period (Figure 3.28).  Stimulation with 5HT 
significantly increased cyclin D1 levels after 6 hours (62.5±5% increase from 
basal, p<0.05, n=5), subsequently levels of cyclin D1 decreased before peaking 
at  16  hours  (107±15%  increase  from  basal,  p<0.01,  n=5)  and  remained 
elevated at 24 hours (85±8% increase from basal, p<0.01, n=3).  Inhibition of 
ROCK was able to abolish the elevation in levels of cyclin D1 induced by 6 hour 
stimulation with 5HT (p<0.05, n=3) (Figure 3.29).  Taken together these results 
highlight the involvement for ROCK in the signalling pathway required for 5HT-
induced ERK activation and proliferation.   108 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.19    Effects  of  MDC  on  receptor  mediated  5HT-induced  ERK 
activation.   
 
CCL-39  cells  were  serum  starved  for  16  hours.    Following  this,  cells  were 
treated with either fluoxetine (1 M) or MDC (100 M) alone or in combination for 
30  minutes.    Cells  were  then  stimulated  for  5  minutes  with  increasing 
concentrations of 5HT (0-10 M) or PMA (2 M).  Cell lysates were prepared and 
equalised  for  protein  concentration  by  BCA  assay.    Samples  were  then 
analysed by SDS-PAGE and immunoblotting using phospho-specific and total 
ERK antibodies.  Blots shown are representative.  Results are expressed as 
mean  ±  SEM  (n=3).    *  p  <  0.05  versus  vehicle  pre-treated  cells  using  an 
unpaired, two tailed t-test.   109 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20  Effects of MDC on 5HTT mediated ERK activation.   
 
CCL-39  cells  were  serum  starved  for  16  hours.    Following  this,  cells  were 
treated  with  either,  ketanserin  and  GR55562  (1 M)  or  MDC  (100 M)  or  a 
combination of both for 30 minutes.  Cells were then stimulated for 5 minutes 
with increasing concentrations of 5HT (0-10 M) or PMA (2 M).  Cell lysates 
were prepared and equalised for protein concentration by BCA assay.  Samples 
were then analysed by SDS-PAGE and immunoblotting using phospho-specific 
and  total  ERK  antibodies.    Blots  shown  are  representative.    Results  are 
expressed as mean ± SEM (n=3).  ** p < 0.01 versus vehicle pre-treated cells 
using an unpaired, two tailed t-test.   110 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21  Effects of N-acetylcysteine (NAC) treatment on 5HT-induced 
ERK activation.   
 
After  serum  starvation  for  16  hours  CCL-39  cells  were  pre-treated  for  30 
minutes  with  N-acetylcysteine  (10mM).    Cells  were  then  stimulated  for  5 
minutes with increasing concentrations of 5HT (0-10 M) or PMA (2 M).  Cell 
lysates were prepared and equalised for protein concentration by BCA assay.  
Samples  were  then  analysed  by  SDS-PAGE  and  immunoblotting  using 
phospho-specific  and total  ERK  antibodies.   Blots  shown  are  representative.  
Results are expressed as mean ± SEM (n=3).  * p<0.05 versus vehicle pre-
treated cells using an unpaired, two tailed t-test.   111 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22  Effects of NAC treatment on 5HT-induced proliferation.  
 
CCL-39 cells were serum starved for 24 hours then incubated with 0-100µM 
5HT in the presence or absence of N-acetylcysteine (NAC) (10mM) for a further 
24  hours,  with  0.5µCi/well  [
3H]-thymidine  added  for  the  final  6  hours  of  this 
incubation.    Cell  were  then  harvested  onto  a  glass  fibre  filter  mat  and  [
3H]-
thymidine incorporation assessed by liquid scintillation counting.  Data shown 
are  representative  of  n=3  assays.    Results  expressed  as  mean  ±  SEM  of 
triplicate samples.  * p<0.05, ** p<0.01 versus vehicle using an unpaired, two 
tailed t-test.   112 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23  Effects of monoamine oxidase inhibition with iproniazid on 
5HT-induced ERK activation.   
 
After serum starvation for 16 hours CCL-39 cells were pre-treated for 1 hour 
with  iproniazid  (0.1mM)  (monoamine  oxidase  inhibitor).    Cells  were  then 
stimulated  for  5  minutes  with  increasing  concentrations  of  5HT  (0-10 M)  or 
PMA (2 M).  Cell lysates were prepared and equalised for protein concentration 
by  BCA  assay.    Samples  were  then  analysed  by  SDS-PAGE  and 
immunoblotting using phospho-specific and total ERK antibodies.  Blots shown 
are representative.  Results are expressed as mean ± SEM (n=3).  Statistical 
analysis  using  unpaired,  two  tailed  t-tests revealed  no  significant  differences 
between vehicle and iproniazid pre-treated cells.   113 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.24    Effects  of  monoamine  oxidase  inhibition  by  iproniazid  on 
5HT-induced proliferation.   
 
CCL-39 cells were serum starved for 24 hours then incubated with 0-100µM 
5HT in the presence or absence of iproniazid (0.1mM) for a further 24 hours, 
with 0.5µCi/well [
3H]-thymidine added for the final 6 hours of this incubation.  
Cell  were  then  harvested  onto  a  glass  fibre  filter  mat  and  [
3H]-thymidine 
incorporation  assessed  by  liquid  scintillation  counting.    Data  shown  are 
representative of n=3 assays.  Results expressed as mean ± SEM of triplicate 
samples.   114 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.25  Effects of Rho-kinase inhibition by Y27632 on 5HT-induced 
proliferation.   
 
CCL-39 cells were serum starved for 24 hours then incubated with 0-100µM 
5HT in the presence or absence of Y27632 (5µM) (Rho-kinase inhibitor) for a 
further 24 hours, with 0.5µCi/well [
3H]-thymidine added for the final 6 hours of 
this incubation.  Cell were then harvested onto a glass fibre filter mat and [
3H]-
thymidine incorporation assessed by liquid scintillation counting.  Data shown 
are  representative  of  n=3  assays.    Results  expressed  as  mean  ±  SEM  of 
triplicate samples.  *** p<0.001 versus vehicle using an unpaired, two tailed t-
test.   115 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.26  Effects of ROCK inhibition with Y27632 on 5HT-induced ERK 
activation.   
 
After  serum  starvation  for  16  hours  CCL-39  cells  were  pre-treated  for  30 
minutes  with  Y27632  (5µM).    Cells  were  then  stimulated  for  5  minutes  with 
increasing concentrations of 5HT (0-10 M) or PMA (2 M).  Cell lysates were 
prepared and equalised for protein concentration by BCA assay.  Samples were 
then analysed by SDS-PAGE and immunoblotting using phospho-specific and 
total ERK antibodies.  Blots shown are representative.  Results are expressed 
as  mean  ±  SEM  (n=4).    *  p<0.05  versus  vehicle  pre-treated  cells  using  an 
unpaired, two tailed t-test.   116 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.27  Effects of Rho-GTPase inhibition with C3 transferase on 5HT-
induced ERK activation.   
 
After serum starvation for 16 hours CCL-39 cells were pretreated for 6 hours 
with cell permeable C3 transferase (specific Rho-GTPase inhibitor).  Cells were 
then stimulated for 5 minutes with 5HT (1 M) or vehicle.  Treatment with PMA 
(2 M) for 5 minutes was used as a positive control for pERK.  Cell lysates were 
prepared and equalised for protein concentration by BCA assay.  Samples were 
then analysed by SDS-PAGE and immunoblotting using phospho-specific and 
total ERK antibodies.  Blots shown are representative.  Results are expressed 
as mean ± SEM (n=4).  * p<0.05 versus 5HT, ** p<0.01 versus vehicle using 
Newman-Keuls multiple comparison test. 
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Figure 3.28  Timecourse of 5HT-induced cyclin D1 accumulation.   
 
CCL-39 cells were serum starved for 16 hours and then stimulated with 5HT 
(1µM) for 0-24 hours.  Cells grown in media containing 10% serum were used 
as a positive control for cyclin D1 accumulation.  Cell lysates were prepared and 
equalised  for  protein  concentration  by  BCA  assay.    Samples  were  then 
analysed  by  SDS-PAGE  and  immunoblotting  using  cyclin  D1  and  GAPDH 
antibodies.  Blots shown are representative.  Results are expressed as mean ± 
SEM (n=5).   * p<0.05, ** p<0.01 versus vehicle using Newman-Keuls multiple 
comparison test.   118 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.29    Effects  of  ROCK  inhibition  with  Y27632  on  5HT-induced 
Cyclin D1.   
 
After  serum  starvation  for  16  hours  CCL-39  cells  were  treated  with  Y27632 
(5 M) and 5HT (1 M) for 6 hours. Cells grown in media containing 10% serum 
were used as a positive control for cyclin D1 accumulation.  Cell lysates were 
prepared and equalised for protein concentration by BCA assay.  Samples were 
then analysed by SDS-PAGE and immunoblotting using cyclin D1 and GAPDH 
antibodies.  Blots shown are representative.  Results are expressed as mean ± 
SEM (n=3).   * p<0.05 versus vehicle and
 † p<0.05 versus 5HT using Newman-
Keuls multiple comparison test.   119 
In order to determine if the ROCK pathway functions selectively downstream of 
either 5HT receptors or 5HTT, various pharmacological agents were employed.  
As described previously, inhibition of ROCK significantly reduced 5HT-induced 
ERK1/2 activation (41±3% reduction, p<0.05, n=3).  Stimulation with α-methyl-
5HT (α-meth) (1 M), a 5HT2-selective agonist, resulted in ERK1/2 activation in 
CCL-39 cells (Figure 3.30).  This activation was around 55±8% of that observed 
with 5HT.  Co-administration of α-meth with Y27632 had no effect on the ability 
of agonist to induce ERK1/2 activation (α-meth induced 54.6±8% of the maximal 
response,  while  α-meth  +  Y27632  induced  56.3±13%  of  maximal  5HT 
response), suggesting that the ROCK pathway is not involved downstream of 
5HT2 receptors.  CP93129, a selective 5HT1B receptor agonist was also used. 
CP93129 (1 M) was also found to induce ERK1/2 activation, with the maximal 
response produced reaching 51±10% of that elicited by 5HT (Figure 3.30).  In 
contrast to α-meth, pre-treatment with Y27632 significantly attenuated the ability 
of the 5HT1B agonist to activate ERK1/2, reducing the level of ERK1/2 activation 
by 76±3% (p<0.05, n=3).  These findings suggest that ROCK is an important 
mediator specifically, downstream of the 5HT1B receptor. 
In light of the fact that there are no selective agonists for 5HTT, selective 5HT 
receptor antagonists were instead used in order to block 5HT receptors thus 
allowing 5HT to act preferentially on 5HTT (Figure 3.31). Inhibition of 5HT2A and 
5HT1B/1D  receptor  significantly  reduced  5HT-mediated  ERK1/2  activation  by 
60±7% (p<0.001, n=3).  However, pre-treatment with Y27632 had not effect on 
the  attenuation  induced  by  these  antagonists.    In addition  to  this,  as  shown 
previously,  citalopram  attenuated  5HT-mediated  ERK1/2  activation  (31±2% 
reduction, p<0.01, n=3) and this response also remained unaffected by ROCK 
inhibiton (32±9%, p<0.01, n=3).   
To further elucidate the mechanism of action as to how ROCK modulates ERK 
phosphorylation, the effect of Y27632 on MEK, the upstream kinase responsible 
for phosphorylating ERK1/2, was studied.  Immunoblotting using a phospho-
specific MEK antibody revealed that Y27632-mediated inhibition of ROCK had 
no effect on 5HT-induced MEK activation (Figure 3.32).   
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Figure 3.30  Effects of ROCK inhibition with Y27632 on 5HT2A and 5HT1B 
receptor-mediated ERK activation.   
 
After serum starvation for 16 hours CCL-39 cells were pretreated for 30 minutes 
with Y27632 (5µM) or vehicle.  Cells were then stimulated for 5 minutes with 
either  5HT  (1 M),  α-methyl5HT  (1 M)  (5HT2A  agonist)  or  CP93129  (1 M) 
(5HT1B agonist).   Treatment with PMA  (2 M) for 5 minutes was used as a 
positive control for pERK.  Cell lysates were prepared and equalised for protein 
concentration by BCA assay.  Samples were then analysed by SDS-PAGE and 
immunoblotting using phospho-specific and total ERK antibodies.  Blots shown 
are representative.  Results are expressed as mean ± SEM (n=3).  * p<0.05 
versus CP93129 treated cells using an unpaired, two tailed t-test.   121 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.31    Effects  of  ROCK  inhibition  with  Y27632  and  selective 
antagonists on 5HT-induced ERK activation.   
 
After serum starvation for 16 hours CCL-39 cells were pre-treated for 1 hour 
with Y27632 (5µM) and either citalopram (1 M), or a combination of ketanserin 
(1 M) and GR55562 (1 M) before stimulation with 5HT (1 M)  for 5 minutes.  
Treatment with PMA (2 M) for 5 minutes was used as a positive control for 
pERK.   Cell lysates were prepared and equalised for protein concentration by 
BCA assay.  Samples were then analysed by SDS-PAGE and immunoblotting 
using  phospho-specific  and  total  ERK  antibodies.    Blots  shown  are 
representative.  Results are expressed as mean ± SEM (n=3).  ** p<0.01, *** 
p<0.001 versus 5HT using Newman-Keuls multiple comparison post test.   122 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.32  Effects of ROCK inhibition with Y27632 on 5HT-induced MEK 
activation.   
 
After  serum  starvation  for  16  hours  CCL-39  cells  were  pre-treated  for  30 
minutes  with  Y27632  (5µM).    Cells  were  then  stimulated  for  5  minutes  with 
increasing concentrations of 5HT (0-10 M) or PMA (2 M).  Cell lysates were 
prepared and equalised for protein conentration by BCA assay.  Samples were 
then analysed by SDS-PAGE and immunoblotting using phospho-specific MEK 
and  total  ERK  antibodies.    Blots  shown  are  representative.    Results  are 
expressed as mean ± SEM (n=3).  Statistical analysis using an unpaired, two 
tailed  t-test  revealed  no  significant  differences  between  vehicle  and  Y27632 
treated cells.   123 
ROCK  has  also  been  previously  reported  to  be  involved  in  facilitating  the 
translocation of active ERK to the nucleus (Liu et al., 2004).  Given the ability of 
Y27632 to attenuate the induction of cyclin D1 in CCL-39 cells (Figure 3.29), 
studies into the role of ROCK in the nuclear translocation of pERK in this cell 
type were also carried out.  Stimulation with 5HT resulted in an increase in the 
level of pERK1/2 in both cytoplasmic and nuclear cell fractions (Figure 3.33).  
Inhibition  of  ROCK  with  5 M  Y27632  specifically  attenuated  ERK1/2 
phosphorylation in the cytoplasm (33±8% reduction, p<0.01, n=4) but had no 
effect on  the  levels  of pERK1/2  present  in  the  nucleus  in  response  to 5HT, 
suggesting  inhibition  of  ROCK  is  unable  to  affect  the  ability  of  pERK1/2  to 
translocate into the nucleus.  
Since inhibition of ROCK resulted in the attenuation of 5HT-induced ERK1/2 
activation, yet had no effect on MEK activation, it may therefore regulate dual 
specificity phosphatases (DUSPs), responsible for de-phosphorylating ERK1/2.  
In order to investigate this hypothesis, the effects of the tyrosine phosphatase 
inhibitor, sodium-ortho-vanadate, on the ability of Y27632 to attenuate ERK1/2 
activation was tested (Figure 3.34).  Treatment with sodium-ortho-vanadate on 
its own significantly increased basal levels of ERK1/2 activation (51±5% versus 
vehicle, p<0.001, n=3).  Stimulation with 5HT in the presence of sodium-ortho-
vanadate resulted in an increase in ERK1/2 activation similar to that of 5HT 
alone.  Moreover, the phosphatase inhibitor was unable to reverse the ability of 
the  ROCK  inhibitor  to  reduce  5HT-induced  ERK1/2  activation,  suggesting 
ROCK does not mediate its effects by regulating DUSPs responsible for de-
phosphorylating ERK1/2. 
In order to further elucidate the mechanisms by which 5HT utilises ROCK to 
mediate its mitogenic effects, the ability of 5HT to directly activate the ROCK 
pathway  was  studied.    To  do  this,  myosin  phosphatase,  a  downstream 
substrate  of  ROCK  was  monitored.    Activation  of  ROCK  results  in  the 
phosphorylation of the myosin binding subunit of myosin phosphatase (MYPT1) 
(Amano  et  al.,  2000).    Immunoblotting  using  a  phospho-specific  antibody  to 
MYPT1 (pMYPT1), revealed that over a period of 2 hours, stimulation with 5HT 
(1 M) had no effect on MYPT1 phosporylation, suggesting that 5HT does not 
directly activate this pathway (Figure 3.35).     124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.33    Effects  of  ROCK  inhibition  with  Y27632  on  the  nuclear 
translocation of pERK.   
 
CCL-39 cells were serum starved for 16 hours.  The cell monolayer was then 
pre-treated for 30 minutes with Y27632 (5 M) or vehicle prior to stimulation with 
5HT (1 M) or PMA (2 M) for 5 minutes.  Cytosolic and nuclear fractions were 
prepared and equalised for protein concentration by Bradford’s assay.  Samples 
were  then  analysed  by  SDS-PAGE  and  immunoblotting  using  a  phospho-
specific ERK antibody.  Immunoblotting using SP1 and GAPDH antibodies was 
also  carried  out  to  determine  the  integrity  of  nuclear  and  cytosolic  fractions 
respectively.   Blots shown are representative. Results are expressed as mean 
± SEM (n=4).  ** p<0.01 using an unpaired two-tailed t-test.   125 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.34  Effects of tyrosine phosphatase inhibition with vanadate and 
ROCK inhibition with Y27632 on 5HT-induced ERK activation.   
 
After serum starvation for 16 hours CCL-39 cells were treated for 30 minutes 
with  either  sodium  ortho-vanadate  (100µM)  or  Y27632  (5µM)  alone  or  in 
combination.  Treatment with PMA (2 M) for 5 minutes was used as a positive 
control for pERK.  Cells were then stimulated with 5HT (1µM) for 5 minutes 
before  cells  were  harvested.    Cell  lysates  were  prepared  and  equalised  for 
protein concentration by BCA assay.  Samples were then analysed by SDS-
PAGE  and  immunoblotting  using  phospho-specific  and  total  ERK  antibodies.  
Blots shown are representative.  Results are expressed as mean ± SEM (n=3). 
 
† p<0.001 versus vehicle, *** p<0.001 versus 5HT using Newman-Keuls multiple 
comparison post test.   126 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.35  Timecourse of effects of 5HT on phosphorylation of myosin 
phosphatase.   
 
Following serum starvation for 16 hours, CCL-39 cells were stimulated with 5HT 
(1µM) for 0-120 minutes.  Cell lysates were prepared and equalised for protein 
concentration by BCA assay.  Samples were then analysed by SDS-PAGE and 
immunoblotting  using  phospho-specific  and  total  antibodies  to  the  myosin 
binding  subunit  of  myosin  phosphatase.    Blots  shown  are  representative.   
Results  are  expressed  as  mean  ±  SEM  (n=3).    Statistical  analysis  using 
Newman-Keuls multiple comparison test revealed no significant differences.   127 
In addition to this, cofilin, another downstream substrate of ROCK, was also 
studied.    When  active,  ROCK  phosphorylates  LIMK,  which  in  turn 
phosphorylates  cofilin  (Amano  et  al.,  2000).    Upon  stimulation  with  5HT,  an 
initial  rapid  increase  in  the  levels  of  phosphorylated  cofilin  (p-cofilin)  was 
observed (51±12% increase from basal).  However, due to large variability, this 
increase was not found to be statistically significant (p>0.05, n=5) (Figure 3.36).  
Furthermore, pre-treatment with the ROCK inhibitor Y27632 had no effect on 
the ability of 5HT to activate cofilin (Figure 3.37), suggesting cofilin is being 
phosphorylated independently of ROCK.   
Finally, the effects of 5HT on actin stress fibres, the formation of which is a Rho 
mediated response, were studied.  Under vehicle conditions, actin stress fibres 
were detected in CCL-39 cells by light microscopy (Figure 3.38).  Stimulation 
with 5HT (1 M) over a period of 2 hours was unable to induce any change in 
the presence of actin stress fibres within the cells.  However, inhibition of ROCK  
was able to disrupt the actin cytoskeleton and abolish the presence of actin 
stress fibres (Figure 3.39).  In light of the findings that 5HT does not appear to 
directly activate the ROCK pathway, but ROCK inhibition is able to disrupt the 
formation of actin stress fibres, the role of the actin cytoskeleton in 5HT-induced 
ERK1/2 activation was investigated.  Given that inhibition of ROCK attenuates 
5HT-induced  ERK1/2 activation  and  also  disrupts  the  actin  cytoskeleton,  the 
effects of  other  inhibitors  on  the  gross  morphology  of  the  actin cytoskeleton 
were determined.  Citalopram, ketanserin, GR55562, NAC and U0126, which 
have all been previously show to attenuate the ability of 5HT to activate ERK1/2 
had no effects on the actin cytoskeleton (Figure 3.40).  The effects of agents 
such  as  cytochalasin  D  and  latrunculin  B  which  are  known  to  disrupt  actin 
cytoskeleton morphology were also analysed.  Latrunculin B mediates its effects 
by associating with actin monomers, preventing them from repolymerising and 
forming filaments (Morton et al., 2000; Spector et al., 1983).  Cytochalasin D 
has a different mode of action disrupting the actin cytoskeleton by binding both 
barbed and pointed ends of actin filaments causing both depolymerisation and 
inhibition of polymerisation (Cooper, 1987; Spector et al., 1983).  Figure 3.41 
demonstrates the ability of both cytochalasin D and latrunculin B to disrupt the 
actin cytoskeleton in CCL-39 cells.  The effect of these agents on 5HT-induced 
ERK activation was also investigated.  Cytochalasin D was found to significantly   128 
attenuate 5HT-induced ERK1/2 activation, with a reduction of around 35±19% 
at the maximal 5HT response (p<0.05, n=3) (Figure 3.42).  Similarly, latrunculin 
B also significantly reduced 5HT-induced ERK1/2 activation.  The maximal 5HT 
response was reduced in this case by 62±8% (p<0.01, n=3) (Figure 3.43).   
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Figure 3.36  Timecourse of effects of 5HT on phosphorylation of cofilin 1.   
 
Following serum starvation for 16 hours, CCL-39 cells were stimulated with 5HT 
(1µM) for 0-120 minutes. Cell lysates were prepared and equalised for protein 
concentration by BCA assay.  Samples were then analysed by SDS-PAGE and 
immunoblotting using phospho-specific cofilin 1 and GAPDH antibodies.  Blots 
shown  are  representative.      Results  are  expressed  as  mean  ±  SEM  (n=5).  
Statistical analysis using Newman-Keuls multiple comparison test revealed no 
significant differences.   130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.37    Effects  of  ROCK  inhibition  with  Y27632  on  cofilin  1 
phosphorylation.   
 
Following serum starvation for 16 hours cells were pre-treated for 30 minutes 
with either vehicle or Y27632 (5 M).  Cells were then either treated with vehicle 
or 5HT (1 M) for 5 minutes.  Treatment with LPA (100 M) for 15 minutes was 
used as a positive control.  Cell lysates were prepared and equalised for protein 
concentration by BCA assay.  Samples were then analysed by SDS-PAGE and 
immunoblotting using phospho-specific cofilin 1 and GAPDH antibodies.  Blots 
shown are representative.   Results are expressed as mean ± SEM (n=4).  * p < 
0.05 versus vehicle using Newman-Keuls multiple comparison test.   131 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.38  Timecourse of effects of 5HT on actin stress fibre formation in CCL-39 cells. 
 
CCL-39 cells were serum starved for 16 hours then stimulated with 5HT (1 M) for 0-120 minutes.  Cells were then fixed with 4% 
paraformaldehyde and the actin cytoskeleton detected by immunofluorescence using Alexa Fluor 594 conjugated-phalloidin.  No 
changes in the actin cytoskeleton were detected following treatment with 5HT.  Images were captured using a Ziess fluorescent 
microscope using x 40 objective lens.  Pictures shown are representative of n=3 experiments. Scale bar represents 100 m.   132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.39  Effects of ROCK inhibition with Y27632 on actin stress fibres 
in CCL-39 cells.   
 
CCL-39  cells  serum  starved  for  16  hours  then  treated  with  either  vehicle  or 
Y27632  (5µM)  for  30  minutes.    Subsequently,  cells  were  fixed  with  4% 
paraformaldehyde and the actin cytoskeleton detected by immunofluorescence 
using  Alexa  Fluor  594-conjugated  phalloidin.    Treatment  with  Y27632  was 
observed to disrupt the actin cytoskeleton.  Images were captured using a Ziess 
fluorescent  microscope  using  x  40  objective  lens.    Pictures  shown  are 
representative of n=3 experiments.  Scale bar represents 100 m.   133 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.40  Effects of signal pathway inhibitors on actin stress fibres in 
CCL-39 cells. 
 
CCL-39  cells  were  serum  starved  for  16  hours  then  treated  with  either 
citalopram  (1 M),  ketanserin  (1 M),  GR55562  (1 M)  for  1  hour  or  N-
acteylcysteine (0.1mM), U0126 (1 M) for 30 minutes.  Subsequently, cells were 
fixed  with  4%  paraformaldehyde  and  the  actin  cytoskeleton  detected  by 
immunofluorescence using Alexa Fluor 594-conjugated phalloidin.  No changes 
in  the  actin  cytoskeleton  were  detected  following  treatment  with  inhibitors.  
Images  were  captured  using  a  Ziess  fluorescent  microscope  using  x  40 
objective lens.  Pictures shown are representative of n=3 experiments.  Scale 
bar represents 100 m.   134 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.41    Effects  of  Cytochalasin  D  and  Latrunculin  B  on  the  actin 
cytoskeleton of CCL-39 cells.   
 
After  serum  starvation  for  16  hours  CCL-39  cells  were  pre-treated  for  30 
minutes  with  either  latrunculin  B  (10µM)  or  cytochalasin  D  (10µM).  
Subsequently,  cells  were  fixed  with  4%  paraformaldehyde  and  the  actin 
cytoskeleton  detected  by  immunofluorescence  using  Alexa  Fluor  594-
conjugated  phalloidin.    Images  were  captured  using  a  Ziess  fluorescent 
microscope  using  x  40  objective  lens.    Treatment  with  latrunculin  B  or 
cytochalasin D was observed to disrupt the actin cytoskeleton.  Pictures shown 
are representative of n=3 experiments.  Scale bar represents 100  m.   135 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.42  Effects of Cytochalasin D on 5HT-induced ERK activation.   
 
After  serum  starvation  for  16  hours  CCL-39  cells  were  pre-treated  for  30 
minutes with cytochalasin D (10µM).  Cells were then stimulated for 5 minutes 
with increasing concentrations of 5HT (0-10 M) or PMA (2 M).  Cell lysates 
were prepared and equalised for protein concentration by BCA assay.  Samples 
were then analysed by SDS-PAGE and immunoblotting using phospho-specific 
and  total  ERK  antibody.    Blots  shown  are  representative.    Results  are 
expressed as mean ± SEM (n=3).  * p < 0.05 versus vehicle pre-treated cells 
using an unpaired, two tailed t-test.   136 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.43  Effects of Latrunculin B on 5HT-induced ERK activation.   
 
After  serum  starvation  for  16  hours  CCL-39  cells  were  pre-treated  for  30 
minutes with latrunculin B (10µM).  Cells were then stimulated for 5 minutes 
with increasing concentrations of 5HT (0-10 M) or PMA (2 M).  Cell lysates 
were prepared and equalised for protein concentration by BCA assay.  Samples 
were then analysed by SDS-PAGE and immunoblotting using phospho-specific 
and  total  ERK  antibodies.    Blots  shown  are  representative.    Results  are 
expressed as mean ± SEM (n=3).  * p < 0.05 , ** p < 0.01 versus vehicle pre-
treated cells using an unpaired, two tailed t-test.   137 
3.3  DISCUSSION 
 
As stated in the introduction, the ability of 5HT to activate ERK MAP kinase 
plays a critical role in its mitogenic effects and as such may contribute to the 
remodelling process that occurs during PAH.  Therefore, investigation into the 
signalling mechanisms utilised by 5HT may  give rise to potential therapeutic 
targets  for  new  drugs  in  the  treatment  of  PAH.    To  further  elucidate  these 
signalling  pathways,  this  study  investigated  potential  mediators  of  the  5HT 
induced  response  and  how  these  components  contributed  to  5HT-mediated 
ERK activation and proliferation. 
Previous studies have characterised the rapid activation of ERK1/2 in PASMCs 
with maximal activation occurring around 5 minutes (Lee et al., 1999).  This is 
consistent with the results shown in Figure 3.1, where 5HT is able to induce a 
rapid  and  transient  activation  of  ERK1/2.    Furthermore,  in  CCL-39  cells  the 
mitogenic  effects  of  5HT  appear  to  be  dependent  on  its  ability  to  activate 
ERK1/2 (Figure 3.2).  Other studies have also confirmed the requirement for 
ERK1/2 activation in 5HT-induced proliferation (Bianchi et al., 2005; Lawrie et 
al.,  2005).  Interestingly,  5HT  only  resulted  in  an  initial  rapid  and  transient 
activation of ERK, with no further activation witnessed over the 24 hour period.  
Previous  studies  have  indicated  that  in  this  cell  type  sustained  MAP  kinase 
activation is required for cyclin D1 induction and DNA synthesis (Balmanno and 
Cook, 1999).  The study suggested agonists such as LPA and TRP-7, which 
caused  only  transient  ERK  activation,  were  poor  inducers  of  proliferation.  
However,  stimulation  with  thrombin,  which  induced  a  sustained  activation  of 
ERK, resulted in a proliferative response.  Work carried out by other groups has 
also shown 5HT was unable to induce late phase ERK activation (Meloche et 
al., 1992) but still induced proliferation in CCL-39 cells (Pouyssegur et al., 1988; 
Lee et al., 1999). 
The role of p38 in 5HT-mediated signalling remains unclear.  It has previously 
been  shown  that  5HT  is  able  to  activate  p38  via  the  5HT2A  receptor  under 
hypoxic  conditions  (Welsh  et  al.,  2004).    Furthermore,  in  NIH3T3  cells 
overexpressing the 5HT2A receptor, 5HT was shown to activate both ERK1/2 
and p38 (Kurrasch-Orbaugh et al., 2003).  In human astrocytoma cells, 5HT has 
also been reported to activate p38 via the 5HT7 receptor (Lieb et al., 2005).  In   138 
contrast to these findings, 5HT was unable to induce activation of p38 in CCL-
39 cells (Figure 3.4).  This is consistent with findings in both bovine PASMCs 
and in rat vascular SMCs where 5HT had no effect on the activation status of 
p38 (Banes et al., 2001; Lee et al., 2001).  Despite being unable to activate p38, 
inhibition of p38 resulted in a marked reduction in 5HT induced proliferation in 
CCL-39s (Figure 3.5).  This phenonenom has also been witnessed in PASMCs 
suggesting p38 may act as a negative regulator of 5HT-induced proliferation 
(Lee  et  al.,  2001).    However,  in  the  present  study,  the  concentration  of 
SB203580  that  was  effective  in  abolishing  proliferation  also  significantly 
attenuated the activation of ERK by PMA (Figure 3.7).  This suggests the ERK 
cascade in general may be affected, thus explaining the effects of SB203580 on 
5HT-induced  proliferation.    In  addition  to  this,  inhibition  of  p38  has  been 
reported to decrease 5HTT activity and 5HT uptake (Samuvel et al., 2005).  The 
effects  of  p38  inhibition  on  5HTT  described  in  this  study  may  contribute  to 
reduction in proliferation observed in Figure 3.5.  
CCL-39 cells have been shown to uptake 5HT, a process which can be blocked 
by  various  inhibitors  of  5HTT  (Lee  et  al.,  1999),  confirming  the  presence  of 
functional 5HTTs in this cell type.  By using pharmacological approaches, this 
study and that of others also suggested the presence of 5HT1B/1D and 5HT2A 
receptors  (Lee  et  al.,  1999).    In  the  present  investigation  the  role  of  5HT 
receptors  and  transporter  in  5HT-induced  ERK  activation  were  assessed.  
Inhibition  of  5HTT  (Figure  3.8),  5HT2A  (Figure  3.12)  or  5HT1B/1D  receptors 
(Figure 3.14) all significantly reduced 5HT-mediated ERK activation.  In addition 
to this, inhibition of anyone of these components resulted in almost complete 
abolition of the proliferative response.  Furthermore, simultaneous inhibition of 
5HT1/2 receptors and 5HTT did not have an additive effect, resulting in a 50% 
reduction  in ERK1/2 activation,  similar to  that  witnessed  by  inhibition of  one 
component  alone  (Figure  3.16).    These  findings  suggest  5HT  receptors  and 
5HTT  may  co-operatively  interact  to  mediate  the  effects  of  5HT.    Several 
examples of cross- talk between GPCRs have been documented.  Gi-coupled 
receptors have been shown to amplify the effects of those coupled to Gq.  For 
example, stimulation of 5HT1B receptors augments SMC contraction induced by 
histamine  (H1)  receptors  or  thromboxane  A2  in  rat  femoral  arteries  and  iliac 
arteries (MacLennan et al., 1993; Yildiz and Tuncer, 1995).  Furthermore, Gq-  139 
coupled receptors have also been reported to augment Gs-coupled receptor-
stimulated adenylyl cyclase activity (Selbie and Hill, 1998).  In support of the 
hypothesis of cross-talk, functional interactions between 5HT1B receptors and 
5HTT  have  been  reported  to  mediate  vasoconstriction  in  small  pulmonary 
arteries (Morecroft et al 2005).  Interactions between 5HTT and 5HT receptors 
have  also  been  demonstrated  by  the  finding  that  chronic  inhibition  of  5HTT 
affects 5HT2A receptor signalling (Damjanoska et al., 2003).  Inhibition of 5HTT 
has  also  been  shown  to  dampen  5HT  receptor  signalling  in  HEK293  cells 
(Johnson et al., 2003).  Furthermore, stimulation of 5HT2A receptors results in 
activation of PKC and increases levels of intracellular calcium (Rahimian and 
Hrdina,  1995),  both  of  which  are  involved  in  the  regulation  of  5HTT 
(Ramamoorthy  et  al.,  1998).    In  addition,  inhibition  of  5HTT  has  also  been 
reported to upregulate 5HT2B receptors in mouse astrocytes (Kong et al., 2002).  
The contribution of 5HTT and 5HT receptors in mediating mitogenic effects has 
been  most  extensively  characterised  in  bovine  PASMCs,  where  interactions 
between signalling pathways induced by receptors and transporter are required 
to  produce  cell  proliferation.  In  this  cell  type,  while  5HTT  appears  to  be 
responsible  for  initiating  signalling  that  results  in  ERK  activation.    5HT2  and 
5HT1B/1D  receptors  are  also  required  to  perpetuate the  proliferative  response 
(Liu  and  Fanburg,  2006).    However,  in  this  case  inhibition of  5HT  receptors 
does not decrease ERK activation but modulates processes required for ERK to 
induce its mitogenic effects.  In human PASMCs stimulation with 5HT appears 
to  result  in  ERK  activation  via  5HT2A  receptor  and  not  5HTT  (Lawrie  et  al., 
2005).  In these PASMCs, 5HTT also plays a role in mediating the effects of 
5HT but is not involved in the activation of ERK.  Taken together these findings 
suggest functional interactions between 5HT receptors and 5HTT and cross-talk 
between  the  signalling  pathways  induced  in  executing  cellular  mitogenesis.  
5HT2A  receptors  have  previously  been  found  to  interact  with  caveolin-1  in 
different cell types, a process which modulates 5HT signalling (Bhatnagar et al., 
2004; Cogolludo et al., 2006).  Caveolin-1 forms an important component of 
caveolae, specialised plasma membrane microdomains that have been found to 
compartmentalize and integrate numerous signalling events including the MAP 
kinase cascade (Shaul and Anderson, 1998).  5HTT has also been reported to 
be  partitioned  into  lipid  microdomains  in  the  plasma  membrane.    The   140 
compartmentalisation of 5HT receptors and 5HTT into specialised areas of the 
membrane may facilitate their ability to cross-talk. 
The role of internalisation in 5HT-induced ERK activation was also assessed.  
In certain circumstances clathrin-mediated endocytosis and caveolin have been 
implicated  in  the  regulation  of  signalling  from  5HT  receptors  and  5HTT 
(Bhatnagar et al., 2004; Della Rocca et al., 1999; Jayanthi et al., 2005).  In this 
instance inhibition of internalisation using the structurally unrelated compounds 
ConA and MDC had little effect on the 5HT-induced ERK activation (Figures 
3.17  and  3.18).    ConA  significantly  increased  ERK  activity  under  basal 
conditions  and  a  similar  increase  was  also  witnessed  in  response  to  5HT, 
suggesting conA may activate ERK MAP kinase pathway in this cell type.  The 
increased activity of ERK observed may be due to the binding of ConA to cell 
surface  glycoproteins.    For  instance  ConA  has  previously  been  shown  to 
crosslink  PZR  glycoproteins,  an  immunoglobulin  superfamily  of  cell  surface 
proteins, resulting in their tyrosine phosphorylation (Zhao et al., 2002).  In CCL-
39  cells  ConA  may  crosslink  receptor  tyrosine  kinases,  resulting  in  their 
activation and thus contributing to the elevated basal levels of ERK activation.  
No effects of 5HT-induced ERK activation were witnessed in response to MDC 
treatment  suggesting  internalisation  from  the  plasma  membrane  is  not  a 
requirement for 5HT-induced ERK activation.  In addition to this, MDC reversed 
the inhibitor effects of 5HT receptor antagonists (Figure 3.20) and the 5HTT 
blocker fluoxetine (Figure 3.19).  This may be due to the ability of MDC to inhibit 
receptor desensitisation and down regulation of 5HTT by preventing receptor 
and  5HTT  internalisation  from  the  plasma  membrane,  thus  potentiating  the 
effects of 5HT.  These findings suggest endocytosis is not a requirement for 
5HT-induced ERK activation and proliferation.  However, it would be beneficial 
to  monitor  receptor  endocytosis  directly  in  this  model  before  drawing  a  final 
conclusion.    Attempts  were  made  to  generate  CCL39  cell  lines  stably 
overexpressing a green fluorescent protein (GFP)-tagged rat 5HT2A receptor in 
order  to  monitor  receptor  internalisation.    Cells  transfected  with  5HT2A-GFP 
receptor  also  confer  resistance  to  the  neomycin  derivative  G418,  allowing 
selection  of  5HT2A-GFP  positive  cells.    Despite  isolation  of  multiple  G418-
resistant  clones  over  several  separate  transfections  that  were  resistant  to  
treatment  with  1  mg/ml  G418,  only  5-10%  of  the  cells  expressed  the  GFP-  141 
tagged  receptor  construct,  as  determined  by  fluorescence  microscopy.  
Moreover, the 5HT2A-GFP cells were also refractory to further enrichment by 
fluorescence-activated cell sorting (FACS) (data not shown). 
ROS  have  also  been  implicated  in mediating  the effects of  5HT.    As  stated 
previously,  ROS  appear  to  be  a  downstream  mediator  of  5HTT,  required  to 
induce  ERK1/2  activation  in  PASMCs.    In  this  study,  N-acetyl-cysteine,  an 
antioxidant,  significantly  reduced  5HT-induced  ERK1/2  activation,  suggesting 
ROS are also required in CCL-39 cells to form part of the mitogenic signalling 
response  (Figure  3.21).    This  is  consistent  with  previous  studies  that  have 
reported the generation of superoxide in this cell type in response to stimulation 
of 5HT (Lee et al., 1999).  The ability of ROS such as O
2- and H2O2 to activate 
ERK has been well documented.  A number of growth factors have been shown 
to generate intracellular ROS production, a process that appears to be essential 
for  their  mitogenic  signalling.    For  instance,  PDGF  stimulated  increases  in  
intracellular ROS are required for ERK activation, DNA synthesis and regulation 
of gene expression (Sundaresan et al., 1995).  Furthermore, in mesangial cells, 
ROS generation via the 5HT2A receptor is though to be responsible for ERK 
activation (Grewal et al., 1999).  The mechanisms by which ROS regulate ERK 
activation  remain  unclear,  although  it  has  been  proposed  they  are  able  to 
regulate the activity of phosphatases responsible for modulating ERK activity 
(Kim et al., 2003). 
ROS  have  also  been  shown  to  play  a  critical  role  in  cardiac  hypertrophy 
(Bianchi  et  al.,  2005)  and  a  variety  of  other  vascular  diseases  (Yung  et  al., 
2006).  In cardiomyocytes, entry of 5HT into the cell via 5HTT is thought to 
result in the formation of H2O2 due to its breakdown by MAO.  The reactive 
oxygen species formed are then responsible for ERK activation and subsequent 
hypertrophy (Bianchi et al., 2005).  In the present study, inhibition of MAO had 
no effect on 5HT-mediated ERK activation, suggesting production of ROS by 
MAO has no role in the proliferative response in CCL-39 cells.  This is similar to 
findings in PASMCs (Lee et al., 1999).  Another study has suggested that ROS 
generation by MAO is not required for ERK activation, but does play a role in 
mediating the nuclear translocation of pERK (Lawrie et al., 2005).  However, 
given  that  inhibition  of  MAO  had  no  effect  on  5HT-induced  proliferation  this 
mechanism is unlikely to occur in CCL-39 cells.   142 
The RhoA/ROCK pathway has also been implicated in the actions of 5HT.  5HT 
has been shown to activate RhoA in rat aortic rings (Sakurada et al., 2001).  
Furthermore, RhoA/ROCK appears to be involved in 5HT-mediated contractions 
in bovine cerebral arteries (Nishikawa et al., 2003).  In addition to its role in 
contraction,  ROCK  may  also  mediate  mitogenic  effects  and  has  been 
suggested to play a role in PDGF BB-induced proliferation in systemic vascular 
SMCs (Chapados et al., 2006).  Based on data presented here, ROCK also 
appears to be involved in mediating 5HT-induced proliferation in CCL-39 cells 
(Figure 3.25).  This effect may be due to the ability of the Rho/ROCK pathway 
to modulate 5HT-induced ERK activation as inhibition of both Rho (Figure 3.27) 
and ROCK (Figure 3.26) significantly reduce 5HT-induced ERK activation.  This 
effect appears to be specific to 5HT as inhibition of ROCK has no effect on 
PMA-induced ERK activation.  Studies in human aortic SMCs have also shown 
the inhibition of ROCK attenuates 5HT-induced ERK activation (Matsusaka and 
Wakabayashi,  2005b).    Conversly,  sustained  activation  of  ROCK  has  been 
found to promote ERK activation in NIH-3T3 fibroblasts (Croft and Olson, 2006).  
ROCK  also  plays  a  role  in  ERK  activation  induced  by  angiotensin  II  in 
mesenteric  resistance  arteries  (Matrougui  et  al.,  2001).    However,  in  these 
studies the mechanisms by which inhibition of ROCK modulates ERK activation 
were not addressed.   
The  requirement  of  ROCK  for  5HT-induced  proliferation  has  been  shown 
previously  in  PASMCs  (Liu  et  al.,  2004).  However  in  that  study  inhibition  of 
ROCK had no effect on ERK phosphorylation, but was required to mediate the 
translocation of active ERK to the nucleus to stimulate the transcription factor 
phosphorylation  required  for  cell  cycle  progression  and  cellular  proliferation.  
Thus, the role of ROCK in nuclear translocation was also investigated in CCL-
39  cells.    These  experiments  suggested  that  ROCK  attenuates  the 
phosphorylation  of  ERK  in  the  cytoplasm  but  has  no  effect  on  the  ability  of 
pERK to translocate to the nucleus (Figure 3.33).  In addition to this, inhibition of 
ROCK was also able to completely abolish 5HT-induced cyclin D1 expression 
(Figure 3.29), consistent with findings by Liu et al 2004.  Rho has previously 
been associated with normal cell cycle progression and expression of  cyclin D1 
(Welsh et al., 2001b; Jaffe and Hall, 2005).  Moreover, ROCK is also involved in 
the  regulation  of  the  cyclin  D1-cdk4  complex  via  ERK-dependent  cyclin  D1   143 
expression (Roovers and Assoian, 2003).  The current study would suggest that 
cytoplasmic  effectors  of  ERK  are  responsible  for  mediating  5HT-induced 
proliferation.  It has previously been reported that in PC12 cells proliferative 
signals  cause  a  transient  activation  of  ERK  which  remains  mainly  in  the 
cytoplasm (Marshall, 1995). 
The  RhoA/ROCK  pathway  may  interact  with  components of  the ERK  MAPK 
cascade upstream of ERK thus explaining the effects of RhoA/ROCK inhibition 
on 5HT-induced ERK activation.  However in CCL-39 cells inhibition of ROCK 
had no effect on 5HT-mediated MEK activation (Figure 3.32).  This suggests the 
Rho/ROCK pathway regulates the phosphorylation status of ERK independently 
of  MEK  its  upstream  kinase.    Various  studies  have  highlighted  interactions 
between  the  RhoA/ROCK  pathway  and  members  of  the  Ras/Raf/MEK/ERK 
signalling  pathway.    Rho-GTPases  have  been  shown  play  a  role  in  Ras 
mediated Raf activation (Li et al., 2001).  Furthermore Raf-1 appears to operate 
as a regulator of Rho downstream signalling associating with ROCK II via its 
amino-terminus in primary mouse keratinocytes (Ehrenreiter et al., 2005).  This 
interaction  controls  the  subcellular  distribution  of  ROCK  II  and  limits  its 
activation.  In mouse embryonic fibroblasts where the BRAF gene has been 
knocked out, levels of ROCK II and pERK where decreased (Pritchard et al., 
2004).  In other cell types active Rho has been shown to bind to MEKK1 and 
stimulate  its  kinase  activity  (Gallagher  et  al.,  2004).    MEKK1,  an  upstream 
kinase in the JNK and p38 pathways is known to bind and function as a scaffold 
for  ERK  (Morrison  and  Davis,  2003).    Mechanisms  as  to  how  interactions 
between the Rho/ROCK pathway and ERK MAP kinase pathway mediate 5HT-
induced  proliferation  remain  unclear.    It  is  possible  that  scaffolding  proteins 
which interact with the MEK/ERK pathway may mediate cross talk between the 
pathways.    It  is  well  documented  that  scaffolding  proteins  target  MEK/ERK 
complexes  to  specific  cellular  location  and  affect  the  activity  of  specific 
components of the signalling cascade (Kolch, 2005). 
Phosphatases play an important role in the regulation of ERK MAP kinases.  It 
is  possible  that  in  CCL-39  cells  the  Rho/ROCK  pathway  may  modulate 
phosphatases  involved  in  the  regulation  of  the  ERK  phosphorylation  and  as 
such, affect its activation in response to 5HT.  Using vanadate as a non-specific 
tyrosine phosphatase inhibitor had no effect on ability of the ROCK inhibitor to   144 
attenuate  5HT-induced  ERK  activation,  suggesting  phosphatases  are  not 
involved  in  mediating  the  effects  of  ROCK  (Figure  3.34).    Treatment  with 
vanadate alone elevates basal activity of ERK presumably by inhibiting DUSPs, 
which  are  responsible  for  maintaining  ERK  activation  status  under  basal 
conditions.    This  effect  may  mask  any  alterations  in  ERK  phosphorylation 
induced  by  vanadate  in  the  presence  of  the  ROCK  inhibitor.    Therefore  the 
ability  of  ROCK  to  modulate  phophatases  involved  in  5HT-induced  ERK 
activation cannot be ruled out.  It may be beneficial to investigate the role of 
phosphatase by other means such as using inhibitors to specific phosphatases 
or monitoring ERK-specific phosphatase activity within the cells.   
It has previously been reported that 5HT modulates the Rho/ROCK pathway via 
the 5HT1B/1D receptor (Liu et al., 2004).  Using selective agonists, this was also 
shown to be the case in CCL-39 cells (Figure 3.30), with 5HT1B/1D receptors 
involved in mediating the effects of ROCK but not 5HT2 receptors.  Interestingly, 
using  5HTT  blockers  to  ensure  the  effects  of  5HT  were  mediated  via  5HT 
receptors,  ROCK  inhibition  had  no  further  effect  in  reducing  5HT-receptor 
mediated  ERK  activation  (Figure  3.31).    This  implies  ROCK  is  not  involved 
downstream of 5HT receptors present in CCL-39 cells.  Furthermore, using 5HT 
receptor antagonists to ensure 5HT acts preferentially via 5HTT, inhibition of 
ROCK  had  no  further  effect  on  the  reduction  in  ERK  activation,  suggesting 
ROCK does not function downstream of 5HTT. 
To  try  and  address  this  issue  further,  the  ability  of  5HT  to  activate  the 
Rho/ROCK pathway was assessed.  Prior studies have shown the ability of 5HT 
to activate this pathway in a variety of tissues and cell types including PASMCs 
(Liu et al., 2004), and aortic SMCs (Matsusaka and Wakabayashi, 2005b). 
In PASMCs 5HT has been shown to activate Rho and its downstream effector 
MYPT1.  However, in CCL-39 cells, following stimulation with 5HT no activation 
of MYPT1 (Figure 3.35) was observed.  This may be due to the high basal level 
of MYPT1 phosphorylation present.  5HT did however elevate levels of p-cofilin, 
another downstream mediator of ROCK (Figure 3.36). Although, this response 
was consistently observed, due to high basal levels and variability it was not 
found to be statistically significant.  Furthermore, this variable phosphorylation 
could not be attenuated by inhibition of ROCK (Figure 3.37).  LIMK is the direct 
upstream mediator of cofilin and can be activated via the Rac/PAK pathway.    145 
This  may  explain  why  inhibition  of  ROCK  is  unable  to  prevent  the 
phosphorylation of cofilin.  In addition to this, under quiescent conditions CCL-
39 cell displayed a high degree of actin stress fibres.  Stimulation with 5HT 
resulted in no notable change in the presence of these fibres (Figure 3.38).  
These findings are in contrast to a study in PASMCs, where application of 5HT 
was  shown  to  cause  disruption  of  the  actin  cytoskeleton  (Day  et  al.,  2006), 
highlighting the differences in 5HT signalling pathways between different cell 
types.  Furthermore the high levels of pMYPT1, p-cofilin and presence of actin 
stress fibres observed in unstimulated CCL-39 cells suggests a high degree of 
basal  Rho  activity,  making  any  potential  increase  in  the  activity  of  the 
Rho/ROCK pathway induced by 5HT difficult to quantify.  In the future it may be 
valuable  to  use  other  methods,  such  as  a  GST-fusion  proteins  containing 
domains  derived  from  Rho  target  proteins  (e.g.  GST-tagged  rhotekin-RBD 
protein) in order to detect the effects of 5HT on the Rho/ROCK pathway.   
Figure 3.39 shows the ability of the ROCK inhibitor to disrupt the presence of 
actin stress fibres in CCL-39 cells.  Given the effects of ROCK inhibition on 
actin stress fibre formation it was hypothesised that the actin cytoskeleton may 
play a crucial role in the regulation of 5HT-induced ERK activation.  Others have 
reported the role of the cytoskeleton in mediating ERK activity.  For example, 
disruption  of  the  actin  cytoskeleton  by  cytochalasin  D  has  been  shown  to 
prevent Raf activation by inhibiting its translocation to the plasma membrane in 
response to GTP loading of Ras (Krepinsky et al., 2005).  The cytoskeleton also 
plays a role in mediating the translocation of active ERK to the nucleus.  For 
instance,  disruption  of  the  actin  cytoskeleton  has  been  shown  to  prevent 
stretch-induced nuclear localisation of ERK in ventricular myocytes, a process 
that  can  be  restored  by  agents  such  as  jasplakinolide,  which  cause  actin 
polymerisation (Kawamura et al., 2003).  ROCK and the actin cytoskeleton are 
also  involved  in  mediating  pressure-induced  ERK  activation  and 
phosphorylation  in  mesenteric  arteries  (Matrougui  et  al.,  2001).    In  order  to 
address whether inhibition of 5HT receptors or 5HTT resulted in any change in 
the cytoskeleton and thus resulted in a reduction in ERK activation, actin stress 
fibres were assessed.  None of the antagonists or inhibitors used previously had 
any notable effect on the presence or distribution of actin stress fibres within the 
cells, suggesting the ability of these inhibitors to attenuate 5HT-induced ERK   146 
activation  is  not  via  modulation  of  the  actin  cytoskeleton  (Figure  3.40).  
However, treatment with cytochalasin D and latrunculin B, agents that disrupt 
the actin cytoskeleton by distinct mechanisms, resulted in a significant reduction 
in 5HT-mediated ERK activation but had no effect on ERK activation induced by 
treatment  with  PMA  (Figure  3.42  and  3.43)  suggesting  these  findings  are 
specific  to  5HT.    Disruption  of  the  actin  cytoskeleton  using  agents  such  as 
cytochalasin D has previously been suggested to inhibit internalisation from the 
plasma membrane.  However, neither MDC nor con A, agents that also inhibit 
internalisation were able to attenuate ERK activation, suggesting that the effects 
of cytochalasin D are due to its ability to disrupt the actin cytoskeleton alone.  
These results imply that in this cell type the actin cytoskeleton, and ROCK in 
particular, play a crucial role in mediating 5HT-induced ERK activation.  The 
role  of  the  actin  cytoskeleton  in  meditating  the  distribution  of  signalling 
components within the cell may be key in the ability of 5HT to activate ERK.  As 
mentioned previously ROCK and the actin cytoskeleton have been reported to 
mediate the translocation of various components of the ERK cascade and thus 
regulate its activity (Krepinsky et al., 2005; Kawamura et al., 2003, Liu et al., 
2004).    Interestingly,  stress  fibre  formation  can  also  directly  regulate  gene 
expression of a subset of serum response factor-dependent genes (Copeland 
and Treisman, 2002; Geneste et al., 2002; Gineitis and Treisman, 2001).   
5HT has previously been shown to induce reorganisation of vimentin filaments 
in  tracheal  SMCs  (Tang  et  al.,  2005).    It  may  therefore  be  beneficial  to 
determine  the  role  of  other  components  of  the  actin  cytoskeleton,  such  as 
microtubules  and  intermediate  fibres  in  mediating  the  effects  of  5HT.    The 
PAK/LIMK pathway is also involved in regulation of the cytoskeleton.  Given the 
apparent importance of the actin cytoskeleton in mediating the effects of 5HT, it 
may prove useful to investigate the potential role of this pathway in the process.  
LIMK has already been implicated in the expression of cyclin D1 (Roovers et al., 
2003) and PAK is thought to be involved in the 5HT-mediated reorganisation of 
vimentin (Tang et al., 2005). 
In CCL-39 cells, entry of 5HT into the cell via 5HTT appears to be required to 
mediate its proliferative effects.  What is unclear however, is where 5HT acts 
once inside the cell.  As stated previously, studies suggest intracellular 5HT 
may  be  broken  down  by  MAO  to  produce ROS,  which  are  involved  in  ERK   147 
activation and thus contribute to cellular proliferation.  This appears not to be 
the  case  in  this  cell  type  as  inhibition  of  MAO  is  unable  to  modulate  5HT-
induced ERK activation.  One other possibility is that once inside the cell 5HT 
acts  as  a  “second  messenger”  modulating  proliferative  signalling  pathways.  
One group has suggested that once inside the cell 5HT is transamidated to Rho 
rendering it constitutively GTP-bound and active (Walther et al., 2003; Guilluy et 
al., 2007).  Other molecules such as spingosine-1- phosphate (S1P) have been 
shown  to  regulate  ERK1/2  activity  via  both  its  extracellular  and  intracellular 
actions (Goodemote et al., 1995).  Thus, it is possible that inside the cell 5HT 
may activate intracellular receptors which form part of a 5HT signal transduction 
pathway.  Indeed, several GPCRs have been detected intracellularly and are 
thought to function in mediating intracellular signalling.  For instance the LPA1 
receptor  has  been  reported  to  be  constitutively  expressed  in  the  nucleus  of 
several mammalian cell types where it participates in the intracellular signalling 
of LPA and regulates protein phosphorylation (Waters et al., 2006).  If this is the 
case  for  5HT,  our  data  would  suggest  that  ROCK  may  be  important  in 
maintaining the intracellular localisation of these receptors. 
It may also prove fruitful to further investigate the role of ROS in this system.  
ROS  have  previously  been  shown  to  be  involved  in  the  activation  of  the 
Rho/ROCK pathway (Jin et al., 2004).  Rho is also thought to contribute to the 
formation  of  superoxide  in  certain  cells  (Kim  et  al.,  2004).    Given  the 
requirement  of  ROS  in  5HT-mediated  ERK  activation,  investigations  into  the 
effects  of  ROCK  inhibition  on  ROS  production  may  shed  some  light  on  the 
mechanisms by which ROCK regulates the 5HT response.  It has previously 
been  shown  that  H2O2  inhibits  phosphatases  PP1  and  PP2A  resulting  in 
increased ERK phosphorylation (Kim et al., 2003).  Therefore, if the Rho/ROCK 
pathway via stimulation with 5HT is responsible for ROS generation in CCL-39 
cells,  its  inhibition  may  affect  the  activity  of  phosphatases  responsible  for 
activating ERK thus attenuating 5HT-incuded ERK activation.  
To summarise, 5HT1B/1D, 5HT2A receptors and 5HTT all appear to play a role in 
mediating 5HT-induced ERK activation and proliferation, suggesting cross-talk 
between receptor and transporter signalling pathways.  ROCK also plays a role 
in mediating the mitogenic effects of 5HT via the 5HT1B/1D receptor.  However, 
5HT does not appear to directly activate the Rho/ROCK pathway, at least not   148 
within  the  means  of  detection  used  in  this  study.    The  ability  of  ROCK  to 
modulate cytoskeletal dynamics appears to be pivotal in its ability to modulate 
5HT-induced ERK activation.    149 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
Characterisation of the Effects of ROCK  
Inhibition on an In Vivo Model of Pulmonary Hypertension.   150 
4.1  INTRODUCTION 
 
As described previously, ROCK is a major downstream effector of the small 
GTP-ase  Rho.    Its  functions  include:  the  dynamic  regulation  of  cytoskeletal 
proteins,  cell  migration,  proliferation  and  smooth  muscle  contraction.  
Dysregulation of the Rho/ROCK pathway has also been implicated in numerous 
pathophysiological  processes  in  the  cardiovascular  system  such  as 
atherosclerosis (Mallat et al., 2003), angina (Masumoto et al., 2002; Mohri et al., 
2003),  myocardial  infarction  (Satoh  et  al.,  2003),  restenosis  (Sawada  et  al., 
2000) and hypertension (Kobayashi et al., 2002).   
RhoA has been found to play a particularly important role in the hypertensive 
process  in  several  in  vivo  models.    For  instance,  increased  expression  and 
activity of RhoA has been observed in  vascular SMCs (Seko et al., 2003), in 
addition to the implication of Rho-dependent signaling pathways, in resistance 
artery remodeling occurring during hypertensive process (Mukai et al., 2001; 
Wesselman  et  al.,  2004).    Moreover,  ROCK  is  thought  to  mediate  calcium 
sensitization in VSMCs, a process involved in the pathobiology of hypertension 
(Uehata  et  al.,  1997).    Furthermore,  in  spontaneously  hypertensive  rats, 
upregulation of ROCK was found to precede the development of hypertension 
(Mukai  et  al.,  2001).    ROCK  has  also  been  shown  to  be  involved  in 
hypertension in humans (Masumoto et al., 2001). 
A growing body of evidence also exists highlighting the role of the Rho/ROCK 
pathway in the pulmonary circulation. Pulmonary artery endothelial cells from 
pulmonary hypertensive piglets have been shown to display increased RhoA 
activity (Wojciak-Stothard et al., 2006).  In addition to this, RhoA activity and 
ROCK 1 protein expression are each elevated in mildly hypoxic fawn hooded 
rats compared to those maintained at sea level (Nagaoka et al., 2005), with 
similar findings also reported in chronically hypoxic rats (Hyvelin et al., 2005).  
The activities of RhoA and ROCK have also been reported to be elevated by 
high flow-induced PAH (Li et al., 2007).  Moreover, exposure of rat PASMCs to 
hypoxia has also been shown to significantly increase ROCK activity (Wang et 
al., 2001).   151 
ROCK  appears  to  play  a  dual  role  in  the  pathophysiology  of  pulmonary 
hypertension  contributing  to  both  vasoconstriction  and  vascular  remodeling.  
Several  laboratories  have  reported  the  vasodilatory  properties  of  ROCK 
inhibition  on  hypoxia-induced  vasoconstriction  in  pulmonary  vessels.    In 
intrapulmonary vascular rings maintained in hypoxic conditions, slow sustained 
contraction was markedly reduced by treatment with Y27632, a ROCK inhibitor 
(Wang et al., 2001; Robertson et al., 2000a).  Furthermore, studies carried out 
in rats suggest that ROCK-mediated calcium sensitization plays a pivitol role in 
the  increased  basal  pulmonary  artery  tone  and  sustained  vasoconstriction 
observed in pulmonary vessels during chronic hypoxia (Nagaoka et al., 2004).   
ROCK-mediated vasoconstriction is also thought to be an important component 
of severe occlusive PAH (Oka et al., 2007). 
In addition to this, chronic treatment with ROCK inhibitors has also been shown 
to  reduce  elevated  pulmonary  artery  pressure  in  models  of  pulmonary 
hypertension.  Administration of fusadil reduced pulmonary artery pressures in 
chronic hypoxic (Nagaoka et al., 2005), high flow-induced (Li et al., 2007) and 
monocrotaline-induced animal models of pulmonary hypertension (Abe et al., 
2004).  Moreover, Y27632 had similar effects, significantly reducing pulmonary 
artery pressures in the chronic hypoxic rat (Hyvelin et al., 2005). ROCK may 
also couple vasoconstriction with vascular remodeling in pulmonary arteries by 
contributing to matrix synthesis in vascular smooth muscle cells (Chapados et 
al.,  2006).    Indeed,  the  beneficial  effects  of  ROCK  inhibition  on  RVH  and 
pulmonary  vascular  remodeling  have  been  described.    For  example, 
administration  of  fusadil  was  found  to  decrease  RVH  and  medial  pulmonary 
artery wall thickness in in vivo models (Nagaoka et al., 2005; Abe et al., 2004; Li 
et al., 2007).  In addition to this, the potentially beneficial effects of sildenifil 
(Sauzeau et al., 2003; Guilluy et al., 2005) and statins (Girgis et al., 2007; Xing 
et al., 2006) in the treatment of PAH may be partially owing to the ability of 
these drugs to inhibit the RhoA/ROCK pathway.  
The  results  discussed  previously  in  chapter  3  suggest  ROCK  as  a  possible 
downstream mediator of 5HT in its proliferative response.  Given the pivotal role 
of 5HT and 5HTT in the development of pulmonary hypertension (Eddahibi et 
al., 2001) and the apparent importance of ROCK, any cross-talk between these 
systems in vivo were investigated.  Specifically, in this chapter, the effects of   152 
ROCK inhibition on chronic hypoxia-induced pulmonary hypertension in WT and 
5HTT
+ mice were assessed. 
   153 
4.2  RESULTS 
 
Initially, relative expression levels of ROCK 1 and ROCK 2 transcripts in whole 
lung tissue from WT and 5HTT
+ under both normoxic and hypoxic conditions 
were assessed.  In the case of ROCK 1, under normoxic conditions WT and 
5HTT
+ mice display similar levels of expression (Figure 4.1).  Hypoxia resulted 
in  the  elevation  of  ROCK  1  transcript  levels  in  WT  and  5HTT
+  mice  (WT: 
359±21%  increase,  p<0.05,  n=5.   5HTT
+: 1041±27%,  p<0.01,  n=5),  with  the 
increase  more  pronounced  in  5HTT
+  mice.    Furthermore,  under  normoxic 
conditions relative levels of ROCK 2 are similar in both WT and 5HTT
+ mice 
(Figure  4.2).    Exposure  to  chronic  hypoxia  on  the  other  hand  caused  a 
significant  increase  in  ROCK  2  levels  in  both  WT  (600±28%  increase  from 
normoxic,  p<0.01,  n=6)  and  5HTT
+  mice  (863±37%  increase  from  normoxic, 
p<0.05, n=6) resulting in similar levels of transcript expression.  This suggests 
that  overexpression  of  5HTT  enhances  the  hypoxia-induced  transcription  of 
ROCK 1. 
The effects of ROCK inhibition on RVP in WT and 5HTT
+ mice maintained in 
both normoxic and hypoxic conditions were assessed.  Hypoxia was found to 
cause a significant elevation in mRVP in WT and 5HTT
+ mice (WT: p<0.01, n=5 
5HTT
+:  p<0.05,  n=5)  (Figure  4.3).    Under  normoxic  conditions  5HTT
+  mice 
exhibited  higher  mRVP  than  WT  mice  (WT:  12.5±1.5mmHg,  5HTT
+: 
16.08±3mmHg).  Furthermore, inhibition of ROCK had no effect on mRVP in 
normoxic WT mice (n=6); it did however reduce the elevated mRVP in normoxic 
5HTT
+  mice  (p<0.05,  n=7).    In  addition  to  this,  under  hypoxic  conditions, 
administration  of  Y27632  attenuated  the  elevated  mRVP  seen  in  WT  mice 
(p<0.05,  n=8).    Moreover,  when  administered  to  5HTT
+  mice  in  hypoxic 
conditions, Y27632 reduced mRVP (p<0.001, n=8) resulting in pressures similar 
to  than  seen  in  normoxic  vehicle-dosed  WT  mice  (5HTT
+  hypoxic  Y27632: 
12.9±3mmHg, n=8, WT normoxic vehicle: 12.5±1.5mmHg, n=8).   154 
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Figure 4.1  Relative expression levels of ROCK 1 transcript in whole lung 
tissue from WT and 5HTT
+ under both normoxic and hypoxic conditions.   
 
Whole lungs were removed from euthanised animals for RNA isolation.  After 
reverse transcription, relative transcript levels of ROCK1 were determined by 
TaqMan RT-PCR.  Results expressed as mean ± SEM relative to levels of 18s 
ribosomal RNA, WT n=5, WT hypoxic n=5, 5HTT
+ n=5, 5HTT
+ hypoxic n=5.  * p 
< 0.05, ** p < 0.01 using Newman-Keuls multiple comparison test. 
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Figure 4.2  Relative expression levels of ROCK 2 transcript in whole lung 
tissue from WT and 5HTT
+ under both normoxic and hypoxic conditions.   
 
Whole lungs were removed from euthanised animals for isolation of RNA.  After 
reverse transcription, relative transcript levels of ROCK 2 were determined by 
TaqMan RT-PCR.  Results expressed as mean ± SEM relative to levels of 18s 
ribosomal RNA, WT n=5, WT hypoxic n=6, 5HTT
+ n=5, 5HTT
+ hypoxic n=6.  * p 
< 0.05, ** p < 0.01 using Newman-Keuls multiple comparison test. 
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Figure  4.3    Effects  of  Y27632  administration  on  mean  right  ventricular 
pressure (mRVP).   
WT and 5HTT
+ mice were maintained in either normoxic or hypoxic conditions 
for 14 days during which period they were administered with either vehicle or 
Y27632 (30mgkg
-1) daily by oral gavage.  Subsequently mRVP was measured 
by  a  transdiaphramatic  approach.    Results  expressed  as  mean  ±  SEM, WT 
vehicle n=8, WT Y27632 n=6, WT vehicle hypoxic n=5, WT Y27632 hypoxic 
n=8,  5HTT
+  vehicle  n=7,  5HTT
+  Y27632  n=7,  5HTT
+  vehicle  hypoxic  n=5, 
5HTT
+  Y27632  hypoxic  n=8.  *  p  <  0.05,  **  p  <  0.01,  ***  p  <  0.001  using 
Newman-Keuls multiple comparison test. 
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Similar effects were also observed on sRVP.  Under normoxic conditions 5HTT
+ 
mice displayed a pulmonary hypertensive phenotype, exhibiting elevated sRVP 
compared to WT mice (WT: 18.7±1.2mmHg, n=8, 5HTT
+: 27.6±3.4mmHg, n=7, 
p<0.05) (Figure 4.4).  Again, hypoxia significantly elevated sRVP in both WT 
and 5HTT
+ mice (WT: p<0.05, 5HTT
+: p<0.01).  Y27632 significantly attenuated 
this response (WT: p<0.05, 5HTT
+: p<0.01) having a more pronounced effect in 
the 5HTT
+ group. 
Comparable trends in dRVP were also noted, with hypoxia elevating pressures 
in both WT (p<0.05) and 5HTT
+ (p<0.01) mice (Figure 4.5).  Under normoxic 
conditions  dRVP  in 5HTT
+  animals  appears  elevated  compared to WT  (WT: 
5.7±1.5mmHg,  n=8,  5HTT
+:  8.9±3.4mmHg,  n=7,  p>0.05).    Administration  of 
Y27632  had  no  effect  on  dRVP  observed  under  normoxic  conditions  in WT 
mice; it did however marginally reduce the elevated pressure seen in 5HTT
+ 
mice.  Notably, the most marked effects of ROCK inhibition occurred in 5HTT
+ 
mice  under  hypoxic  conditions,  where  Y27632  significantly  reduced  the 
elevation in dRVP (p<0.01) and returned pressures near to levels witnessed in 
normoxic  WT  animals  (WT  normoxic  vehicle:  5.7±1.5mmHg,  n=8,  5HTT
+ 
hypoxic  Y27632:  5.5±2.4mmHg,  n=8).    These  findings  show  that  ROCK 
inhibition, attenuates hypoxia-induced increases in RVP and that this effect is 
most notable on sRVP.  Given that sRVP is significantly higher in 5HTT
+ mice, 
the benefical effects of ROCK inhibition are more pronounced in these mice.  
The effects of Y27632 observed were specific to the pulmonary circulation as 
mean systemic arterial pressures and heart rates were found to be unaltered by 
administration of Y27632 (Table 4.1).  Furthermore, neither overexpression of 
the 5HTT gene nor chronic hypoxia has any effect on systemic haemodynamics 
(Table 4.1).   158 
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Figure 4.4  Effects of Y27632 administration on systolic right ventricular 
pressure (sRVP).   
WT and 5HTT
+ mice were maintained in either normoxic or hypoxic conditions 
for 14 days during which period they were administered with either vehicle or 
Y27632 (30mgkg
-1) daily by oral gavage.  Subsequently sRVP was measured 
by  a  transdiaphramatic  approach.    Results  expressed  as  mean  ±  SEM, WT 
vehicle n=8, WT Y27632 n=6, WT vehicle hypoxic n=5, WT Y27632 hypoxic 
n=8,  5HTT
+  vehicle  n=7,  5HTT
+  Y27632  n=7,  5HTT
+  vehicle  hypoxic  n=5, 
5HTT
+  Y27632  hypoxic  n=8.    *  p  <  0.05,  **  p  <  0.01  using  Newman-Keuls 
multiple comparison test.   159 
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Figure 4.5  Effects of Y27632 administration on diastolic right ventricular 
pressure (dRVP).   
WT and 5HTT
+ mice were maintained in either normoxic or hypoxic conditions 
for 14 days during which period they were administered with either vehicle or 
Y27632 (30mgkg
-1) daily by oral gavage.  Subsequently dRVP was measured 
by  a  transdiaphramatic  approach.    Results  expressed  as  mean  ±  SEM, WT 
vehicle n=8, WT Y27632 n=6, WT vehicle hypoxic n=5, WT Y27632 hypoxic 
n=8,  5HTT
+  vehicle  n=7,  5HTT
+  Y27632  n=7,  5HTT
+  vehicle  hypoxic  n=5, 
5HTT
+  Y27632  hypoxic  n=8.    *  p  <  0.05,  **  p  <  0.01  using  Newam-Keuls 
multiple comparison test.  
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Table 4.1  Effects of Y27632 administration on systemic arterial pressure 
(SAP) and heart rate (HR).   
WT and 5HTT
+ mice were maintained in either normoxic or hypoxic conditions 
for 14 days during which period they were administered with either vehicle or 
Y27632  (30mgkg
-1)  daily  by  oral  gavage.    Subsequently  SAP  and  HR  were 
measured  by  cannulation  of  the  right  carotid  artery.    Results  expressed  as 
mean  ±  SEM.  No  significant  differences  between  groups  were  found  using 
Newman-Keuls multiple comparison test.   161 
The effects of ROCK inhibition on RVH were also assessed (Figure 4.6). In WT 
animals under normoxic conditions, administration of Y27632 had no effect on 
the  RV/LV+S  ratio  (n=7).    Exposure  to  chronic  hypoxia  induced  a  marked 
elevation in this ratio (p<0.001, n=14) and treatment with Y27632 had no effect 
on this hypertrophic response (n=9).  Similarly, in 5HTT
+ mice, Y27632 had no 
effect on the RV/LV+S ratio under normoxic conditions (n=10) and exposure to 
chronic  hypoxia  markedly  increased  RVH  (p<0.001,  n=14).    However,  in 
contrast to WT mice, when administered with Y27632, 5HTT
+ mice exhibited 
significantly reduced RVH under hypoxic conditions (p<0.001, n=9). 
Pulmonary  vascular  remodeling  was  also  assessed  (Figure  4.7).    Hypoxia 
significantly elevates the percentage of remodeled arteries in WT and 5HTT
+, 
with the remodelling observed in 5HTT
+ mice more marked (16.8±1%  versus 
23.3±2%, p < 0.001, n=6).  In addition, administration of Y27632 under hypoxic 
conditions  significantly  attenuates  the  percentage  of  remodeled  pulmonary 
arteries in WT (12.6±0.8%, p<0.01, n=4) and 5HTT
+ mice (11.7±0.8%, p<0.001, 
n=7). 
Taken together, these observations suggest that inhibition of ROCK not only 
reduces  elevated  pulmonary  artery  pressure  but  also  markedly  attenuates 
pulmonary vascular remodeling.  These inhibitory effects are more prominent in 
5HTT
+ mice, highlighted by the fact that ROCK inhibition selectively reduces 
RVH in these mice. 
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Figure  4.6    Effects  of  Y27632  administration  on  right  ventricular 
hypertrophy.   
WT and 5HTT
+ mice were maintained in either normoxic or hypoxic conditions 
for 14 days during which period they were administered with either vehicle or 
Y27632  (30  mgkg
-1)  daily  by  oral  gavage.    Following  haemodynamic 
measurement hearts were removed and right ventricular hypertrophy assessed 
by  calculating  the  ratio  of  the  right  ventricle  to  left  ventricle  plus  septum 
(RV/LV+S).  Results expressed as mean ± SEM, WT vehicle n=12, WT Y27632 
n=7, WT vehicle hypoxic n=14, WT Y27632 hypoxic n=9, 5HTT
+ vehicle n=14, 
5HTT
+ Y27632 n=10, 5HTT
+ vehicle hypoxic n=14, 5HTT
+ Y27632 hypoxic n=9.  
*** p < 0.001 using Newman-Keuls multiple comparison test. 
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Figure 4.7  Effects of Y27632 administration on the pulmonary vascular 
remodelling.   
WT and 5HTT
+ mice were maintained in either normoxic or hypoxic conditions 
for 14 days during which period they were administered with either vehicle or 
Y27632  (30  mgkg
-1)  daily  by  oral  gavage.    Following  haemodynamic 
measurement  lung  tissue  was  removed  for  analysis.  Results  expressed  as 
mean ± SEM, WT vehicle n=6, WT Y27632 n=4, WT vehicle hypoxic n=6, WT 
Y27632 hypoxic n=4, 5HTT
+ vehicle n=7, 5HTT
+ Y27632 n=5, 5HTT
+ vehicle 
hypoxic n=6, 5HTT
+ Y27632 hypoxic n=7.  **p<0.05, ** p< 0.01, *** p < 0.001 
using Newman-Keuls multiple comparison test. 
 
   164 
4.3  DISCUSSION 
 
ROCK  is  thought  to  play  a  role  in  the  pathophysiology  of  several  vascular 
diseases including PAH.  5HT and 5HTT are also implicated in the development 
of the condition.  Given the results discussed in Chapter 3 of this thesis and 
studies carried out by others (Liu et al., 2004), potential cross-talk between 5HT 
signaling pathways and ROCK were investigated in vivo. 
Chronic hypoxia is a commonly used model of pulmonary hypertension (Marcos 
et al., 2003; Long et al., 2006; Eddahibi et al., 1998), and in this study, exposure 
of  WT  mice  to  hypoxia  resulted  in  elevated  RVP  and  RVH,  hallmarks  of 
experimental PAH.  As mentioned previously 5HTT is thought to be involved in 
the  development  of  PAH  and  consistent  with  previously  published  results 
(MacLean  et  al.,  2004;  Guignabert  et  al.,  2006),  5HTT
+  mice  appeared  to 
display a spontaneously pulmonary hypertensive phenotype, with significantly 
elevated sRVP under normoxic conditions.  Polymorphisms in the 5HTT gene 
promoter associated with overexpression of 5HTT, have also been observed in 
a large percentage of patients with PAH (Eddahibi et al., 2001). 
ROCK  is  an  important  mediator  of  vascular  tone  and  has  previously  been 
implicated in hypoxic pulmonary vasoconstriction, with its inhibition attenuating 
vasoconstriction in isolated rat lung and pulmonary arteries (Robertson et al., 
2000a; Fagan et al., 2004).  This may explain the ability of ROCK inhibition to 
significantly  attenuate  sRVP  in  both WT  and  5HTT
+  mice  (Figure  4.4).    The 
effects  of  ROCK  inhibition  appears  specific  to  the  pulmonary  circulation,  as 
Y27632 had no effect on mSAP or HR (Table 4.1).  The beneficial effects of 
ROCK inhibition on RVP observed in this study are consistent with findings by 
others  in  chronically  hypoxic,  fawnhooded  and  monocrotaline  treated  rats 
(Hyvelin  et  al.,  2005;  Nagaoka  et  al.,  2006;  Abe  et  al.,  2004;  Guilluy  et  al., 
2005). 
The beneficial effects of ROCK inhibition on RVP appear more pronounced in 
5HTT
+ mice, with all parameters of RVP significantly attenuated (Figures 4.3 to 
4.5).    The  more  marked  effect  of  ROCK  inhibition  in  these  mice  is  also 
highlighted by the fact that Y27632 appears to specifically attenuate hypoxia 
induced RVH in 5HTT
+ mice but not WT mice (Figure 4.6).  Others have also 
suggested  the  beneficial  effects  of  ROCK  inhibition  on  RVH  in  chronically   165 
hypoxic  rats  (Abe  et  al.,  2004;  Guilluy  et  al.,  2005;  Nagaoka  et  al.,  2006).  
Furthermore,  inhibition  of  ROCK  has  previously  been  shown  to  attenuate 
pulmonary vascular remodelling and vessel wall thickness in a variety of models 
of pulmonary hypertension (Abe et al., 2004; Guilluy et al., 2005; Nagaoka et 
al., 2006).  These finding agree with the present study in which administration of 
the ROCK inhibitor Y27632 significantly attenuated hypoxia-induced pulmonary 
vascular remodelling (Figure 4.7). 
Moreover,  the  effects  of  chronic  hypoxia  on  relative  levels  of  ROCK  1  and 
ROCK 2 transcript were assessed.  Hypoxia resulted in elevation of ROCK 2 in 
both WT and 5HTT
+ to a similar extent.  In the case of ROCK 1 however, a 
more  marked  increase  was  observed  in  5HTT
+  mice  (Figure  4.1).    This 
observation may also be related to the augmented effects of ROCK inhibition on 
RVP, vascular remodelling and RVH in 5HTT mice.  These findings suggest a 
potential link between 5HTT and ROCK 1 expression.   
A number of studies have previously shown the ability of hypoxia to upregulate 
RhoA in a variety of cell types and tissues, including PASMCs (Bailly et al., 
2004),  PAECs  (Wojciak-Stothard  et  al.,  2006)  and  rat  pulmonary  arteries 
(Guilluy  et  al.,  2005).    Increased  protein  levels  of  ROCK  1  have  also  been 
reported  in  the  pulmonary  arteries  of  fawnhooded  rats  kept  at  high  altitude 
(Nagaoka et al., 2006).  Furthermore, consistent with findings in the present 
study, elevated ROCK 1 and 2 mRNA levels have been observed in lungs from 
chronically  hypoxic  rats  (Hyvelin  et  al.,  2005).    However,  the  mechanisms 
resulting  in  increased  ROCK  expression  during  hypoxia  have  not  been 
addressed. 
Hypoxia is known to modulate the expression of a wide variety of genes.  One 
major  class  of  transcription  regulators  activated  in  response  to  hypoxia  are 
hypoxia inducible factors (HIF) (Wang et al., 1995).  HIF-1α, HIF-2α (Ema et al., 
1997; Tian et al., 1997; Flamme et al., 1997), HIF-3α (Gu et al., 1998) subtypes 
have been identified, with HIF-1α most ubiquitously expressed and extensively 
characterised (Semenza, 2004).  HIF comprises of heterodimeric transcription 
factors HIFα and HIFβ, which bind to consensus DNA binding motifs within the 
regulatory promoter region of hypoxia responsive genes, known as the hypoxia 
response elements (HRE), resulting in transcriptional regulation of the target 
gene (Wang et al., 1995).    166 
A large number of genes with a wide range of functions are regulated by HIF-1 
including VEGF (Levy et al., 1995),  inducible NOS (iNOS) (Melillo et al., 1995), 
cyclo-oxygenase 2 (COX-2) (Kaidi et al., 2006) erythropoietin (EPO) (Semenza 
and Wang; 1992, Semenza et al., 1991) and GLUT1 (Chen et al., 2001).  It is 
possible that ROCK genes may also be upregulated by HIF-1 under hypoxic 
conditions, thus explaining the increased mRNA levels observed in this study in 
chronically  hypoxic  mice.    Indeed,  data  analysis  of  the  promoter  region  of 
murine  ROCK  1  and  ROCK  2  genes  identified  potential  HIF-1  consensus 
sequences,  suggesting  HIF-1  may  be  involved  in  hypoxia-mediated  ROCK 
upregulation (Figure 4.8).  
Other  transcription  factors,  such  as  nuclear  factor  kappa  B  (NFкB),    cAMP 
response element binding protein (CREB), p53, Egr-1 Sp-1 and AP-1 have all 
been found to be activated either directly or indirectly by hypoxia (Cummins and 
Taylor, 2005), contributing to altered gene transcription.  Hypoxic activation of 
the  afore  mentioned  transcription  regulators  may  also  contribute  to  the 
increased  transcript  levels  of  ROCK  observed  under  chronically  hypoxic 
conditions in the present study.  Indeed, data analysis of the promoter region of 
the human ROCK gene suggested several possible cis DNA elements including 
AP-1 and Sp-1 (Shimokawa and Takeshita, 2005).  However, the function of 
these  elements  has  not  been  evaluated.    Similarly,  data  anlaysis  of  murine 
ROCK 1 and ROCK 2 identified a potential Sp-1 and AP-1 binding sites in each 
promoter  region.    This  analysis  also  detected  potential  NFкB  and  CREB 
transcription factor binding sites. 
In  addition  to  this,  inflammatory  stimuli  may  be  involved  in  the  regulation  of 
ROCK expression during hypoxic conditions.   Hypoxic activation of NFкB has 
been found to increase the level of inflammatory mediators such as COX-2, 
tumour necrosis factor α (TNFα) and interleukin-6 (IL-6).  The upregulation of 
inflammatory mediators by this mechanism may influence ROCK expression, as 
angiotensin  II  and  interleukin  1β  (IL-1β)  have  previously  been  shown  to 
increase the expression and function of ROCK in vascular SMCs.  This process 
was dependent of NFкB (Hiroki et al., 2004).  
Hypoxia  also  activates  various  kinases,  which  may  result  in  altered  gene 
transcription.  The MAP kinases ERK (Stenmark et al., 2002; Minet et al., 2000), 
p38 (Stenmark et al., 2002; Welsh et al., 2001a) and JNK (Stenmark et al.,   167 
2002) have been found to be activated under hypoxic condition, as have other 
protein kinases such as PKC (Yuan et al., 2005), PKA (Beitner-Johnson et al., 
1998), CaMK (Beitner-Johnson et al., 1998; Yuan et al., 2005) and Src (Thobe 
et  al.,  2006).    Activation  of  such  kinases  during  hypoxia  may  result  in  the 
modulation  of  signalling  pathways  and  alterations  in  gene  transcription, 
accounting for the increased levels of ROCK transcript.  For instance, there is 
evidence to suggest that in various circumstances activation of p38 results in 
the  expression  of  various  inflammatory  mediators  including  TNFα  and  iNOS 
(Wang et al., 2004).  Given the effect of inflammatory stimuli on ROCK, this may 
in turn result in its upregulation.  Furthermore the increased entry of 5HT into 
cells in 5HTT
+
 mice may potentiate signal transduction resulting in the increased 
transcription of ROCK 1. 
Paracrine factors released during hypoxia may also contribute to the regulation 
of ROCK activity.  Mediators such as adenosine are released during hypoxic 
conditions. The  accumulation  of  extracellular  adenosine  has  previously  been 
found  to  affect  the  transcription  of  genes  such  as  VEGF  and  eNOS 
(Ramanathan  et  al.,  2007;  Min  et  al.,  2006).    Therefore,  accumulation  of 
adenosine  could  potentially  effect  ROCK  expression  by  activating  signal 
transduction pathways that mediate its transcription.  Furthermore, given both 
adenosine and p38 both play important roles in the regulation of 5HTT activity 
(Zhu et al., 2004; Zhu et al., 2005), the increased presence of these mediators 
during  hypoxic  conditions  may  contribute  to  the  augmented  hypoxic-
upregulation of ROCK 1 in 5HTT
+ mice.    
To  conclude,  the  more  pronounced  beneficial  effects  of  ROCK  inhibition  on 
RVP  and  vascular  remodelling  in  5HTT
+  mice  and  the  ability  of  Y27632  to 
reduce right ventricular hypertrophy in 5HTT+ mice but not WT mice, suggests 
cross-talk  between  5HT  and  ROCK  signaling  systems.    This  hypothesis  is 
consistent with the marked elevation in the expression of ROCK1 observed in 
the lungs of 5HTT+ mice in response to hypoxia.  Whilst, both ROCK 1 and 
ROCK 2 promoter regions contain potential HIF-1 binding sites explaining their 
upregulation  during  hypoxia,  the  mechanisms  as  to  how  overexpression  of 
5HTT  results  in  increased  transcript  levels  of  ROCK  1  in  the  lung  requires 
further investigation.  
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Figure  4.8    Schematic  diagram  showing  the  potential  position  of  HIF-1 
consensus  sequences  in  the  promoter  region  of  murine  ROCK  1  and 
ROCK 2 genes.  
 
Data analysis of ROCK 1 and ROCK 2 genes revealed several potential HIF-1 
binding sites in their promoter regions. For each gene, a 2kb region upstream of 
the transcription initiation site was analysed for HIF-1 consensus sequences 5’-
GCTGT-3’ and 5’-ACTGT-3’.    169 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
FINAL DISCUSSION   170 
SUMMARY 
 
5HT  is  a  monoamine,  synthesised  by  the  body  from  dietary  tryptophan  and 
plays a major role in wide variety of physiological and pathological processes, 
including pulmonary hypertension (Levy, 2006, MacLean et al., 2000, Hoyer et 
al., 2002).  Evidence exists implicating 5HT in the vasoconstriction and vascular 
remodelling that occurs during PAH (MacLean et al., 2000).  5HT has been 
shown to act as a mitogen in a variety of cell types (Lee et al., 1999, Liu and 
Fanburg, 2006, Lawrie et al., 2005, Bianchi et al., 2005) and it is this effect that 
may contribute to the vascular remodelling that occurs in patients with PAH.  
This project has characterised signalling pathways utilised by 5HT to induce 
fibroblast proliferation, in particular highlighting the role of the Rho/ROCK in this 
process.    Furthermore,  using  an  in  vivo  model  where  the  5HTT  protein  is 
overexpressed, inhibition of the Rho/ROCK pathway was found to have marked 
beneficial effects on the symptoms of PAH. 
In Chapter 3, examination of 5HT mitogenic signalling using CCL-39 hamster 
lung  fibroblasts  revealed  that  proliferation  was  ERK-dependent  and  that 
5HT1B/1D  receptors,  5HT2A  receptors  and  5HTT  were  all  required  for  optimal 
ERK activation and proliferation, suggesting cross-talk between 5HT receptors 
and  the  transporter.    Furthermore,  pharmacological  inhibition  of  Rho/ROCK  
pathway  significantly  inhibited  5HT  induced  ERK  activation,  cyclin  D1 
accumulation  and  proliferation.    However,  no  effect  on  5HT-induced  MEK 
activation  or  on  the  ability  of  active  ERK  to  translocate  to  the  nucleus  was 
observed.  Instead, inhibition of the ROCK was found to specifically inhibit the 
activation of a cytoplasmic pool of ERK.   These findings suggest that ROCK 
inhibition  may  reduce  the  ability  of  MEK  to  promote  ERK  phosphorylation.  
Furthermore, ROCK functions downstream of the 5HT1B receptor in mediating 
5HT-induced  ERK  activation.    In  the  cell  type  used  in  this  study,  the  direct 
activation  of  Rho/ROCK  pathway  by  5HT  was  not  detected  by  means  of 
immunoblotting for the activation of downstream substrates of ERK.  However, 
actin  stress  fibres  were  detected  in  the  cells  prior  to  stimulation  with  5HT, 
suggesting a high basal activity of Rho which may mask the effects of 5HT on 
the  Rho/ROCK  pathway.    The  function  of  ROCK  in  maintaining  cytoskeletal   171 
intergrity is central to its role in 5HT-induced ERK activation in this cell type as 
disruption of the actin cytoskeleton by other agents such as latrunculin B and 
cytochalasin D also markedly attenuate the ability of 5HT to activate ERK.  The 
role of the ROCK and the actin cytoskeleton in mediating 5HT-induced ERK 
activation  are  specific  to  5HT  pathways  as  neither  inhibition  of  ROCK  nor 
disruption  of  the  actin  cytoskeleton  had  any  effect  on  the  ability  of  PMA  to 
activate ERK. 
In Chapter 3, this study characterised the effects of ROCK inhibition on 5HT-
induced  ERK  activation  and  proliferation,  however  it  may  also  be  useful  to 
determine the effects of ROCK activation on these processes, as this would be 
expected to promote proliferation.  One possible way in which to address the 
effects  of  ROCK  activation  would  be  to  use  a  conditionally  active  ROCK 
construct.  Indeed, a study carried out by Croft et al 2006, using a conditionally 
activated ROCK-estrogen receptor (ROCK-ER) fusion construct, reported that 
activation of ROCK-ER by an estrogen analogue was sufficient to stimulate cell 
cycle  progression  in  NIH  3T3  mouse  fibroblasts.    Based  on  the  findings  in 
Chapter 3, estrogen-mediated ROCK-ER activation in CCL-39 cells would be 
expected to potentiate 5HT-stimulated proliferation and ERK activation.    
Chapter 3 also suggesst that the ROCK pathway, via 5HT1B stimulation controls 
MEK activation of a cytoplasmic pool of ERK.  One possible mechanism by 
which many GPCRs are able to activate specific pools of ERK is via the action 
of scaffolding proteins such as β-arrestin, which can mediate the recruitment of 
Src or Raf/MEK/ERK signalling complexes following agonist stimulated receptor 
phosphorylation (DeFea et al., 2000, Wang et al., 2006b, Shenoy et al., 2006).  
Much  work  has  been  carried  out  on  the  regulation  of  5HT2A  receptor 
phosphorylation and interactions with β-arrestin (Bhatnagar et al., 2001, Gray et 
al., 2003, Gray and Roth, 2001, Gray et al., 2001).  However little evidence on 
5HT1B  receptor  regulation  exists.    Interestingly,  data  analysis  of  the  protein 
sequence  of  the  human  5HT1B  receptor  revealed  a  cluster  of  serine  and 
threonine residues within its third intracellular loop.  This is characteristic of G-
protein-coupled receptor kinase (GRK) phosphorylation sites, which have a high 
affinity of β-arrestins.  Similar sites have previously been described for other 
GPCRs, including the V2 vasopressin receptor and the α2A adrenoreceptor (Pao 
and Benovic, 2005, Innamorati et al., 1997).  Therefore, future experiments to   172 
characterise  5HT1B  receptor  regulation  may  be  useful  in  determining  the 
mechanisms by which 5HT, via the 5HT1B receptor and the Rho/ROCK pathway 
specifically controls a cytoplasmic pool of ERK.  
The results presented in Chapter 3 also identify a role for the actin cytoskeleton 
in 5HT-mediated mitogenesis.  It appears that ROCK maintains the integrity of 
the  cytoskeleton  in  order  to  facilitate  5HT-mediated  ERK  activation  and 
proliferation.    These  findings  may  be  of  physiological  relevance  as  other 
components involved in the control of actin cytoskeletal dynamics have been 
implicated in the development of PAH.  LIMK, a key regulator of actin dynamics, 
has been found to interact with the tail region of the BMPR2 receptor, a process 
which  inhibits  LIMK  activity  (Foletta  et  al.,  2003).    A  BMPR2  mutant  with  a 
truncation in the COOH-terminus that has also been described in patients with 
PAH was reported to be unable to bind or inactivate LIMK (Foletta et al., 2003).  
Given the role of BMPR2 in the development of PAH these findings suggest that 
deregulation  of  actin  dynamics  may  contribute  to  the  pathobiology  of  PAH.  
Furthermore,  the  upregulation  cofilin-2  and  LIMK  2  have  been  reported  in 
cultured  PASMCs  and  in  pulmonary  arteries  from  monocrotaline-treated  rats 
(Dai  et  al.,  2006).    Increased  levels  of  these  proteins  were  suggested  to 
promote cell motility, a process that may contribute to vascular remodelling and 
occlusion of pulmonary arteries.  The cytoskeleton also plays a vital role in the 
regulation of pulmonary vascular permeability.  For example, actin filaments are 
of importance to endothelial cell permeability, with disruption of these filaments 
resulting  in  decreased  endothelial  barrier  integrity  and  infiltration  of 
inflammatory mediators, a process that occurs in disease states such as acute 
lung injury and acute respiratory distress syndrome (Dudek and Garcia, 2001).  
Therefore, cytoskeletal integrity may have a widespread role in PAH affecting 
both BMPR2 and 5HT signalling.     
Give  the  apparent  role  of  ROCK  in  mitogenic  5HT-activated  signalling 
pathways, Chapter 4 investigated the role of ROCK in a chronic hypoxic mouse 
model  of  PAH, using transgenic mice that ubiquitously  overexpress  5HTT  in 
order to determine any potential interactions between 5HT and ROCK pathways 
in vivo. 
Using  quantitative  RT-PCR,  chronic  hypoxia  was  found  to  upregulate  both 
ROCK 1 and ROCK 2 transcripts, with the upregulation of ROCK 1 potentiated   173 
in 5HTT
+ mice.  Furthermore, ROCK inhibition resulted in a marked reduction in 
hypoxia-induced sRVP and vascular remodelling, effects that were significantly 
greater in 5HTT
+ mice compared to WT.  In addition, the hypoxia-induced RVH 
that occurred in both WT and 5HTT
+ groups was only sensitive to ROCK in 
5HTT
+ mice.  Taken together, Chapters 3 and 4 highlight a role for Rho/ROCK 
pathway in the development of PAH and suggest interactions between 5HT and 
Rho/ROCK systems in mediating the mitogenic effects of 5HT.   
In Chapter 4, inhibition of ROCK was found to have more significant effects in 
5HTT
+ mice, an effect which may be due to the potentiated hypoxia-induced 
upregulation  of  ROCK  1.    The  increased  expression  of  ROCK  transcript 
detected  in  the  chronic  hypoxic  mouse  model,  suggested  increased  ROCK 
activity, which may contribute to the remodelling process and cell proliferation.  
Analysis of mouse lung tissue by immunoblotting is required to determine the 
levels of ROCK protein, as well as the activation status of downstream ROCK 
substrates, in order to confirm that ROCK activity is increased during hypoxia. 
Recently  it  has  been demonstrated  that entry  of  5HT  into the  cell  via  5HTT 
mediates  the  prolonged  activation  of  Rho  by  the  transglutaminase-mediated 
serotinylation of RhoA (Guilluy et al., 2007, Walther et al., 2003).  This may 
contribute to the potentiated effects of hypoxia in 5HTT
+ mice, given the more 
marked  beneficial  effects  of  ROCK  inhibition  in  these  animals.    If  this 
mechanism is functional in fibroblasts, using the data presented in Chapters 3 
and 4, a potential model to explain how the enhanced expression of ROCK 1 
observed  in  5HTT
+  mice  promotes  remodelling  by  enhancing  the  mitogenic 
effects of 5HT in fibroblasts may be proposed (Figure 5.1).  In this model, entry 
of 5HT into the cell via 5HTT facilitates the transglutaminase (TG)-catalysed 
serotonylation  of  Rho,  rendering  it  constitutively  active.    Serotonylated  Rho 
proteins can then bind and activate ROCK1 and ROCK2.  As ROCK1 transcript 
levels are markedly elevated in response to hypoxia and 5HTT overexpression, 
this  may  be  the  predominant  isoform  affected.    In  pulmonary  fibroblasts, 
enhanced ROCK expression may facilitate 5HT1B receptor activation of the ERK 
pathway  by  assisting  MEK-mediated  ERK  phosphorylation.    To  confirm  this 
hypothesis  the  phenomenon  of  serotonylation  must  be  confirmed  in  the 
fibroblasts studied.  For instance, detection of 5HT binding to RhoA may be 
determined by immunoprecipitating RhoA from 5HT stimulated fibroblasts and   174 
subsequently  immunoblotting  using  an  anti-5HT  antibody.    However,  in 
disagreement  with  the  hypothesis  of  serotonylation,  pretreatment  of  CCL-39 
cells with MDC had no effect on 5HT stimulated ERK activation (Figure 3.18).  
MDC inhibits the transglutaminase enzyme required for serotonylation to occur 
and thus if serotonylation occurs it CCL-39 cells it may have been expected that 
MDC  would  inhibit  5HT-induced  ERK  activation.    MDC  has  previously  been 
found to inhibit binding of 5HT to RhoA in mouse aortic SMCs (Guilluy et al., 
2007).  However,  the  concentration  of  MDC  (200 M)  used  in  this  study  was 
significantly higher than that used in Chapter 3 (100µM) and this may explain 
why MDC pre-treatment was unable to inhibit 5HT-stimulated ERK activation.  
Therefore, the process of serotonylation cannot be ruled out in CCL-39 cells.  
Furthermore, given the hypoxia-induced upregulation of ROCK in mice, future 
experiments may include the use of a hypoxic cellular model to determine if this 
phenomenon also occurs in vitro and to ascertain any changes that may arise in 
the  ROCK-dependent  5HT  mitogenic  signalling  during  hypoxia.    Studying 
signalling pathways under hypoxic conditions and also the use of a primary cell 
line  derived  from  mouse  pulmonary  arteries  would  allow  a  more  direct 
comparision and intregration between  the cellular signal transduction pathways 
investigated and  the chronic hypoxic mouse model of PAH.   
This  study  highlights  the  role  of  ROCK  in  the  development  of  pulmonary 
hypertension and indicates cross-talk between 5HT and Rho/ROCK signalling 
pathways.  The results are of clinical relevance, given ROCK inhibitors such as 
fusadil are currently being investigated as potential therapies for PAH (Ishikura 
et al., 2006).  Furthermore, inhibition of ROCK appears to have selective effects 
on the pulmonary circulation, as shown in this study (Table 4.1) and by others 
where  fusadil  selectively  induces  vasodilation  in  pulmonary  arteries  but  not 
aorta in an animal model of PAH (Jiang et al., 2007).  In addition to this, other 
agents such as sildenafil and statins appear to mediate their beneficial effects 
on the symptoms of PAH via inhibition of the ROCK pathway (Xing et al., 2006, 
Guilluy et al., 2005).  To conclude, ROCK appears to be a promising therapeutic 
target in the treatment of PAH, with drugs targeting ROCK having beneficial 
effects  on  pulmonary  vasoconstriction  and  pulmonary  vascular  remodelling.  
The findings in this study confirm ROCK’s importance in the development PAH   175 
and suggest potential mechanisms of action for the therapeutic effects of ROCK 
inhibitors.   176 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1  Proposed model of how chronic hypoxia and increased 5HTT 
activity control 5HT-mediated proliferation via ROCK. 
 
Overexpression of 5HTT results in elevated levels of 5HT entering the cell.  Entry 
of  5HT  facilitates  the  transglutaminase  (TG)-catalysed  serotinylation  of  Rho, 
resulting  in  the  constitutive  activation  of  Rho.    Active  Rho  then  binds  and 
activates ROCK, predominantly ROCK 1.  Active ROCK is required for 5HT1B 
receptor-mediated phosphorylation and activation of ERK by MEK.  Once active 
ERK mediates cellular proliferation and contributes to vascular remodelling.   177 
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